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Abstract 
 
Alzheimer’s disease (AD) is one of the leading cause of death; being the only 
cause to have increased attribution to death necessitates the understanding of its 
etiology. Several pathological features, including accumulation of misfolded proteins 
(i.e., amyloid-; A), metal ion dyshomeostasis, and loss of acetylcholine (ACh) 
neurotransmission, are suggested in AD pathogenesis. Current AD therapeutics focus 
on inhibition of acetylcholinesterase (AChE) for mitigating ACh breakdown. Extensive 
studies indicate a potential interconnection between A and metal ions (i.e., Cu2+/Zn2+) 
as well as between A and AChE. Aforementioned factors or their inter-relationships in 
neuropathogenesis have been unclear, however. To understand the correlation 
between these factors, efforts have been made toward the development of small 
molecules as chemical tools, capable of targeting them and subsequently regulating 
their reactivity. 
For such purposes, in this thesis, diphenylpropynone (DPP; A imaging probe) 
derivatives, bioapplicable molecules (i.e., curcumin, found in curry and enediyne, 
framework used in cancer research), as well as a multifunctional hybrid molecule 
(hybrid 5) were developed and investigated toward their targets. DPP derivatives are 
observed to interact with A species and metal ions. The bifunctionality (A interaction 
and metal chelation) of these derivatives is able to influence the reactivity (metal-
induced A aggregation) of metal-associated A (metalA) species in vitro. The 
GdIIIDTPA-curcumin conjugate, a synthesized, A specific MRI agent, is also found to 
target metalA species and modulate metal-triggered A aggregation. This study 
presents the potential to develop a theranostic (diagnostic and therapeutic) agent all-in-
one. The enediyne derivative, with its proclivity to generate radicals, is shown to target 
metalA species and control the A aggregation possibly via multiple properties (i.e., 
metal chelation, A interaction, radical generation). Lastly, hybrid 5 interacts with 
xxxi 
 
various targets (A, metals, and AChE), is able to inhibit AChE activity with and without 
A and metals, and modulate metal-induced A aggregation in the absence and 
presence of AChE. Through this finding, the feasibility of designing a single molecule for 
multiple functions was indicated. Taken together, the presented studies demonstrate the 
development of small molecules as chemical tools that can be used to understand the 
involvement of multiple factors in AD pathogenesis.  
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Chapter 1: Metals and Proteins in Alzheimer’s Disease 
 
 
 
 
 
A portion of this chapter was presented in a publication [Lee, H. J.;‡ Korshavn, K.;‡ 
Kochi, A.; Derrick, J. S.; Lim, M. H. Chem. Soc. Rev. 2014 in press (‡ Equal 
contribution)]. 
 
1.1. Alzheimer’s disease (AD) 
 AD is currently the most prevalent form of neurodegenerative disease, afflicting 
over 5 million people, making it the sixth leading cause of death in the United States 
alone.1 The symptomatic signs and pathological features of AD have been identified, yet 
the complete understanding of the disease onset and progression still remains elusive. 
Due to the complex nature of this disease and limited understanding of AD etiology, the 
drugs available are able to only offer temporary symptomatic alleviation.2-6 The 
hallmarks of AD are the accumulation of misfolded protein aggregates which are 
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composed mainly of neurofibrillary tangles consisting of hyperphosphorylated tau 
proteins and senile plaques made up of amyloid- (A peptides, as well as 
morphological changes (e.g., shrinkage) in post mortem brain.2-7 In the A plaques, 
concentrated metal ions, such as Cu, Zn, and Fe have observed, suggesting metal ion 
dyshomeostasis/miscompartmentalization may be involved in initiation and progression 
of AD. Moreover, upon binding of redox active metals to A, excess reactive oxygen 
species (ROS) is generated, potentially establishing the oxidative stress environment 
shown in AD brain.2-6,8 In addition to the possible A and metal ion pathology, synaptic 
dysfunction in the cholinergic system has been correlated to AD. An inter-relationship 
between the various factors (i.e., A, metal ion, cholinergic dysfunction) has been 
suggested toward neurodegeneration, but it still remains to be elucidated. 
 
1.2. Function of metals in the brain 
How could metal ion miscompartmentalization and dyshomeostasis potentially 
influence the neurodegeneration that has been observed in AD-afflicted patients? In 
order to answer this question, a basic understanding of biologically available metals and 
their functions is necessary. Metal ions serve many vital roles, including acting as 
secondary messengers in cellular signaling, stabilizing proteins’ structures, catalyzing 
enzymatic reactions, and transporting dioxygen (O2) throughout the body.2,9,10 In order 
to maintain proper function, metal ion homeostasis is tightly controlled. In particular, 
three transition metals (i.e., Cu, Zn, Fe) has garnered attention in the AD field, due to 
the colocalization of the metal ions within senile plaques, consisting of A, observed in 
AD-afflicted brain.2,3,6,8  
 Copper is the third most abundant transition metal in the body, and the copper in 
the brain accounts for ca. 9% of total copper in the body.9,10 The major oxidation states 
of copper are +1 and +2. Cu+ is typically found in the intracellular environment while 
Cu2+ is more common in the extracellular environment.10 Copper in the brain is 
categorized into two main groups, either bound to proteins, including CcO for ATP 
production, SOD1 for ROS regulation, and Cp for iron metabolism, or unbound in labile, 
synaptic pools.2,9,10 
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 The importance of copper is evident in mitochondrial oxidative phosphorylation 
(OXPHOS), a multi-step electron transport chain necessary for the formation of the 
proton gradient utilized for ATP production.11 CcO is the terminal enzyme of OXPHOS 
and consists of 13 subunits, three of which serve as the catalytic centers (Cox 1-3) 
containing copper and heme. Electrons transfer between copper and iron centers is 
coupled to the generation of a proton gradient.11 Another critical metalloprotein found 
both in the mitochondrial intermembrane and the cytoplasm is SOD1, a 32 kDa 
homodimeric copper- and zinc-containing enzyme.10,12 Through a two-step redox 
reaction on the copper center at the catalytic site, SOD1 converts harmful superoxide 
radicals (O2−•) that escape from the mitochondria into O2 and hydrogen peroxide 
(H2O2).2,12 Loss of copper results in complete inactivation of the enzyme.12 Copper is 
also present in proteins which regulate iron homeostasis. Cp, the major carrier for 
copper in plasma, is a multicopper oxidase that is paramount for iron metabolism.2,10 
 Zinc is the second most abundant metal in the body, and it is most concentrated 
in the brain.10 Like copper, zinc is either protein-bound or labile forms.10 The majority of 
the zinc in biology is protein-bound, where it is regulated (i.e., MTs) and transported 
(i.e., zinc transporters (ZnTs)) to play a role in other biological processes or aid in 
conformational stability of protein (e.g., SOD1)2,10 ZnT3-knockout mice studies 
demonstrated that the accumulation of Zn2+ was not associated with synaptic vesicles, 
suggesting that MTs, not ZnTs, may help maintain an equilibrium between protein-
bound and labile Zn2+ pools.2 SOD1 binds zinc to stabilize the active structure, 
facilitating copper catalyzed antioxidant activity.13 Studies of amyotrophic lateral 
sclerosis (ALS) indicate that SOD1 adopts an ALS-linked, mutant-like conformation in 
the absence of bound zinc.13 This structural change allows specific protein-protein 
interactions between SOD1 and Derlin-1 which induces endoplasmic reticulum stress 
responses, such as protein synthesis inhibition and ZnT induction.13 The labile zinc pool 
is also necessary for neuronal transmission; Zn2+ is released into the synaptic cleft, 
along with glutamate, following the excitation of glutamatergic neurons.2,9,10 Although 
the role of Zn2+ in neurotransmission is not fully understood, it is suggested to be 
involved in the modulation of neurotransmission through interaction with other 
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biomolecules, such as N-methyl-D-aspartate (NMDA) and -aminobutyric acid (GABA) 
receptors, to regulate their reactivity.2,9,10,14 
The most abundant transition metal ion in the brain is iron, likely related to the 
high demand of O2.10 Iron is required for many biological processes, including OXPHOS 
(vide supra), neurotransmitter production, and O2 transport/storage. Iron is 
physiologically found mainly in two oxidation states, +2 and +3; Fe2+ is bound to 
proteins, such as hemoglobin and HO1, while approximately 25% of the body’s iron is 
chelated to transferrin and ferritin in the Fe3+ state.2,10 Ferritin, a globular protein 
consisting of 24 subunits, binds up to 4,500 atoms of iron in order to protect cells from 
iron-mediated oxidative damage and allow for the release of Fe3+ when needed.10,15  
In addition to iron itself being indispensable for diverse critical functions in the 
body, products generated upon the breakdown of heme, an iron containing cofactor, 
have physiological roles as antioxidants and anti-inflammatory agents.16 Heme is 
degraded by hemeoxygenase (HO) enzymes.16 Three isoforms of HO have been 
characterized: HO1 is induced by oxidative stress, HO2 is constitutively active, and HO3 
is newly identified (its function is still unclear).16,17 HO1 is used in a defense mechanism 
against cellular oxidative stress in concert with SOD1.16 HO2 is implicated in the 
maintenance of heme homeostasis and the prevention of nitric oxide (NO)-mediated 
damage, such as inflammation and glutamate excitotoxicity.18,19 HO1 and HO2, in 
conjunction with NADPH and cytochrome P450 reductase, catabolize heme to produce 
biliverdin, carbon monoxide, and labile Fe2+.16,17 Some biliverdin can then be further 
reduced to bilirubin by biliverdin reductase.16 The products of HO1- and HO2-mediated 
heme breakdown, biliverdin and bilirubin, may mitigate oxidative stress by acting as 
antioxidants and remove a potential pro-oxidant source, heme.16,17 HO3 was found to 
be a retrotransposition of the HO2 gene and has been suggested to be involved in 
heme binding and O2 sensing.16,17 
As described above, copper, zinc, and iron play critical roles in normal biological 
processes. Misregulation of these metal ions lead up to detrimental effects in the body, 
such as the loss of metal ion observed to inactivate SOD1 activity12 or misconformation 
of SOD1 in absence of zinc in ALS (vide supra).13 Due to the observations of metal 
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involvement in neurodegenerative diseases (e.g., AD), metal ion homeostasis has 
gained attention as a possible underlying cause of disease neuropathology. 
 
1.3. Misfolded proteins in AD 
 
1.3.1. Amyloid precursor protein in AD  
A pathological feature of AD, senile plaques, are composed of A peptides, 
which are initially generated from a transmembrane amyloid precursor protein (APP).2,4-
6,8 Three isoforms exist (APP675, APP751, and APP770), where the most common found in 
neuronal cells is APP695.4,6,8,20 The role in which APP plays in normal physiology is still 
unknown, but possible roles in metal ion homeostatsis20-22 as well as ferroxidase activity 
has been suggested.2,6,8,23 Two possible binding sites of APP have been suggested; E1 
(124-189; APP695 numbering)24 and E2 (313-388)25 with dissociation constant (Kd) of ca. 
10-8 M (Cu2+) and 10-6 M (Zn2+)2,8,25,26  
 A peptide can be generated by APP cleavage via two pathways: non-
amyloidogenic and amyloidogenic (Figure 1.1).2,4-6,8 For the non-amyloidogenic 
pathway, initial incision is made between K687 and L688 (APP770 numbering) by -
secretase, releasing sAPP, followed by cleavage at either V711/I712 or A713/T714 by 
-secretase to generate A17-40 and A17-42, respectively.2,4-6,8 The two common forms of 
A associated with AD are A40 and A42, which are produced via the amyloidogenic 
pathway. APP is cleaved between M671 and D672 by -secretase, releasing sAPP. 
Subsequent cleavage by -secretase produces the amyloidogenic peptides.2,4-6,8 
 
1.3.2 Amyloid- in AD 
Aggregation of these A peptides occurs via a “nucleation-dependent growth 
mechanism” which consist of two phases: lag phase and elongation phase (Figure 
1.2).6,8,27,28 During the lag phase, monomeric peptides self-associate and aggregate into 
oligomeric species, which forms thermodynamically unfavorable nuclei.29 Once the lag 
phase is surpassed, elongation occurs,30 where the nucleus acts as a template for A 
fibril formation.6,8,29 Various factors (i.e., solution pH (aggregation accelerated near  
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Figure 1.1. Cleavage of APP by -, -, and -secretases. APP cleavage is initiate by -secretase 
followed by -secretase to generate A17-40/42 via non-amyloidogenic pathway. Proposed pathogenic 
A40/42 is produced upon -/-secretase cleave (amyloidogenic pathway). A42 sequence is shown; black: 
bordering APP amino acids (AA); yellow: proposed metal binding sites; blue: hydrophilic AA residues; 
purple: hydrophobic AA residues. 
 
protein’s isoelectric point); peptide concentration; natural tendency of a peptide to 
aggregate; exogenous species (proteins, metal ions)) have been shown to influence the 
initiation and aggregation rate of A peptide.8 Furthermore, the morphology of  
 
 
 
Figure 1.2. Nucleation-dependent growth mechanism for amyloid fibril formation. In the lag phase, the 
soluble monomers self-aggregate to generate a nucleus and is used as a base for the rapid generation of 
A fibrils in the elongation phase.  
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generated A fibrils are impacted by conditions in which aggregation occurs, such as 
temperature, pH, agitation, or addition of exogenous components (e.g., metal ions, 
proteins).8,27,28,30 Though the exact species of A that lead to neurotoxicity is still highly 
debated, recent studies have implicated oligomeric species, such as dimers, trimers, 
hexamers, and dodecamers, to exhibit neurotoxicity in AD neurodegeneration.8,31-35 AD 
could be classified as either “gain of toxic” function or “loss of function” disease.6,8 
Aggregated A species have been implicated to have detrimental effects, such as 
interacting with membrane and acting as cation-selective ion channels,36,37 effecting 
signaling pathways (i.e., breakdown of signal transduction via altering membrane 
potential or weakening neuroplasticity),8,38,39 and aiding in the formation of oxidative 
stress environment observed in AD.2,8,9,40 In addition to the misfolded proteins 
displaying toxic effects, A species can also lead to loss of function of many proteins 
that are essential in normal biological conditions. A fibrils could also act as a possible 
sink for metal ions, promoting metal ion miscompartmentalization, vide infra.8,9,40  
 
1.4. Metal ions, proteins, and AD 
 
1.4.1. Effect of metal ion dysregulation on proteins in AD 
As described in the section 1.2, metal ions may be critical for the maintenance of 
proper structure and function for a variety of proteins, including CcO, SOD1, Cp, MTs, 
and HO1 (Figure 1.3). The AD environment (i.e., miscompartmentalized/altered 
distribution of metal ions and the promotion of oxidative stress) may lead to protein 
activity disruption2,10 or the initial misregulation of these proteins may promote the 
conditions observed in AD environment.2,10,11 Although it is still debated whether 
changes in compartmentalization and localization of metal ions are directly involved in 
AD etiology, the perspective that dysregulated metals could cause oxidative stress 
(Figure 1.3) is taken for this dissertation, which is believed to be correlated to AD 
development. In addition, the interaction of metal ions with A and their effects on A 
aggregation and toxicity have been relatively well characterized.2,5,40,41  
Copper-/iron-bound Aspecies, along with labile redox-active metal ions, could 
generate reactive oxygen species (ROS) via Fenton-like reactions (eqn 1-5).2,6,8,40 A 
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fibrils could also act as a possible sink for metal ions, promoting metal ion 
miscompartmentalization (Figure 1.3).8,9,40 Hereafter, how metal ions, both labile and 
protein-bound, may relate to the generation and clearance of ROS, a possible factor in 
the onset and progression of AD, will be discussed. 
 
ACu2+ + reductant          ACu+ + reducant+   
ACu+  + O2                     ACu2+O2•–   (eqn 1) 
ACu2+O2•–  + e– + H+     ACu2+HO2•–   (eqn 2) 
ACu2+HO2•–  + H+          ACu2+ + H2O2   (eqn 3) 
AMn+  +  H2O2                 AM(n-1)+  +  HOO•  +  H+ (eqn 4) 
AMn+  +  H2O2                 AM(n+1)+  +  HO•  +  OH– (eqn 5) 
 
Organisms have natural antioxidant defense mechanisms that regulate the 
required amount of ROS present in the body; however, in the diseased state, the 
system in place for ROS elimination and production (e.g., SOD1 and CcO, respectively, 
vide supra) may malfunction, leading to ROS accumulation and oxidative stress.2,10 
High levels of ROS can oxidize lipids and proteins, rendering them unstable and/or 
nonfunctional, as well as modify DNA which can cause genetic mutations.2  
In vitro studies have shown that copper, zinc, and iron can coordinate with A 
generating metalA complexes; furthermore, it has been shown that coordination of A 
to either Cu+/2+ or Zn2+ can facilitate peptide’s aggregation in vitro.2,6,8,9,41 High 
concentrations of metals have been shown to be colocalized in A plaques: Cu (ca. 0.4 
mM), Zn (ca. 1 mM), and Fe (ca. 0.9 mM).2,6,8,10 The coordination of CuA is very 
dynamic and pH dependent.2,9,40 The predominant coordination at physiologically 
relevant pH (i.e., 7.4) for Cu2+ and Cu+ is 3N1O (three nitrogen donor atoms and one 
oxygen donor atom; believed to be H6, H13/14, N-terminal amine, and D1 carboxylate) 
and 2N (two nitrogen donor atoms; suggested to be H13 and H14), respectively. A 
binds to Cu2+ at a 1:1 stoichiometric ratio, with Kd ranging from ca. 10-11 to 10-7 M2,8,42,43 
A also complexes with Cu+ at a 1:1 ratio, with Kd of ca. 10-7 M (A42).6,8,44 
CuAspecies have a redox potential = 0.30 V versus normal hydrogen electrode 
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(NHE).2,9,41 AZn2+ has been shown to coordinate four to six ligands, with a consensus 
via H6/13/14,2 while the other ligands (4-6) vary depending on conditions.2,6 
 
 
Figure 1.3. Possible interplay of metal ions in inducing oxidative stress and influencing protein activity. (a) 
Redox active metal ions (i.e., Cu2+ (blue spheres), Fe3+ (red spheres)) and their complexes with A could 
produce reactive oxygen species (ROS) through Fenton-like reactions. Zn2+ (green spheres) has also 
been observed to inhibit oxidative phosphorylation (OXPHOS) as well as modify SOD1 structure in 
mitochondria, leading to Zn2+-triggered ROS production. Imbalance between the formation and removal of 
ROS could cause oxidative stress. (b) Aggregated A may act as a sink for metal ions, contributing to 
altered bioavailability of metal ions. Metal ion dyshomeostasis and/or oxidative stress could interfere with 
critical biological functions (i.e., ATP production, ROS breakdown, maintenance of metal ion 
homeostasis) of proteins, such as cytochrome c oxidase (CcO), Cu/Zn superoxide dismutase (SOD1), 
ceruloplasmin (Cp), metallothioneins (MTs), and hemeoxygenase 1 (HO1).  
 
A complexes with Zn2+ at a 1:1 ratio, with Kd from 10-9 to 10-6 M2,6,42 Few 
structural studies have been reported for iron coordination to A due to the propensity of 
Fe2+ to oxidize to Fe3+ and precipitate as Fe(OH)3 and other complexes.41 Preliminary 
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results proposed D1, E3, and H6/13/14 may be involved in Fe2+ coordination by A.41 
The redox potential of Fe2+/Fe3+ in the A-iron-nitriloacetic acid complex was 
determined to be 0.23 V versus NHE.45 Fe2+ binds to A with Kd ca. 10-4 M.8,46 
Redox inert Zn2+ could also take part, indirectly, in ROS generation.47 Upon 
subjection of neurons to toxic intracellular zinc concentrations, ROS accumulation as 
well as lipid peroxidation have occurred.47 Due to the natural production of ROS during 
OXPHOS and the natural escape of 1-3% of that ROS, mitochondria are considered a 
primary contributor to oxidative stress in neurons.2,48 It has been observed that Zn2+ 
could inhibit OXPHOS at multiple sites (i.e., ubiquinone, glycerol-3-phosphate 
dehydrogenase, and complex I/II/III/IV(IV; CcO), with complex III believed to be the 
most sensitive to Zn2+ inhibition.47 Zinc was found to inhibit the Q cycle (arresting 
electron transfer) and a putative zinc binding site was speculated as a part of the proton 
channel of complex III.47 In addition, reduced CcO activity is consistently found in the 
diseased brain.48 CcO deficiency in relation to ROS production was assessed in the 
COX10 knockout AD mouse model (lacking in one of the hemes in the CcO catalytic 
site), but increased ROS formation was not demonstrated in the presence of decreased 
CcO activity.49 These findings indicate that the oxidative stress induced by high levels of 
Zn2+ may not arise from CcO dysfunction, but rather from a disturbance upstream from 
CcO in OXPHOS, perhaps through Zn2+ inhibition of different OXPHOS sites.47 Zn2+ 
also has been hypothesized to increase ROS formation through interference with the 
Krebs cycle in the mitochondria.47 In the Krebs cycle, ROS is generated following NADH 
oxidation of O2 by -ketoglutarate dehydrogenase.47 Zn2+ was shown to accelerate this 
reaction five-fold through an unknown mechanism, possibly contributing to ROS 
overproduction.47  
Along with overproduction of ROS by various metal ions, loss of ROS 
detoxification machinery could overwhelm the endogenous antioxidant system.2,10 
Current research has found one of the key antioxidant enzymes, SOD1, to be a major 
target of oxidation.50 Choi, et al. identified four brain SOD1 isoforms from human AD-
afflicted brains with different isoelectric points (pI = 6.3, 6.0, 5.7, and 5.0).50 Relative 
increase of all isoforms was observed, with a six-fold increase of the acidic (pI 5.0) 
isoform. In addition, SOD1 was shown to aggregate and associate with A plaques and 
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neurofibrillary tangles.50 Moreover, a 7.59 fold increase in oxidation of pI 6.0 isoform 
was determined, with C146 irreversibly oxidized in AD brain.50 C57 and C146 create an 
intramolecular disulfide bond with each other that is necessary to maintain proper 
conformation and enzymatic activity of SOD1; oxidation of one of these prevents the 
generation of the disulfide bond and hinders enzymatic function.51 The malfunction of 
SOD1 may be a factor for the accumulation of ROS, ultimately leading to oxidative 
stress and neurodegeneration.10,50  
In AD patients, increased apo-Cp (copper-unbound form without normal 
function) levels and decreased activity of Cp have been observed.2 These altered 
concentrations may exacerbate toxic conditions observed in AD where labile iron 
promotes oxidative damage.2 Since Cp has been known to play a central role in cellular 
homeostasis, including metal and oxidative stress regulation,2 expression of 
metalloproteinases that degrade A2 ferroxidase activity,2,52 and H2O2 scavenging,52 
diminished presence of the metallated form and lowered protein activity could trigger 
aberrant pathological events (e.g., A accumulation, oxidative stress, metal ion 
dyshomeostasis). Due to the iron ion dysregulation that has been observed in AD, a 
possible relationship between the iron ion dyshomeostasis and disruptions of ferritin has 
been proposed. No changes in ferritin levels have been observed in the diseased state 
to date, however.15  
MTs are another class of proteins affected by oxidative stress.2 Four isoforms, 
MT1-4, have been identified. MT1/2 are found in most tissues and MT3/4 are present in 
specialized tissue, such as the brain and epithelial tissue, respectively.2,10 MT1/2 in the 
brain are expressed mainly in the astrocytes which maintain CNS homeostasis, blood-
brain barrier (BBB) integrity, and neuronal metabolism, as well as express 
metalloproteinases that catabolize amyloids.2 In AD, MT1/2 have been shown to be 
upregulated and MT3 levels have been shown to be altered, but a consensus has not 
been reached as to how it changes.2 MT3 is brain-specific and can coordinate up to 
nine atoms of zinc under excess Zn2+ conditions.10 Subsequent release of MT-bound 
Zn2+ induced by ROS has been implicated in AD pathogenesis. In the characteristic 
oxidative stress environment of the AD-affected brain, Zn2+ could be released from MTs, 
which could then induce Zn2+ excitotoxicity resulting in cell death by various 
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mechanisms, such as upregulation of glutamate receptor activity to cytotoxic levels, 
overstimulation of NO-involved pathways, or generation of ROS (vide supra).10 
HO1 has also been shown to be increased during oxidative stress to mitigate 
ROS (vide supra).16,17 HO1 has been observed to be overexpressed in neurons and 
astrocytes, particularly of the parenchyma in AD and is present in senile plaques. It is, 
however, suppressed in cerebral spinal fluid.16 HO1 has also been conceptualized as a 
double-edged sword. The beneficial antioxidant capacity of bilirubin and biliverdin 
gained after heme metabolism could be nullified by the release of Fe2+ which could 
enter a redox cycle and promote ROS generation.16 
 
1.4.2. Cholinergic system in AD 
Additionally, the cholinergic system also has been implicated in AD 
neurodegeneration; initially stemming from the observation of the loss of cholinergic 
neurons that release acetylcholine (ACh) in basal forebrain in AD.53-56 ACh is important 
in many neurological signaling pathways, such as the two major parts of the autonomic 
nervous system, which are responsible for the regulation of internal organs/glands as 
well as nerve plasticity, sustainment of attention, and promotion of the rapid eye 
movement cycle during sleep.57,58 In the AD-affected brain, ACh release (induced by 
depolarization) and choline uptake (necessary to recyclize into the ACh pathway of 
synthesis to produce more ACh) have been shown to be diminished.55,59-62 Reduced 
nicotinic ACh receptors (nAChRs) and muscarinic ACh receptors (mAChRs), which bind 
to the released ACh, in both pre-/postsynaptic neurons have been observed.53,54,59 
Studies indicate A may also interact with both receptors. A specifically has high 
affinity toward 7nAChR; the interaction showed multiple effects (i.e., impair the release 
of ACh (presynaptic neuron) and maintenance of long-term potentiation; internalization 
and accumulation of A in neurons).53,54,63-65 Current therapeutic efforts have been put 
forth to increase the reduced levels of ACh by inhibiting acetylcholinesterase, AChE, 
responsible for cleaving the neurotransmitter.66-68  
AChE is a serine hydrolase from the esterase family,69,70 whose primary function 
is breaking down ACh to terminate cholinergic neurotransmission.70-72 AChE consists of 
-sheet surrounded by -helices that contains a catalytic triad in the esteric site, located 
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at the bottom of 20 Å deep cavity composed of aromatic amino acids. (catalytic triad: 
S200, H440, and E327; Torpedo californica; electric eel AChE)70,72-74 The -anionic site 
(W84, Y121, F330), located near the esteric site, interacts with the quaternary 
ammonium atom of ACh and is responsible for its correct orientation within the 
enzyme.70,72,75,76  
Situated on the surface of AChE near the cavity entrance, is the peripheral 
anionic site (PAS) consisting of amino acids, including Y70, D72, Y121, W279, and 
Y334.72,77 A has been correlated to AChE itself, where AChE has been found to be 
accumulated in A plaques.78 Studies have suggested that AChE promotes A 
aggregation in vitro79 and in AD mouse model.80 It has been shown that A interacts 
with PAS of the enzyme, which facilitates A fibril formation.81 Current AD therapeutics 
(i.e., tacrine, galantamine, donepezil, and rivastigmine) target different binding sites of 
AChE; tacrine and galantamine binds onto the -anonic site; donepezil complexes with 
PAS; rivastigmine binds at the esteric site.59,72,82 Only modest improvements in disease 
progression after treatment, as well as low tolerability of treatment in some patients 
have been observed, however.2-6,70,72 Therefore, fundamental understanding of how the 
multiple factors, from the different aspects of AD pathogenesis, must be first illustrated 
in order to develop effective therapeutics. 
 
1.4.3. Use of small molecules to understand the relationship between A, metal 
ions, and/or AChE 
In order to elucidate the relationship between multiple pathological factors (i.e., 
A, metal ions, loss of ACh/inhibition of AChE), advances have been focused on the 
development of small molecules which could be used as chemical tools to gain insight 
into the interconnection (Figure 1.4).2,3,83 The basic understanding of each facet to 
neuropathogenesis in this complex disease will help establish a foundation to which an 
effective therapeutic could be built upon. Initial findings indicated metal-induced A 
aggregation could be reversed in vitro by the use of metal chelators. Hence metal 
chelation therapy (e.g., bathophenathroline; Figure 1.4) was examined; however, 
bioapplicability was low due to BBB impermeability and nonspecific metal binding.83,84 
This investigation resulted in concreting a potential metal correlation to AD pathology 
 
14 
 
and small molecule framework containing metal chelation have been explored since 
then. 
 
 
Figure 1.4. Multifunctional small molecules that can be used to investigate A, metal ions and/or AChE 
inhibtion in AD by combining properties of A interaction (green), metal chelation (blue), and/or AChE 
inhibition (orange). Multifunctional molecules are shown in the purple box. Abbreviations for compounds: 
p-I-stilbene = N,N-dimethyl-4-[(1E)-2-(4-iodophenyl)ethenyl]benzenamine; EGCG = epigallocatechin-3-
gallate; ThT = thioflavin-T, 2-[4-(dimethylamino)phenyl]-3,6-dimethylbenzothiazolium; CQ, clioquinol, = 5-
chloro-7-iodo-8-hydroxyquinoline; barthophenanthroline = 4,7-diphenyl-1,10-phenanthroline; tacrine = 
1,2,3,4-tetrahydroacridin-9-amine; rivastigmine = 3-(1-(dimethylamino)ethyl)phenyl)ethyl(methyl) 
carbamate; XH1 = N,N-bis[2-[[2-[[4-(2-benzothiazolyl)phenyl]amino]-2-oxoethyl](carboxymethyl)amino] 
ethyl]glycine; HBT = 2-(2-hydroxyphenyl)benzothiazole; L2-b = N1,N1-dimethyl-N4-(pyridin-2-ylmethyl) 
benzene-1,4-diamine; Genistein = 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; Hybrid 5 = 6-
{[10-((6-chloro-1,2,3,4-tacrine)amino)decyl]amino}picolinaldehyde; BTc = 2-(benzo[d]thiazol-2-yl)phenyl 
dimethylcarbamate; IQM-622 : 7-(((((1,2,3,4-tetrahydroacridin-9-yl)amino)methyl)amino)methyl)quinolin-8-
ol; 13k = 5-hydroxy-2-phenyl-7-(3-(4-(3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)piperazin-1-yl) 
propoxy)-4H-chromen-4-one. 
 
The exploration of 8-hyrdoxyquniline (8HQ) derivative, clioquinol (CQ; Figure 
1.4), a U.S. F.D.A. approved lipophilic small molecule that can permeate through the 
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BBB, and its derivative PBT2, has shown their ability to disrupt the interaction between 
metal ions and A, sequester the metal ions and act as an ionophore (transport metal 
ions across the membrane for redistribution.3,83,85,86 Although 8HQ derivatives could not 
directly illustrate the connection between A and metal ions due to the lack of an A 
interaction moiety, it has lead strides in validating the possible metal ion 
dyshomeostasis as a possible therapeutic route.6,85-88 
Advancements in small molecule designs have been made, where a rational 
structure-based approach has been utilized in order to achieve bifunctional or 
multifunctional small molecules (Figure 1.4). Bifunctionality in the framework stems from 
having an A interaction moiety and a metal chelation moiety in one molecule. This 
desired molecular structure can be achieved either via the linkage approach (i.e., 
chelation moiety is appended onto an A interaction moiety by a linker) or the 
incorporation approach (i.e., chelation moiety is directly inserted onto the A interacting 
moiety with minimal change to the core framework) (Figure 1.4). Many chemical tools 
have been developed using known A contrasting agents (e.g., ThT, stilbene) to garner 
the high binding affinity of these ligands toward A species.3,83,87-92 In addition to 
synthesized compounds, natural products, including myricetin and EGCG, have also 
been extensively studied as possible molecular structures that have the ability to 
interact with metal ions and A.83,88,93-97 
Multifunctional small molecules have been pursued as possible AD therapeutics, 
which were influenced by the combination of scaffolds that target two hallmarks of AD: 
Apeptides and loss of ACh.2-4,6,8,98-101 Employing molecular scaffolds inspired by A 
imaging agents, natural products, or other biologically relevant compounds (bifunctional 
small molecules, vide supra), A targeting moieties have been appended onto 
molecular framework that demonstrated AChE inhibiting activities, including currently 
marketed AD drugs (Figure 1.4).101-104 Further development and investigation of these 
small molecules would be valuable in elucidating the inter-relationship between the 
multiple facets observed in AD pathogenesis. 
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1.5. Conclusion 
The intricate collaboration of the different pathological factors in AD adds to the 
disease complexity and poses a challenge in development in effective therapeutic 
drugs. Strides in clarifying the relationship between the multiple neuropathological 
facets have been made; however, only potentially scratching the surface of the enigma 
of AD etiology. Small molecules, with both bifunctional and multifunctional properties, 
have been employed to elucidate how the various pathological features impact the 
onset and progression of AD. The fundamental knowledge gained from these studies 
may allow to: (1) understand what components (i.e., effects toward a particular 
pathological feature) are necessary to develop an effective chemical tool to illustrate the 
interconnection; (2) expedite the discovery of diagnostic tools as well as drugs for AD. 
To fully achieve these goals, complete insight into the processes of A aggregate 
formation and the effects of the interaction of other components (i.e., metal ions, 
proteins) toward disease development is necessary. 
 
1.6. Scope of this thesis 
Pursuit of different molecular scaffold using the synthetic approach discussed 
above, toward targeting and modulating metalA species, in addition to having other 
opportune moieties within one compound, has been carried out. Different structural 
frameworks, such as A imaging agents or natural products, have been employed in 
understanding AD neuropathogenesis, but their application toward metal-associated A 
has been minimally pursued. Furthermore, multifunctional molecules designed to 
understand the correlation between A, metal ions, and/or AChE has recently been 
investigated. As such, the studies presented in this thesis investigate chemical tools that 
may help elucidate the interconnection between the different AD pathogenic factors. 
Chapter 2 details the use of a bifunctional small molecule with diphenylpropynone 
(DPP) scaffold, an A imaging agent, toward metalA species. Subsequently, Chapter 
3 describes modification upon the DPP derivatives, examined in Chapter 2, to improve 
reactivity toward metalA species, lower cytotoxicity, as well as gain an understanding 
of a structure-reactivity-cytotoxicity relationship. Chapter 4 encompasses the 
investigation of the reactivity of GdIIIDTPA-curcumin conjugate (Gd-cur), shown 
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previously to interact with A aggregates, toward metalA species, as a possible 
theranostic tool. Chapter 5 reports reactivity of enediynes (extensively studied potential 
anti-cancer drug)105-107 that contain similar metal chelation moiety to bidentate and 
tetradentate compounds that demonstrate metalA reactivity,88,91,92,108 toward 
metalA. Chapter 6 describes the use of a multifunctional small molecule, containing 
metalA interaction moiety appended onto an AChE inhibitor, to understand the 
interconnection between A, metal ions, and/or AChE. 
Overall, the designed compounds have demonstrated the ability to control metal-
induced A aggregation in vitro, as well as being a potent AChE inhibitor 
(multifunctional small molecule, the hybrid 5; Chapter 6). These studies, motivated by 
the use of rational structure-based design, are promising start in the attempt to 
understand the complex etiology of AD. The present investigations have aided in 
illustrating a structure-interaction-reactivity-cytotoxicity relationship, in addition to setting 
a foundation to illustrate the potential role of metal ions in AD pathology.  
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Chapter 2: Reactivity of Diphenylpropynone Derivatives Toward Metal-
Associated Amyloid- Species  
 
 
 
 
 
 
The results presented in this chapter for diphenylpropynone derivatives were previously 
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2.1. Introduction 
Alzheimer’s disease (AD) is a fatal neurodegenerative disease that affects more 
than 5 million people in the United States.1,2 A pathological hallmark of the diseased 
brain is an accumulation of misfolded amyloid- (A) aggregates.2-8 Monomeric A 
peptides, generated from the proteolytic cleavage of the transmembrane amyloid 
precursor protein, can further aggregate to produce oligomers, protofibrils, and 
eventually fibrils. It is still not completely understood which conformation of A is 
associated with AD neuropathogenesis; however, recent evidence has proposed that 
soluble oligomers might be the toxic species due to their ability to interrupt 
neurotransmission.4,5,9 In addition to A species, elevated concentrations of transition 
metals, such as Fe, Cu, and Zn, have been observed within the deposits of A 
aggregates.2,7,8,10-15 The possible relationship between metal-associated A species 
(metalA species) and neurotoxicity has been suggested based on observations that 
upon binding to A, metal ions facilitate peptide aggregation as well as enhance 
oxidative stress caused by overproduction of reactive oxygen species;2,4,5,7,8,12-21 
however, this connection has not been clearly revealed. 
To gain a better understanding of the involvement of metalA species in AD 
pathogenesis, recent advancements in the development of chemical reagents to 
specifically target metalA species and modulate their interaction and reactivity have 
been made.2,7,8,21-33 Among them, rationally designed small molecules with both metal 
chelation and A interaction properties (defined as bifunctionality) have been devised. 
Some of the compounds have been fashioned based on the incorporation approach 
(Figure 2.1), where a metal chelation site is directly inserted into a known A imaging 
agent with minimal structural modifications, along with consideration of criteria for 
possible brain uptake.8,21-25,27-35 These molecules have been shown to be able to control 
the interactions and reactivity of metalA species in vitro and/or in living cells, 
suggesting that the incorporation approach (Figure 2.1) could be considered as a 
promising design strategy to fashion suitable chemical reagents for uncovering the 
potential role of metalA species in AD development. 
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Herein, we report the design and preparation of a new class of bifunctional small 
molecules (DPP1 and DPP2, Figure 2.1), composed of a diphenylpropynone 
framework, as chemical reagents for targeting and regulating metalA species, the 
characterization of their interactions with metal ions and A species, as well as the 
investigation of their in vitro reactivity with metalA species. From our overall results 
and observations, the diphenylpropynone scaffold could be a structural feature for 
constructing chemical reagents for investigating metalA species. Moreover, the 
dimethylamino functionality in DPP2 was observed to be an important moiety for 
potentially enhancing A interaction of the compound, as reported previously,29,31,36 
offering noticeable reactivity with metalA species.  
 
 
Figure 2.1. Incorporation approach (top) and structures of small molecules (bottom). Left to right: 3-(4-
(dimethylamino)phenyl)-1-(4-iodophenyl)prop-2-yn-1-one; DPP1 = 3-phenyl-1-(pyridin-2-yl)prop-2-yn-1-
one; DPP2 = 3-(4-(dimethylamino)phenyl)-1-(pyridin-2-yl)prop-2-yn-1-one.  
 
2.2. Results and discussion 
 
2.2.1. Design consideration, preparation, and characterization of 
diphenylpropynone derivatives for targeting and modulating metalA species 
The diphenylpropynone scaffold was shown to have high binding affinity (ca. 6 
nM) for A aggregates; thus it has been utilized for the design of an A plaque imaging 
probe (Figure 2.1).37 Based on the incorporation approach, a nitrogen donor atom was 
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installed into this framework to generate a metal chelation site with an oxygen donor 
atom from the carbonyl group, which afforded two bifunctional molecules (DPP1 and 
DPP2, Figure 2.1). Furthermore, a minor structural difference between DPP1 and DPP2 
(i.e., a dimethylamino functionality, suggested to be critical for A interaction)29,31,36 was 
included to understand a structure-reactivity relationship. DPP1 was synthesized as 
previously established.38-40 The new compound, DPP2, was prepared by slight 
modifications to a previously report method (Scheme 2.1).40 
 
Scheme 2.1. Synthesis of DPP2 
 
 
 
To predict potential druglike and BBB penetration properties of the structural 
scaffolds of DPP1 and DPP2, we calculated values of Lipinski’s rules and 
logBB.7,34,35,41,42 As shown in Table 2.1, the theoretical values indicate that both 
compounds are druglike and possibly BBB permeable. To verify this prediction for BBB 
penetration of compounds, we performed in vitro PAMPA-BBB following a previously 
reported procedure.29,41-43 Permeability values (logPe) was measured to be 4.2 (± 0.1) 
for both DPP1 and DPP2 (Table 2.1). On the basis of empirical classification of BBB-
permeable molecules (i.e., verapamil),29,41-43 DPP1 and DPP2 would also be likely to 
cross the BBB. 
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Table 2.1. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe) of DPP1 and 
DPP2. 
Calculationa DPP1 DPP2 
Lipinski’s rules & 
others 
MW 207 250 ≤ 450 
clogP       2.47       2.63 ≤ 5.0 
HBA        2        3 ≤ 10 
HBD        0        0 ≤ 5 
PSA      30.0      33.2 ≤ 90 
logBB        0.0618        0.0390 
< 1.0 (poorly 
distributed in the 
brain. 
logPeb 4.2 ± 0.01 4.2 ± 0.01  
CNS +/ 
Predictionc 
CNS+ CNS+ 
logPe < 5.4 (CNS+) 
           > 5.7 (CNS) 
    
a MW, molecular weight; clogP, calculated logarithm of the octonal-water partition coefficient; HBA, 
hydrogen-bond acceptor atoms; HBD, hydrogen-bond donor atoms; PSA, polar surface area; logBB = 
0.0148 x PSA + 0.152 x clogP + 0.130. b The values of –logPe were measured by the Parallel Artificial 
Membrane Permeability Assay for BBB (PAMPA-BBB). c Compounds categorized as central nervous 
system, CNS+ have the ability to permeate through the BBB and target the CNS. In the case of 
compounds assigned as CNS they have poor permeability through the BBB and therefore, their 
bioavailability into the CNS is considered to be minimal. 
 
Along with BBB permeability, the solution speciation of DPP1 and DPP2 was 
determined through UV-vis variable-pH titration experiments (I = 0.10 M NaCl; room 
temperature; pH 210).27,29-33,44,45 As summarized in Figure 2.2, titration results 
indicated a single acidity constant (pKa) for DPP1 (pKa = 2.035(5)) and two pKa values 
for DPP2 (pKa1 = 7.106(1) and pKa2 = 2.959(4)). These pKa values suggest that 
monoprotonated, diprotonated, and neutral species exist in solution of DPP2 depending 
on pH (from 2 to 10), while the monoprotonated and neutral forms of DPP1 are present 
in this pH range (Figure 2.2). In addition, the generated solution speciation diagrams of 
DPP1 and DPP2 exhibit that their neutral forms are relatively predominant at 
physiologically relevant pH (i.e., 7.4) (DPP1, 100%; DPP2, ca. 65%). 
 
2.2.2. Metal binding properties of DPP1 and DPP2 
Metal binding properties of DPP1 and DPP2 (specifically, Cu2+ and Zn2+) were 
studied by UV-vis and NMR spectroscopy. Upon the addition of CuCl2 (120 equiv) to a 
solution of DPP1 and DPP2 in EtOH, new optical bands were observed, indicative of 
Cu2+ binding to the ligand (Figure 2.3a). In particular, in the presence of Cu2+, DPP2, 
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which has a dimethylamino group, showed a distinguishable optical shift from 407 nm to 
525 nm. NMR was employed to investigate the interaction of DPP1 or DPP2 with Zn2+. 
When 1 equiv of ZnCl2 was introduced in a solution of DPP1 or DPP2 (in CD3CN), 
noticeable downfield chemical shifts of the pyridyl protons were recorded (Figure 2.3b), 
demonstrating that Zn2+ binding to the ligand occurred through the pyridyl N-donor  
 
 
Figure 2.2. Solution speciation studies of DPP1 and DPP2. Top: UV-vis spectra of DPP1 (40 M, left) 
and DPP2 (20 M, right) in the range of pH 210. Middle: Solution speciation diagrams for DPP1 (left) 
and DPP2 (right) (FL = fraction of compound with given protonation). Bottom: Acidity constants (pKa) of L 
(L = DPP1 or DPP2). Charges are omitted for clarity. a Error in the parentheses is shown in the last digit. 
Conditions: I = 0.10 M NaCl; room temperature. 
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atom.45 Overall, both UV-vis and NMR studies confirmed Cu2+ and Zn2+ binding to 
DPP1 and DPP2.To further identify binding stoichiometry and affinity, the solution 
speciation investigation of Cu2+DPP2 complexes was carried out through UV-vis 
variable-pH titration experiments (1:2 [Cu2+]/[DPP2]; I = 0.10 M NaCl, room 
temperature). Based onthe pKa values of DPP2 and these titration results, stability 
constants for the Cu2+DPP2 complexes were obtained (Figure 2.4, M + LH  M(LH) 
(log1 = 12.99(9)); M + L  ML (log2 = 5.85(3)); M = Cu2+, L = DPP2). A solution 
speciation diagram was  
 
Figure 2.3. Cu2+ or Zn2+ binding of DPP1 and DPP2. (a) UV-vis spectra of DPP1 (left) and DPP2 (right) 
with CuCl2 (120 equiv) in EtOH at room temperature (incubation for 2.5 h (for DPP1) and 5 min (for 
DPP2)). (b) 1H NMR spectra of DPP1 (left, black) or DPP2 (right, black) with ZnCl2 (red) in CD3CN at 
room temperature ([compound] = 4 mM; [ZnCl2] = 4 mM). 
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generated from these stability constants, suggesting that the major species at pH 7 are 
a mixture of Cu(LH) and CuL complexes in a ratio of 3:2. Free Cu2+ was shown up to pH 
7, indicating pCu = 6.6 at pH 6.6 (pCu = log[Cuunchelated]) (Figure 2.4).27,29,31-33,44,45 The 
pCu value suggests the approximate dissociation constant (Kd) of Cu2+DPP2 to be ca. 
high nanomolar. When compared to the reported Kd values of Cu2+A (picomolar to 
nanomolar),2,5,7,8,12,14,21 DPP2 may interact with Cu2+ from soluble Cu2+A species. In 
order to test if Cu2+ binding of ligand occurs in the presence of A, a solution containing 
DPP2 with Cu2+-treated A was monitored by UV-vis. The new spectral features that 
coincided with those of the Cu2+DPP2 complex without A were observed, suggesting  
 
 
Figure 2.4. Solution speciation investigation of the Cu2+DPP2 complexes. Top left: UV-vis spectra (pH 
27) of Cu2+DPP2 complexes. ([Cu2+]/[L] = 1:2; [Cu2+]total = 10 M; 7 h incubation with ligand (L) prior to 
pH titration, L = DPP2; room temperature). Top right: Solution speciation diagram of the Cu2+DPP2 
complexes (FCu = fraction of free Cu and Cu complexes). Bottom: Stability constants (log) of the 
Cu2+DPP2 complexes. Charges are omitted for clarity. a Error in the parentheses is shown in the last 
digit. b The species containing CuL2 was introduced into the calculation model yielding a good fit to the 
data. 
 
an interaction of DPP2 with Cu2+ in the presence of A (Figure 2.5), Cu2+ binding of 
DPP2 with A occurred more slowly than that without A, proposing that A might 
interfere with metal binding to the ligand. Taken together, our spectroscopic studies 
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present the capability of DPP1 and DPP2 to chelate Cu2+ and Zn2+, as well as the 
potential interaction of DPP2 with Cu2+ in the presence of A species, which may be 
associated with its noticeable reactivity toward metalA species (vide infra). 
 
 
Figure 2.5. Cu2+ binding studies of DPP2 in the absence and presence of A at pH 6.6. (a) UV-vis 
spectra of A (black), [A + CuCl2] (blue), and [A + CuCl2 + DPP2] (1:1:2 ratio, 30 min to 4h incubation; 
various colors). (b) UV-vis spectra of DPP2 without (orange) and with CuCl2 (green). Conditions: [A] = 25 
M; [CuCl2] = 25 M; [DPP2] = 50 M; 20 mM HEPES, pH 6.6, 150 mM NaCl; room temperature. 
 
The metal selectivity of DPP1 and DPP2 was also determined by competitive 
reactions with Cu2+ over biologically relevant divalent metal ions (Mg2+, Ca2+, Mn2+, 
Fe2+, Co2+, Ni2+, and Zn2+), which was monitored by UV-vis. As depicted in Figure 2.6, 
DPP1 and DPP2 displayed selectivity for Cu2+ over Mg2+, Ca2+, Mn2+, and Zn2+. Binding 
of both ligands to Co2+ and Ni2+ was also observed. Considering the lower abundance of 
Co2+ and Ni2+ than Cu2+ in biological systems,46,47 the overall selectivity of DPP1 and 
DPP2 may be sufficient to be used for targeting and interacting with Cu2+A species in 
heterogeneous biological environments like the brain. 
 
2.2.3. A interaction with DPP1 and DPP2 studied by MS and docking studies 
The interaction of DPP1 and DPP2 with A40 in the absence of metal ions were 
probed by ESI-MS, tuned to preserve noncovalent protein-ligand interactions.48 At a low 
A concentration (10 M), a small signal corresponding to the interaction between 
DPP2 (30 M) and the A monomer in the 3+ charge state could be detected, whereas 
no interaction between DPP1 (60 M) and the peptide was observed under these 
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conditions (Figure 2.7). At high concentrations of the peptide (100 M) and compounds 
(600 M), both DPP1 and DPP2 interacted with A species to different extents (Figure 
2.8a). Data for DPP1 indicated that the molecule interacted broadly with A monomers 
and oligomers in 1:1, 2:1, and 3:1 A to ligand ratios. In the case of DPP2, a stronger 
preference toward larger A oligomers was shown, but with similar stoichiometries as 
DPP1. The total bound intensities recorded from MS data, and those from individual 
oligomeric species were shown in Figure 2.8b and Table 2.2. 
 
 
Figure 2.6. Metal selectivity studies of DPP1 (a and b; 40 M) and DPP2 (c and d; 20 M) in EtOH. Blue 
bars represent the addition of CuCl2 (8) to solutions of the ligand with other divalent metal ions (black 
bars; 1, MgCl2; 2, CaCl2; 3, MnCl2; 4, FeCl2; 5, CoCl2; 6, NiCl2; 7, ZnCl2) in a ratio of 1:1 (a and c) or 1:25 
(b and d) Cu2+ to M2+ followed by 5 min incubation at room temperature. The absorbance at 360 nm (for 
DPP1) and 580 nm (for DPP2) was used for the calculation of AM/ACu. * Indicates that precipitation was 
observed in the solution. 
 
The intensities shown were normalized for both nonspecific interactions and 
artifactual complexes formed during the electrospray process using A:ThT binding data 
as a control, and ion mobility separation was used to separate oligomers that 
overlapped in m/z.6,48,49 From these data, it was clear that, at high concentrations, a 
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higher proportion of DPP1 was bound to A species than DPP2, but that both could be 
classified as having weak A affinity in solution (low mM Kd). Therefore, a weak 
A/compound interaction was captured by MS. Normalized intensity MS data suggest 
that DPP2 binding was almost exclusively driven through A multimer interactions 
(Figure 2.8b). Overall our MS results suggest that although both compounds could 
interact with A species at high concentrations, DPP2 was able to bind A species at 
both low and high concentrations. 
 
 
Figure 2.7. Interactions of (a) DPP1 (60 M) and (b) DPP2 (30 M) with A40 (10 M) determined by 
nano-electrospray ionization-mass spectrometry (nESI-MS). Binding of DPP2 to A monomer was 
observed in a ratio of 3:1 in the 3+ charge state (incubation = 2 h on ice). 
 
To visualize the potential interaction between A and DPP1/DPP2, docking 
studies by AutoDock Vina50 were performed using the previously determined NMR 
structure (PDB 2LFM)51 of A40 monomer. Typically, both compounds were positioned 
between the -helix and the unstructured N-terminal side of A (Figure 2.8c and 2.9). 
Most docked structures showed a nonspecific orientation of the ligand with respect to 
the surface features of A. Our preliminary docking studies support the potential 
interaction of the compounds with A monomer. 
 
2.2.4. Effects of DPP1 and DPP2 on metal-free and metal-induced A aggregation 
in vitro 
Confirming metal binding and A interaction properties (bifunctionality) of DPP1 
and DPP2, their influence on in vitro metal-free and metal-induced A aggregation was 
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studied.26-33 Two different experiments (inhibition and disaggregation) were performed 
to investigate whether DPP1/DPP2 can control the formation of metal-free and metal-
induced A aggregates (inhibition, Figure 2.10) or transform preformed metal-free and 
metal-induced A aggregates (disaggregation, Figure 2.11). Various-sized A species 
from both studies were monitored by gel electrophoresis and SDS-PAGE followed by  
 
 
 
Figure 2.8. Interactions of DPP1 and DPP2 with A. (a) MS data for the complexes of A40 and DPP1 or 
DPP2 ([A] = 100 M; [compound] = 600 M; M = monomer, D = dimer, and T = trimer). Many binding 
stoichiometries were detected, including 1:1 (star), 2:1 (square), and 3:1 (triangle). (b) A histogram 
showing the total bound MS signal intensity, normalized for nonspecific interactions and ESI-MS artifacts, 
for each binding stoichiometry observed in (a). (c) Docking studies of DPP1 (orange) and DPP2 (green) 
with A40 (PDB 2LFM) by AutoDock Vina. Poses for both compounds were overlapped in this 
conformation (other conformations, see Figure 2.9). The helical region of A (H13-D23) is highlighted in 
color (tan) in both the cartoon (top) and surface (bottom) representation. 
 
Western blot with an anti-A antibody (6E10), whereas morphological changes were 
identified by transmission electron microscopy (TEM).26,28-33,52 
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Table 2.2. Raw MS signal intensity data for the interaction of DPP1 or DPP2 with A40. 
 
 
The inhibition studies, as shown in Figure 2.10, demonstrated a different 
reactivity of DPP1 or DPP2 toward metal-induced A species over metal-free 
Aspecies. In the case of metal-involved A aggregation, A species with a wide range 
of MW were indicated with DPP2 for both Cu2+- and Zn2+-treated samples upon longer 
incubation (Figure 2.10a, lanes 6 and 9). In the samples containing DPP1 (lanes 5 and 
8), less intense gel bands were detected across the longer incubation time, suggesting 
that further A aggregation may have occurred. The reaction of DPP1 or DPP2 with 
metal-free A also exhibited a different distribution of various-sized A species (Figure 
2.10a, lanes 2 and 3). A species formed with compounds in both metal-mediated and 
metal-free conditions were not completely denatured by SDS implying that these 
molecules may generate different A assemblies (Figure 2.10b). TEM images of metal-
induced A species incubated with DPP2 for 24 h revealed smaller amorphous 
aggregates compared to DPP1; some of the metal-free A species treated with DPP1 
and DPP2 presented similar morphology to those untreated with compounds (Figure 
2.10c). Overall, DPP1 and DPP2 displayed their ability to recognizably modulate metal-
induced A aggregation to different extents. 
Furthermore, for the disaggregation experiment (Figure 2.11), DPP2-treated 
metal-triggered A aggregates presented different-sized A species than DPP1-treated 
samples, indicating that DPP2 could alter the properties of preformed A aggregates to 
a greater extent than DPP1 (Figure 2.11). In the metal-free conditions, more various-
sized A species were indicated in the presence of DPP2 than DPP1 (in particular, at 4 
h, Figure 2.11, lanes 2 and 3). The A species generated with compounds in both  
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Figure 2.9. Docking studies of DPP1 and DPP2. Cartoon (left) and surface (right) versions of possible 
conformations of DPP1 (orange) and DPP2 (green) docked with A40 (PDB 2LFM) by AutoDock Vina. The 
helical region of A (H13-D23) in the surface representation is highlighted in color (tan) and hydrogen 
bonding is indicated with dashed lines (2.5-2.8 Å). Conformation A is also depicted in Figure 2.8c. 
Bottom: Calculated binding energies of DPP1 and DPP2 to A. 
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metal-triggered and metal-free conditions were relatively stable in the presence of SDS 
(Figure 2.11b). As shown in Figure 2.11c, DPP2 was able to reorganize preformed 
structured metalA aggregates to amorphous species more noticeably than DPP1. 
Taken together, the results from both inhibition and disaggregation experiments 
presented that DPP1 and DPP2 could regulate metal-involved A aggregation over 
metal-free aggregation in vitro differently. Moreover, the structural variation (i.e., 
dimethylamino functionality) may enhance the contact with A species via hydrogen 
bonding and/or hydrophobic interactions,29,31,36 which may afford greater reactivity 
toward metalA species. 
 
2.3. Conclusion 
Following the incorporation approach, we have developed two bifunctional small 
molecules (DPP1 and DPP2) composed of a metal chelation site and 
diphenylpropynone framework (for A interaction), which could possible serve as 
chemical reagents to target and modulate metalA species in vitro. Their bifunctionality 
(metal-chelation and A interaction) was confirmed by physical methods and preliminary 
docking studies. Biochemical and TEM studies revealed that DPP1 and DPP2 could 
modulate metal-induced A aggregation in vitro. Notably, DPP2, which has a 
dimethylamino group, exhibited more apparent reactivity toward metalA species, 
compared to DPP1. This suggests that the interaction and reactivity of molecules with 
metalA species can be tuned by such structural variations, proposing a structure-
interaction-reactivity relationship. DPP1 and DPP2, however, would be limited in their 
biological applications since they displayed cytotoxicity in living cells at low micromolar 
concentrations (Figure 2.12). Overall, the promising in vitro reactivity of these potentially 
BBB-permeable molecules toward metalA species warrants pursuit of structural 
modifications that would improve the viability of diphenylpropynone derivatives in 
biological settings, followed by more detailed characterization by MS and molecular 
modeling. Our studies have demonstrated the capability of two diphenylpropynone 
derivatives to target metalA species and modulate their interaction and reactivity in 
vitro, which can be further optimized toward the development of future chemical 
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Figure 2.10. Inhibition experiment (scheme, top). Analysis of various-sized A species by (a) gel 
electrophoresis and (b) SDS-PAGE (nonreducing conditions) with Western blot using an anti-A antibody 
(6E10). (c) TEM images of the 24 h incubated samples. Conditions: [A] = 25 M; [CuCl2 or ZnCl2] = 25 
M; [compound] = 50 M; pH 6.6 (for Cu2+ samples) or 7.4 (for metal-free and Zn2+ samples); 4, 8, or 24 h 
incubation; 37 °C; constant agitation. 
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Figure 2.11. Disaggregation experiment (scheme, top). Analysis of various-sized A species by (a) gel 
electrophoresis and (b) SDS-PAGE (nonreducing conditions) with Western blot using an anti-A antibody 
(6E10). (c) TEM images of the 24 h incubated samples. Conditions: [A] = 25 M; [CuCl2 or ZnCl2] = 25 
M; [compound] = 50 M; pH 6.6 (for Cu2+ samples) or 7.4 (for metal-free and Zn2+ samples); 4, 8, or 24 h 
incubation; 37 °C; constant agitation.  
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Figure 2.12. Cytotoxicity of DPP1 and DPP2 at various concentrations (24 h incubation) in murine Neuro-
2a neuroblastoma cells, which was determined by a MTT assay. Values of cell viability (%) were 
calculated relative to cells treated with 1% v/v DMSO.  
 
reagents for investigating metalA species in biological systems. 
 
2.4. Experimental section 
 
2.4.1. Materials and procedures 
All reagents were purchased from commercial suppliers and used as received unless 
otherwise stated. The compound, 3-phenyl-1-(pyridin-2-yl)prop-2-yn-1-one (DPP1) was 
prepared following previously reported methods.38-40 A40 (DAEFRHDSGYEVHHQKLV- 
FFAEDVGSNKGAIIGLMVGGVV) was purchased from AnaSpec (Fremont, CA). An 
Agilent 8453 UV-visible (UV-vis) spectrophotometer was used to measure the optical 
spectra. Transmission electron microscopy (TEM) images were recorded with a Philips 
CM-100 transmission electron microscope. A SpectraMax M5 microplate reader 
(Molecular Devices, Sunnyvale, CA) was employed for the measurement of absorbance 
for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Parallel 
Artificial Membrane Permeability adapted for the BBB (PAMPA-BBB) assays. Nuclear 
magnetic resonance (NMR) spectra of small molecules and for Zn2+ binding studies 
were obtained by a Varian 400 MHz NMR spectrometer. Mass spectrometric 
measurements for compounds were conducted by a Micromass LCT Electrospray time-
of-flight mass spectrometer. Mass spectrometric studies for investigating the interaction 
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of DPP1 and DPP2 with the peptide were carried out on a Waters Synapt G2 ion-
mobility mass spectrometer (Milford, MA). 
 
2.4.2. Preparation of 3-(4-(dimethylamino)phenyl)-1-(pyridin-2-yl)-2-propyn-1-one 
(DPP2) 
DPP2 was synthesized by slight modifications to a previously reported procedure 
(Scheme 2.1).40 To a solution of 4’-dimethylaminophenyl acetylene (0.42 g, 2.9 mmol) in 
dry tetrahydrofuran (THF, 5 mL) was added n-butyllithium (0.72 mL, 2.9 mmol, 2.5 M 
solution in hexanes) dropwise by a syringe over 5 min at 40 C. The reaction mixture 
was allowed to stir at 40 C for 10 min and then warmed to 15 C. After 30 min, the 
mixture was cooled to 78 C (dry ice/acetone) and a solution of Weinreb’s amide (0.40 
g, 2.4 mmol in 9 mL of dry THF) was introduced through a syringe. The reaction mixture 
was allowed to react at 78 C for 10 min and then warmed to room temperature and 
followed by 1 h stirring. The reaction was quenched by adding saturated aqueous 
NaHCO3 (2 mL), diluted with EtOAc (10 mL), and washed with brine (2 x 25 mL). The 
aqueous layer was extracted with EtOAc (2 x 15 mL), and the combined organic 
solutions were dried over MgSO4 and filtered, followed by removal of the solvent in 
vacuo. The crude product was purified by silica gel chromatography (CH2Cl2:EtOAc = 
9:1) to yield an orange product (202 mg, 0.81 mmol, 28%). 1H NMR (400 MHz, CDCl3)/ 
(ppm): 8.77 (d, J = 4.8 Hz, 1 H), 8.14 (d, J = 7.6 Hz, 1 H), 7.82 (td, J = 7.6, 1.6 Hz, 1 H), 
7.57 (d, J = 8.4 Hz, 2 H), 7.44 (m, 1 H), 6.59 (d, J = 8.4 Hz, 2 H), 2.98 (s, 6 H). 13C NMR 
(100 MHz, CDCl3)/ (ppm): 177.6, 153.7, 151.8, 149.7, 136.8, 135.6, 126.9, 123.3, 
111.4, 105.5, 100.2, 89.3, 39.9. HRMS: Calcd for [M+H]+, 251.1179; Found, 251.1176. 
 
2.4.3. Parallel Artificial Membrane Permeability Assay adapted for blood-brain 
barrier (PAMPA-BBB) 
PAMPA-BBB experiments were carried out using the PAMPA Explorer kit (Pion 
Inc. Billerica, MA) with modification to previously reported protocols.29,41-43 Each stock 
solution was diluted with pH 7.4 Prisma HT buffer (Pion) to a final concentration of 25 
M (1% v/v final DMSO concentration) and 200 L were added to the wells of the donor 
plate (number of replicates = 12). BBB-1 lipid formulation (5 L, Pion) was used to coat 
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the polyvinylidene fluoride (PVDF, 0.45 M) filter membrane on the acceptor plate. The 
acceptor plate was placed on top of the donor plate forming a sandwich and the brain 
sink buffer (BSB, 200 L, Pion) was added to each well of the acceptor plate. The 
sandwich was incubated for 4 h at ambient temperature without stirring. UV-vis spectra 
of the solutions in the reference, acceptor, and donor plates were measured using a 
microplate reader. The PAMPA Explorer software v. 3.5 (Pion) was used to calculate 
the −logPe for each compound. CNS± designations were assigned by comparison to 
compounds that were identified in previous reports.29,41-43 
 
2.4.4. Determination of solution speciation for DPP1, DPP2, and the Cu2+DPP2 
complex 
The pKa values for DPP1 and DPP2 were determined by UV-vis variable-pH 
titrations based on a previously reported procedure.27,29,31-33,44,45 To establish the pKa 
values, a solution (100 mM NaCl, 10 mM NaOH, pH 12) of DPP1 (40 M) or DPP2 (20 
M) was titrated with small aliquots of HCl. At least 30 spectra were recorded in the 
range of pH 210. Similarly, a solution containing DPP2 (20 M) and CuCl2 in a ratio of 
2:1 was titrated with small additions of HCl and at least 30 spectra were recorded over 
the range of pH 27. The acidity and stability constants were calculated by using the 
HypSpec program (Protonic Software, UK).53 Speciation diagrams for DPP1, DPP2, and 
Cu2+–DPP2 complexes were modeled using the HySS2009 program (Protonic 
Software).54 
 
2.4.5. Metal binding studies 
The interaction of DPP1 and DPP2 with Cu2+ and Zn2+ was determined by UV-vis 
and 1H NMR spectroscopy, respectively, based on previously reported procedures.28-
33,45 A solution of ligand (20 M in EtOH) was prepared, treated with 1 to 20 equiv of 
CuCl2, and incubated at room temperature for 2.5 h (for DPP1) or 5 min (for DPP2). The 
optical spectra of the resulting solutions were measured by UV-vis. The interaction of 
DPP1 or DPP2 with ZnCl2 was observed by 1H NMR. ZnCl2 (1 equiv) was added to a 
solution of DPP1 or DPP2 (4 mM) in CD3CN. The metal selectivity of both compounds 
was investigated by measuring the optical changes upon addition of 1 equiv of CuCl2 to 
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a solution of ligand (DPP1 = 40 M; DPP2 = 20 M in EtOH) containing 1 equiv or 25 
equiv of a divalent metal chloride salt (MgCl2, CaCl2, MnCl2, FeCl2, CoCl2, NiCl2, or 
ZnCl2). The Fe2+ samples were prepared anaerobically (all solutions were purged with 
N2). Quantification of the metal selectivity was calculated by comparing and normalizing 
the absorption values of metalligand complexes at  = 360 nm (for DPP1) or 580 nm 
(for DPP2) to the absorption at this wavelength before and after the addition of CuCl2 
(AM/ACu). Cu2+ binding of DPP2 in the presence of A was examined by UV-vis. A (25 
M) was treated with CuCl2 (25 M) in 20 mM HEPES (2-[4-(2-hydroxyethyl)piperazin-
1-yl]ethanesulfonic acid), pH 6.6, 150 mM NaCl for 2 min at room temperature. DPP2 
(50 M) was added to the resulting solution, followed by 0.54 h incubation. For 
comparison, the optical spectra of DPP2 (50 M) were measured in the absence and 
presence of CuCl2 (25 M; 0.54 h incubation) without A at pH 6.6. 
 
2.4.6. A interaction of DPP1 and DPP2 by mass spectrometry  
The interaction of DPP1 or DPP2 with A40 was investigated by nanoelectrospray 
ionization-mass spectrometry (nESI-MS) that was carried out on a Synapt G2 
quadrupole-ion mobility-mass spectrometry system. Samples were prepared by mixing 
stock solutions of DPP1 or DPP2 (prepared in DMSO) and A40 (dissolved in 100 mM 
ammonium acetate, pH 6.8) to generate desired final concentrations of the peptide and 
the compound. Mixtures were incubated on ice or at room temperature for 2 or 4 h, 
respectively and then analyzed. To produce protein complex ions, an aliquot of the 
sample (ca. 5 L) was sprayed from the nESI emitter using a capillary voltage of 1.4 kV, 
with the source operating in positive ion mode and the sample cone operated at 50 V. In 
order to normalize nESI-MS data for non-specific and electrospray artifact interactions 
which could occur at high concentrations, data were acquired for A samples containing 
thioflavin-T (ThT), a compound known to have no affinity for soluble forms of the A 
peptide,55 under identical concentration conditions as our DPP1 and DPP2 experiments. 
Any ThT binding observed was assumed to be due to either non-specific binding or the 
electrospray process, and subtracted from the intensities of the DPP1 and DPP2 
interactions observed.56 This procedure was performed over a broad range of 
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concentrations. The mass spectra were acquired with the following settings and tuned 
to avoid ion activation and to preserve non-covalent protein–ligand complexes:48 
backing pressure, 7.3 mbar; IMS pressure reading, 3.09 mbar; ToF analyzer pressure, 
1.14 × 10−6 mbar. 
 
2.4.7. Docking studies 
Flexible ligand docking studies using AutoDock Vina50 for DPP1 and DPP2 were 
conducted against the A40 monomer from the previously determined aqueous solution 
NMR structure (PDB 2LFM).51 Ten conformations were selected from 20 conformations 
within the PDB file (1, 3, 5, 8, 10, 12, 13, 16, 17, and 20). The MMFF94 energy 
minimization in ChemBio3D Ultra 11.0 was used to optimize the structures of the 
ligands for the docking studies. The structural files of DPP1, DPP2, and the peptide 
were generated by AutoDock Tools and imported into PyRx,57 which was used to run 
AutoDock Vina. The search space dimensions were set to contain the entire peptide. 
The exhaustiveness for the docking runs was set at 1024. Docked poses of the ligands 
were visualized with A using Pymol. 
 
2.4.8. Amyloid- (A) peptide 
A40 was used in all A experiments. A40 peptide (1 mg) was dissolved with 
ammonium hydroxide (NH4OH, 1% v/v, aq), aliquoted, lyophilized, and stored at 80 C. 
A stock solution (ca. 200 M) was prepared by redissolving A with NH4OH (1% v/v, aq, 
10 L) followed by dilution with ddH2O. All A solutions were prepared following 
previously reported procedures.28-32 The buffered solutions (20 M HEPES, pH 6.6 (for 
Cu2+ samples) or pH 7.4 (for metal-free and Zn2+ samples), 150 M NaCl) were used for 
both inhibition and disaggregation studies. For the inhibition experiment, A (25 M) 
was first treated with a metal chloride salt (CuCl2 or ZnCl2, 25 M) for 2 min followed by 
addition of a compound (DPP1 or DPP2, 50 M in DMSO, 1% v/v final DMSO 
concentration). The resulting samples were incubated at 37 C for 4, 8, or 24 h with 
constant agitation. For the disaggregation experiment, A and a metal chloride salt 
(CuCl2 or ZnCl2) were initially incubated at 37 C for 24 h with steady agitation. The 
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compound was added afterwards followed by additional 4, 8, or 24 h incubation at 37 C 
with constant agitation. 
 
2.4.9. Gel electrophoresis/sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) with Western blot 
The A peptide experiments (as described above) were analyzed by both gel 
electrophoresis and SDS-PAGE with Western blot using an anti-A antibody (6E10).28-
32,52 Each sample containing 25 M A (10 L) was separated using either a 1020% 
gradient Tris-tricine gel (Invitrogen, Grand Island, NY) or SDS gel (4% stacking gel; 
10% resolving gel; non-reducing conditions). The gel was transferred to a nitrocellulose 
membrane and blocked overnight with bovine serum albumin (BSA, 3% w/v, Sigma, St. 
Louis, MO) dissolved in Tris-buffered saline (TBS, Fisher, Pittsburg, PA) containing 
0.1% Tween-20 (TBS-T, Sigma). The membrane was treated with 6E10 (1:2,000; 2% 
BSA in TBS-T, Covance, Princeton, NJ) for 4 h at room temperature. The membrane 
was probed with a horseradish peroxidase-conjugated goat anti-mouse secondary 
antibody (1:5,000; Cayman Chemical, Ann Arbor, MI) in 2% BSA in TBS-T solution for 1 
h at room temperature. The protein bands were visualized using the Thermo Scientific 
Supersignal West Pico Chemiluminescent Subtrate (Rockford, IL). 
 
2.4.10.  Transmission electron microscopy (TEM) 
Samples for TEM were prepared following a previously reported method.28-31,33,52 
Glow-discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, 
Hatfield, PA) were treated with samples from either inhibition or disaggregation 
experiments (5 L) for 2 min at room temperature. Excess sample was removed with 
filter paper and washed with ddH2O five times. Each grid was stained with uranyl 
acetate (1% w/v, ddH2O, 5 L) for 1 min. Uranyl acetate was blotted off and grids were 
dried for 15 min at room temperature. Images of samples were taken by a Philips CM-
100 transmission electron microscope (80 kV, 25,000x magnification). 
 
2.4.11.  Cytotoxicity (MTT Assay) 
The murine neuro-2a (N2a) neuroblastoma cell line was purchased from the 
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American Type Culture Collection (ATCC, Manassas, VA). The cell line was maintained 
in media containing 45% Dulbecco’s modified Eagle’s medium (DMEM) and 50% OPTI-
MEM (GIBCO), supplemented with 5% fetal bovine serum (FBS, Sigma), 2 mM 
glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (GIBCO). The cells were 
grown and maintained at 37 °C in a humidified atmosphere with 5% CO2. Cell viability 
upon treatment of compounds was determined using the MTT assay (Sigma). N2a cells 
were seeded in a 96 well plate (15,000 cells in 100 L per well) and treated with various 
concentrations of DPP1 and DPP2 (250 M, final 1% v/v DMSO). After 24 h incubation 
at 37 °C, 25 L MTT (5 mg/mL in phosphate buffered saline, PBS, GIBCO, pH 7.4) was 
added to each well and the plates were incubated for 4 h at 37 °C. Formazan produced 
by the cells was dissolved by addition of a solution (100 L) containing N,N-
dimethylformamide (DMF, 50% v/v, aq, pH 4.5) and sodium dodecyl sulfate (SDS, 20% 
w/v) overnight at room temperature. A microplate reader was used to measure the 
absorbance (A600).  
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Chapter 3: Tuning Reactivity of Diphenylpropynone Derivatives with Metal-
Associated Amyloid- Species via Structural Modifications 
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3.1. Introduction  
Alzheimer’s disease (AD) is a global economic and social issue, currently 
affecting 5.4 million Americans and an estimated 24 million people worldwide.1 To date, 
there is no known cure for AD and prevailing treatments only offer symptomatic relief for 
a short duration of time.2-6 Recently, a particular emphasis has been placed on 
therapeutics for misfolded amyloidogenic peptides, amyloid- (A) peptides, commonly 
found in AD brains.2-7 The etiology of AD, however, remains elusive due to the 
complexity emerging from the limited understanding of pathological features. The role of 
A itself and its potential inter-relationships with other multiple factors, such as metal ion 
dyshomeostatsis and oxidative stress, have been suggested.2-4,5,6,8 Interactions 
between metal ions (e.g., Cu2+ and Zn2+) and A have been demonstrated to facilitate 
peptide aggregation and enhance oxidative stress via generation of reactive oxygen 
species.2,3,6,8,9 The involvement of metal-associated A(metalA) species in the onset 
and progression of AD, however, has been unclear and contentious, due to the limited 
availability of suitable chemical reagents to target metalA species and probe their link 
to neurotoxicity. 
In order to elucidate potential associations of metalA species with AD 
pathogenesis, recent efforts have been made toward the development of chemical 
reagents to target metalA species, control the interactions between metal ions and A 
species, and alter their reactivities (e.g., metal-triggered A aggregation).3,6,9,10 The 
structures of these reagents are rationally selected to achieve both metal chelation and 
A interaction (bifunctionality).11-16 Recently, a diphenylpropynone derivative (DPP2) 
was constructed through a rational structure-based design principle (incorporation 
approach), where a metal chelation site was directly installed into an A interacting 
framework with minimal structural modifications (Figure 3.1).16 DPP2, with a 
dimethylamino functionality, has demonstrated the ability to control both metal-free and 
metal-induced A aggregation in vitro to different extents; however, due to its 
cytotoxicity, it could be only implemented for in vitro applications.16 Further 
investigations on the structural modifications of DPP2 would be valuable to improve its 
reactivity toward metal-free and metal-associated A species and cytotoxicity, as well 
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as to establish a relationship between chemical structures, reactivity with A and 
metalA species, and toxicity in cells. Thus, we present the design, preparation, 
characterization, and in vitro metal-free and metal-associated A reactivity of a 
structurally modified DPP2 series (C1/C2, P1/P2, and PA1/PA2, Figure 3.1). The 
results and observations presented in this study illustrate that our structural variations 
on DPP2 were shown to (i) tune metal binding and A interaction properties of small 
molecules, thus altering their influence on both metal-free and metal-induced A 
aggregation in vitro; (ii) reduce their cytotoxicity; and (iii) maintain their potential BBB 
permeability. 
 
 
Figure 3.1. A class of DPP derivatives (C1/2, P1/2, and PA1/2). Chemical structures of chalcone 
derivative ([125I]-(E)-3-(4-(dimethylamino)phenyl)-1-(4-iodophenyl)prop-2-en-1-one), DPP2 (3-(4-
(dimethylamino)phenyl)-1-(pyridin-2-yl)prop-2-yn-1-one), L2-b (N1,N1-dimethyl-N4-(pyridin-2-ylmethyl) 
benzene-1,4-diamine), C1 ((E)-3-phenyl-1-(pyridin-2-yl)prop-2-en-1-one), C2 ((E)-3-(4-(dimethylamino) 
phenyl)-1-(pyridine-2-yl)prop-2-en-1-one), P1 (3-phenyl-1-(pyridin-2-yl)propan-1-one), P2 (3-(4-(dimethyl 
amino)phenyl)-1-(pyridin-2-yl)propan-1-one), PA1 (N-phenylpicolinamide), and PA2 (N-(4-(dimethyl 
amino)phenyl)picolinamide). Atoms for potential metal binding are highlighted in blue. The green box 
indicates metal chelation site from DPP2. 
 
3.2. Results and discussion 
 
3.2.1. Design consideration and preparation of C1/2, P1/2, and PA1/2 
A small molecule, DPP2, has been observed to target A and metalA species 
and noticeably modulate metal-free and metal-induced A aggregation in vitro to 
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different extents; however, it presented cytotoxicity at low micromolar concentrations.16 
A series of compounds (C1/C2, P1/P2, and PA1/PA2, Figure 3.1) were designed based 
on the structural modifications of DPP2 in order to improve its reactivity with A and 
metalA species, mitigate its cytotoxicity, as well as to establish a structure-reactivity-
cytotoxicity relationship. For the design of the compounds, the structural portion of 
DPP2 for metal chelation, 2-pyridyl ketone,16 was first retained in these frameworks 
(Figure 3.1). Metal chelation of C1/C2 and P1/P2 could occur through nitrogen and 
oxygen (N/O) donor atoms from 2-pyridyl ketone, while in PA1/PA2, N/O (2-pyridyl 
ketone) or N/N (pyridine and amide) donor atoms may be involved in metal binding.17 
Secondly, the triple bond with a carbonyl group (ynone) in DPP2, which may act as a 
Michael acceptor and cause cytotoxicity,18-20 was modified (i.e., reduction or derivation 
of the triple bond; Figure 3.1).  
 
Scheme 3.1. Synthetic routes of C1/2, P1/2, and PA1/2 
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This structural alteration could vary overall structural rigidity. C1/C2 were produced by 
reduction of the triple bond to a double bond; the backbone of C1/C2 was also found in 
the framework of an A imaging agent, which is a chalcone derivative (Figure 3.1).21 For 
P1/P2, the double bond was further reduced to a single bond. PA1/PA2 were fashioned 
through combining the 2-pyridyl ketone moiety from DPP2 and the aniline portion from 
L2-b via an amide moiety instead of the carbon linker shown in DPP2, C1/C2, and 
P1/P2. Similar to DPP2, L2-b (Figure 3.1) was previously designed to serve as a 
potential chemical reagent to investigate metalA species in vitro and in living cells.13 
Lastly, a dimethylamino group, suggested to be important for A interaction,13,16,22 was 
incorporated into the frameworks of C2, P2, and PA2. For preparation, C1/C2 and 
PA1/PA2 were synthesized based on previously reported methods with modifications 
(Scheme 3.1).23-26 P1/P2 were generated through the selective hydrogenation of C1/C2 
in the presence of 10 wt % Pd/C (Scheme 3.1). 
 
3.2.2. Effects of C1/2, P1/2, and PA1/2 on metal-free and metal-induced A 
aggregation in vitro 
In order to understand the effect of structural variations on compound reactivity 
toward metal-free and metal-inducedAaggregation, inhibition (Figure 3.2) and 
disaggregation (Figure 3.3) studies were conducted. Size distributions and 
morphologies of the resulting A species from the two experiments were monitored by 
gel electrophoresis followed by Western blot with an anti-A antibody (6E10) and TEM, 
respectively.12-16,27  
The influence of C1/C2, P1/P2, and PA1/PA2 on formation of metal-free and 
metal-treated A aggregates was first examined (inhibition studies, Figure 3.2). Among 
these compounds, C2 demonstrated the greatest reactivity with metal-free and metal-
associated A species to different extents, as confirmed by gel analysis. From metal-
free A aggregation with C2 treatment, a wide molecular weight (MW) distribution of A 
species was observed (Figure 3.2a, left, lane 3), which was also enhanced with 
prolonged incubation. Moreover, TEM images, obtained from the sample incubated with 
C2 for 24 h (without metal ions), revealed thinner fibrils with diverse lengths compared 
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to those generated under compound-free conditions (Figure 3.2b). In the case of metal-
induced A aggregation, C2 presented differences in control of A aggregate formation 
in the reaction with Cu2+A over that with Zn2+A. Upon treating Cu2+A species with 
C2, various-sized A species were visualized by gel electrophoresis (Figure 3.2a, lane 
6); while species (MW ≤ 25 kDa) were exhibited from the sample containing A, Zn2+, 
and C2 (Figure 3.2a, lane 9). The modulation of A aggregation by C2 in the absence 
and presence of metal ions was also distinguished by TEM. A mixture of fibrils and  
 
 
Figure 3.2. Inhibition experiment: modulation of A aggregate formation in the absence and presence of 
metal ions (scheme, top) by C1/2, P1/2, and PA1/2. (a) Analysis of the size distribution of the resulting A 
species by gel electrophoresis with Western blot using an anti-A antibody (6E10). (b) Visualization of the 
morphologies of the A species from samples that were incubated with C1 or C2 for 24 h by TEM. 
Conditions: [A] = 25 M; [CuCl2 or ZnCl2] = 25 M; [compound] = 50 M (compound = C1/2, P1/2, or 
PA1/2; pH 6.6 (for Cu2+ samples) or 7.4 (for metal-free and Zn2+ samples); various inhibition time; 37 °C; 
constant agitation. 
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amorphous aggregates (mainly, unstructured A species) was detected in metal-treated 
conditions, whereas fibrils were mostly indicated from metal-free analogues. 
As shown in Figure 3.2, alterations in structural scaffold differentiated reactivity 
toward A aggregation (with and without metal ions). First, C1, which does not contain a 
dimethylamino group on the backbone compared to that of C2 (Figure 3.1), did not 
significantly regulate the generation of A aggregates (Figure 3.2a, left, lanes 2, 5, and 
8). Second, as the carboncarbon triple bond (CC) between two structural moieties (2-
pyridyl ketone and dimethylaniline) in DPP216 was reduced to a double bond (CC) in 
C2 (Figure 3.1), reactivity was changed toward A aggregation in the absence and 
presence of metal ions. Under metal-free conditions, C2 afforded A species with a 
diverse range of MW starting from 4 h24 h, while DPP2 exhibited less control on A 
aggregation as time progressed.16 Cu2+-containing samples presented A species with 
a various distribution of MW after 24 h with C2 and DPP2.16 Notably, this reactivity was 
more apparent with C2 at early time period. A aggregates < 25 kDa were indicated 
over time when treated with Zn2+ and C2. A species (MW ≤ 25 kDa) were also 
observed in the case of DPP2 at a short incubation time (e.g., 4 h), yet species showing 
different sizes were yielded after 24 h.16 Third, upon substitution of the double bond in 
C2 to a single bond in P1/P2 (Figure 3.1), reactivity toward metal-free and metal-
triggered A aggregation disappeared (Figure 3.2a, middle). Lastly, for PA1/PA2, 
composed of 2-pyridyl ketone and an aniline portion via an amide linkage (Figure 3.1), 
some reactivity was detected toward Cu2+-treated A species after 24 h incubation 
(Figure 3.2a, right, lanes 5 and 6). In addition, PA2, which has a dimethylamino 
functionality, showed slight modulation of Zn2+-induced A aggregation after 24 h 
(Figure 3.2a, right, lanes 9). In contrast to their reactivity toward metalA, PA1/PA2 did 
not display any significant influence on metal-free A species even with longer 
incubation time. This general reactivity of PA1/PA2 was distinct from that of DPP216 or 
C2. 
Moreover, transformation of preformed metal-free and metal-induced A 
aggregates by C1/C2, P1/P2, or PA1/PA2 was also investigated (disaggregation 
studies, Figure 3.3). Upon incubation of these compounds, similar size distributions of 
 
55 
 
resulting A aggregates were confirmed by gel electrophoresis in comparison to those 
shown in the inhibition experiment (Figures 3.2 and 3.3). In particular, C2 was able to 
noticeably disassemble preformed metal-free and metal-mediated A aggregates 
(Figure 3.3a). A species generated from the disaggregation experiment employing C2 
displayed an array of MW and morphologies analogous to those in the inhibition studies  
 
 
 
Figure 3.3. Disaggregation experiment: disassembly of preformed, metal-free or metal-induced A 
aggregates by C1/2, P1/2, or PA1/2 (scheme, top). (a) Analysis of the size distribution of resulting A 
species by gel electrophoresis with Western blot (anti-A antibody, 6E10). (b) TEM images of the 24 h 
samples containing C1 or C2 from (a). Conditions: [A] = 25 M; [CuCl2 or ZnCl2] = 25 M; [compound] = 
50 M (compound = C1/2, P1/2, or PA1/2); pH 6.6 (for Cu2+ samples) or 7.4 (for metal-free and Zn2+ 
samples); various inhibition time; 37 °C; constant agitation. 
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(Figures 3.2 and 3.3). The samples containing metal-treated A species followed by 
addition of DPP216 were visualized to have relatively more dispersion in MW than those 
with C2. In the metal-free condition, however, diverse-sized A species were exhibited 
over longer incubation only in the presence of C2. As observed in inhibition studies, C1 
and P1/P2 were not able to influence the disassembly of preformed A aggregates in 
both metal-absent or metal-present cases; the modulation of these peptide aggregates 
was indicated with PA1/PA2 only after 24 h. Thus, structural variations, such as the 
introduction of flexibility into the framework and/or incorporation of a dimethylamino 
moiety, afforded altered reactivity with metal-free and metal-treated A species in both 
inhibition and disaggregation studies. Both experiments suggest that C2, with a double 
bond replacing the triple bond in DPP2,16 displayed the greatest control in regulating A 
aggregate generation as well as disassembling preformed A aggregates (in both 
absence and presence of metal ions) to varying degrees in vitro. Furthermore, the 
backbones of P and PA, designed by further modification of the double bond in C2 to a 
single bond and an amide bond, respectively, presented no or slight modulation on the 
formation or disaggregation of metal-free or metal-induced A aggregates. Taken 
together, results and observations from both inhibition and disaggregation experiments 
imply that structural features, such as scaffold rigidity and substituents, may be 
essential for directing in vitro reactivity of small molecules toward metal-free and metal-
induced A aggregation. 
 
3.2.3. Metal binding properties of C1/2, P1/2, and PA1/2 
To investigate the effect of structural variation on metal binding properties of 
C1/C2, P1/P2, and PA1/PA2 (containing a similar putative metal chelation site as 
DPP2, 2-pyridyl ketone16), the ability of C1/C2, P1/P2, or PA1/PA2 to bind Cu2+ and 
Zn2+ was first examined by UV-vis and 1H NMR spectroscopy, respectively (Figures 3.4 
and 3.5). As shown in Figure 3.4, changes in UV-vis spectra (i.e., new optical bands 
and/or change in absorbance intensity) were exhibited upon treatment of CuCl2 (15 
equiv) with C1/C2, P1/P2, or PA1/PA2 in EtOH, indicating Cu2+ interaction of these 
compounds. Noticeable optical shifts from ca. 431 nm and 332 nm to 564 nm and 408 
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nm were detected after CuCl2 treatment of C2 and PA2, respectively. In addition to Cu2+ 
coordination, Zn2+ binding of C1/C2, P1/P2, and PA1/PA2 were studied by 1H NMR  
 
 
 
Figure 3.4. Cu2+ binding studies of C1/2, P1/2, and PA1/2. UV-vis spectra of (a) C1 and C2, (b) P1 and 
P2, and (c) PA1 and PA2 with CuCl2 (1-5 equiv) in EtOH. Conditions: [C1 or C2] = 20 M; [P1/P2 or 
PA1/PA2] = 50 M; room temperature; incubation for 2 or 10 min. 
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(Figure 3.5). NMR was employed for Zn2+ binding studies due to the lack of significant 
optical changes of these ligands with ZnCl2. The introduction of 13 equiv of Zn2+ to a  
 
 
 
Figure 3.5. Zn2+ binding studies of C1/2, P1/2, and PA1/2 by 1H NMR spectroscopy in CD3CN at room 
temperature. NMR spectra of (a) C1 (black, 2 mM) with ZnCl2 (red, 5 mM), (b) C2 (black, 4 mM) with 
ZnCl2 (red, 12 mM), (c) P1 (black, 4 mM) with ZnCl2 (red, 8 mM), (d) P2 (black, 4 mM) with ZnCl2 (red, 8 
mM), (e) PA1 (black, 8 mM) with ZnCl2 (red, 14 mM), and (f) PA2 (black, 8 mM) with ZnCl2 (red, 13 mM). 
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CD3CN solution of C1/C2, P1/P2, or PA1/PA2 resulted in downfield chemical shifts of 
the pyridyl protons, demonstrating the involvement of the N donor atom from the 
pyridine ring (Figure 3.1) for Zn2+ binding. Moreover, the  and  protons of C1/C2 and 
P1/P2 displayed chemical shifts with Zn2+ treatment, which indicated that the O donor 
atom of the carbonyl group may also be associated in Zn2+ binding. In PA1/PA2, the  
 
 
Figure 3.6. Solution speciation studies of C1/2, P1/2, and PA1/2. UV-vis variable-pH titration spectra (left) 
and solution speciation diagrams (right) of (a) C1 and C2 (pH 210), (b) P1 and P2 (pH 210), (c) PA1 
and PA2 (pH 110) (FL = fraction of species at the given pH). Acidity constants (pKa) of L (L = C1/2, P1/2, 
or PA1/2) are summarized in the table. Conditions: [L] = 20 M (L = C1 or C2) or 50 M (L = P1, P2, PA1, 
or PA2); I = 0.10 M NaCl; room temperature. Charges are omitted for clarity. a The error in the last digit is 
shown in the parentheses. 
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amide proton shifted upfield and sharpened in the presence of Zn2+, suggesting that the 
N donor atom of the amide moiety may be involved in metal coordination.28,29 Overall, 
C1/C2, P1/P2, and PA1/2, generated via structural modification from DPP2, were able 
to bind to metal ions, such as Cu2+ and Zn2+, possibly through the N and/or O donor 
atoms, similar to DPP2.16 
To understand solution speciation of our chemical series in the absence and 
presence of Cu2+, UV-vis variable-pH titration experiments were conducted.11,13,16 
Spectrophotometric titrations of compounds, C1/C2, P1/P2, and PA1/PA2, were first 
performed to estimate the acidity constant (pKa) values (Figure 3.6; C1, pKa = 2.57(4); 
C2, pKa1 = 3.23(1), pKa2 = 4.00(1); P1, pKa = 2.59(5); P2, pKa1 = 2.44(2), pKa2 = 5.40(4); 
PA1, pKa = 1.69(9); PA2, pKa1 = 1.38(5), pKa2 = 4.91(8)). The diagrams depicted based 
on acidity constants indicated the presence of two forms of ligand (neutral and 
monoprotonated species; L and LH; L = C1, P1, and PA1; pKa: protonation of the pyridyl 
N), as well as three forms of ligand (neutral, monoprotonated, and diprotonated species; 
L, LH, and LH2; L = C2, P2, and PA2; pKa1: protonation of the pyridyl N, pKa2: 
protonation of the dimethylamino N) (Figure 3.6). The pKa2 values of C2, P2, and PA2 
are lower than that of DPP2 (pKa2 = 7.01(6)),16 which implies that neutral species would 
be present in a greater magnitude at a physiologically relevant pH (i.e., 7.4). Overall, all 
six compounds are expected to mainly exist in the neutral form at pH 7.4, suggesting 
their potential penetration through the blood-brain barrier (BBB; vide infra).13,16,30-32 
Through solution speciation experiments of C2/P2/PA2 in the presence of CuCl2, 
their Cu2+ binding stochiometries, affinities, and the distribution of Cu2+ligand species 
were investigated (Figure 3.7).11,13,16 Based on the measured pKa values of ligands 
above, the stability constants (log) of Cu2+C2/P2/PA2 complexes were first 
determined (Figure 3.7; Cu + LH  Cu(LH) (log1); Cu + L  CuL (log2); Cu + 2L 
 CuL2 (log3); for C2, log1 = 8.73(0), log2 = 5.62(8); for P2, log1 = 6.50(1), log2 
= 3.76(9); for PA2, log1 =7.76(9), log2 = 4.17(7), log3 = 3.86(5)). Based on log 
values, greater stability of Cu2+ligand complexes was shown in the order of C2, PA2, 
and P2. Second, solution speciation diagrams were also modeled using these stability 
constants, indicating that (i) complexation occurred between Cu2+ and ligand in mainly  
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Figure 3.7. Solution speciation studies of the Cu2+C2, Cu2+P2, and Cu2+PA2 complexes. UV-vis 
variable-pH spectra (left) and solution speciation diagrams (right) of (a) Cu2+C2 (pH 27), (b) Cu2+P2 
(pH 27), and (c) Cu2+PA2 (pH 17) (FCu = fraction of free Cu and CuL complexes at the given pH). 
Conditions: [Cu2+]/[L] = 1:2, [L] = 20 M (L = C2) or 50 M (L = P2 or PA2); incubation of ligand with Cu2+ 
for 30 min (L = C2 and PA2) or 2 h (L = P2) prior to pH titration; room temperature. Stability constants 
(log) of CuL complexes are summarized in the table. Charges are omitted for clarity. a The error in the 
last digit is shown in the parentheses. 
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1:1 ratio (Cu:L; L = C2, P2, or PA2), (ii) free Cu2+, CuL and Cu(LH) complexes were 
present in the solution containing Cu2+ and L (L = C2 or PA2), and (iii) free Cu2+ and 
CuL complexes were shown in the sample of P2. At pH 7,33 the complexes of CuL were 
present in solution at ca. 80%, 20%, and 40% for C2, P2, and PA2, respectively. From 
the diagrams, the values of pCu (pCu = –log[Cuunchelated]) of these compounds were also 
calculated to be 5.79, 4.70, and 4.81 at pH 6.634-36 for C2, P2, and PA2, respectively. 
Thus, the approximate dissociation constants (Kd ≈ [Cuunchelated]) for C2, P2, and PA2 
with Cu2+ were predicted to be in the micromolar range, making them slightly weaker 
metal chelators compared to DPP2 (pCu  = 6.6, ca. low micromolar).16  
 
 
 
Figure 3.8. Metal selectivity studies of C1 (a, 20 M), C2 (b, 20 M), P1 (c, 50 M), (d) P2 (50 M), (e) 
PA1 (50 M), and PA2 (f, 50 M) in EtOH. Green bars represent the addition of CuCl2 (8) to solutions 
containing the ligand and another divalent metal ion (grey bars; 1, MgCl2; 2, CaCl2; 3, MnCl2; 4, FeCl2; 5, 
CoCl2; 6, NiCl2; 7, ZnCl2) in a ratio of 1:1 (left) and 25:1 (right) MCl2:CuCl2 followed by 5 min incubation at 
room temperature. Absorbance at 400 nm (for C1), 650 nm (for C2), 320 nm (for P1), 300 nm (for P2), 
350 nm (for PA1), and 480 nm (for PA2) were used for the calculation of AM/ACu. The observed higher 
absorbance after Cu2+ addition to solution containing ligand and another metal ion compared to that of the 
control (ligand and Cu2+ only) may be due to the absorbance from ligand binding to another metal ion at 
the wavelength selected for analysis. * Indicates precipitation in the solution or interference with 
unidentified species in spectra.  
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Different Cu2+ binding affinities of our ligands could be resulted from the influence of 
electron density on the donor atoms for metal binding through structural variations (e.g., 
structural moieties between the 2-pyridyl ketone and aniline portions). Higher binding 
ability of DPP2 and C2 for Cu2+ in comparison with those of P2 and PA2 as well as 
Ainteraction properties may direct their ability to modulate Cu2+-induced 
Aaggregation. 
Furthermore, potential selectivity of C2, P2, and PA2 for Cu2+ over other 
biologically relevant divalent metal ions (Mg2+, Ca2+, Mn2+, Fe2+, Co2+, Ni2+, and Zn2+) 
was studied by competition reactions which were monitored by UV-vis. As depicted in 
Figure 3.8, at an equimolar concentration of another metal ion and Cu2+, the spectral 
changes after Cu2+ addition indicated possible binding of compounds to Cu2+ in the 
presence of other divalent metal ions, similar to DPP2.16 Moreover, these results may 
suggest a slightly higher selectivity for Cu2+ by C2, P2, and PA2 in the solution 
containing CoCl2 or NiCl2, compared to DPP2.16 At a supramolar ratio of another 
divalent metal ion to Cu2+ (25:1), P2 appeared to be more selective for Cu2+ than C2 
and PA2. 
 
3.2.4. Interaction of C1/2 with A species monitored by isothermal titration 
calorimetry (ITC)
In order to shed some light on possible interactions of C1/C2, P2, PA2, and 
DPP2 with A40, ITC experiments were performed following previously reported 
methods.37 Measured heat changes during the titration indicated potential interaction of 
our compounds with A.38 The titration data for C1 and C2 were fitted using a one-site 
binding model, while the data for DPP2 were fitted with a sequential binding model 
(Figure 3.9). Based on the binding models, the best-fit values [binding stoichiometries 
(N), binding constants (KA), enthalpy changes (ΔH), and Gibbs free energy (ΔG)] of 
these molecules were determined (Table 3.1). The binding affinities of all three ligands 
with A were estimated to be in the same range (ca. 104105 M-1). The higher binding 
stoichiometry of C2 to A, compared to that of C1, however, implied that C2 may be 
able to interact with A to a greater extent (Table 3.1). This may explain the better 
reactivity of C2 toward A species over C1 observed from A aggregation studies (vide 
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supra, Figures 3.2 and 3.3). DPP2 also presented similar binding affinity toward A as 
C2. Overall C2 and DPP2 were shown to interact with A in an energetically 
favorabable manner (Table 3.1). 
 
 
Figure 3.9. Integrated enthalpy change (ΔH) upon injection of (a) C1, (b) C2, and (c) DPP2 into a solution 
of A ([compound] = 200 M; [A] = 20 M; 20 M HEPES, pH 7.4, 150 M NaCl; 10% v/v DMSO; 25 
°C). Solid lines were generated by fitting the experimental data employing the one-site binding (for C1 
and C2) or sequential binding model (for DPP2). 
 
Table 3.1. Thermodynamic parameters (binding stoichiometry (N), binding constants 
(KA), enthalpy change (ΔH), and Gibbs free energy (ΔG)) of interactions between C1/2 
or DPP2 with A40 at 25 °C. 
 
 
C1 C2 DPP2a 
N 0.88 ± 0.27 2.12 ± 0.06 
KA (M-1) 2.38 ± 0.56 x 105 1.61 ± 0.26 x 105 
4.06 ± 1.00 x 105 
7.27 ± 1.26 x 104 
3.97 ± 0.80 x 104 
ΔH (kJ/mol) 15.48 ± 9.16 10.93 ± 0.58 
12.87 ± 0.21 x 105 
33.70 ± 2.52 x 104 
−15.18 ± 3.70 x 104 
ΔG (kJ/mol) 
−0.69 ± 0.58 −29.72 ± 0.40 
−32.01 ± 0.61 
−27.75 ± 0.43 
−26.25 ± 0.50 
 
a Themodynamic values for DPP2 were calculated using a sequential binding mode. 
 
3.2.5. Docking studies for possible conformations of C1/2 with A 
To visualize and further explore the possible interaction between A and C1 or 
C2, docking studies were carried out using AutoDock Vina39 utilizing the previously 
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determined NMR structure (PDB 2LFM)40 of monomeric A40 (Figure 3.10). A and 
C1/C2 were observed to interact with each other through nonspecific and/or direct 
intermolecular interactions (e.g., hydrogen bonding,  stacking), with most 
conformations that exhibited C1/C2 docking between the -helix and the N-terminal 
random coil, similar to DPP2.16 These interactions were calculated to have binding 
energies ranging from −5.8 to −4.9 kcal/mol and −5.9 to −4.8 kcal/mol for C1 and C2, 
respectively (Figure 3.10). As shown in all conformations, C1 and C2 did not dock at the 
same sites on A and were situated offset from each other when docked at similar sites 
(Figure 3.10). The observations from preliminary docking studies suggest that C1 and 
C2 could interact differently with A, possibly related to the presence of a 
dimethylamino group in C2. This may further support the different reactivity toward A 
aggregation of C1 and C2 in vitro (vide supra, Figures 3.2 and 3.3). 
 
3.2.6. Cell toxicity of C1/2, P1/2, and PA1/2 
Cytotoxicity studies of C1/C2, P1/P2, and PA1/PA2 illustrated a potential 
relationship between molecular scaffold and cytotoxicity. Human neuroblastoma SK-N-
BE(2)-M17 cells were treated with various concentrations of compounds and cell 
viability was measured using the MTT assay (Figure 3.11).13,16,27 Overall, through 
reduction of the conjugated triple bond to a double bond in C1/C2, cell viability (ca. 60% 
viability at 50 M) was improved compared to that of DPP2 (ca. 20% viability at 50 
M).16 Furthermore, complete removal of the ,-unsaturated moiety in P1/P2 and 
PA1/PA2 significantly mitigated cytotoxicity of compounds (ca. 80% cell viability up to 
200 M concentration). Through structural modifications, we were able to improve the 
cytotoxicity of DPP2.16 
 
3.2.7. Predicted blood-brain barrier (BBB) permeability of C1/2, P1/2, and PA1/2 
To probe whether the scaffold modifications in the six compounds could alter 
structural parameters required for BBB permeability predicted with DPP2,16 the values 
of Lipinski’s rules and logBB were first calculated.30,31,41,42 Based on the calculated 
values (Table 3.2), all six compounds indicated drug-likeness and possible brain uptake.  
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Figure 3.10. Docking studies of C1 and C2 with A40 monomer. Top: conformation of C1 (yellow) and C2 
(red) with cartoon (left) and surface (right) depictions of A40 (PDB 2LFM) by AutoDock Vina. The helical 
region of A in the surface representation is depicted in light grey. Hydrogen bonding is indicated with 
dashed lines (2.0-2.7 Å). Bottom: summary of calculated binding energies of C1 and C2 to each A 
conformation. 
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To confirm the potential BBB penetration prediction, an in vitro PAMPA-BBB assay was 
performed, following a previously reported method.16,30-32 Based on the empirical 
classification of BBB-permeable molecules (e.g., verapamil),16,30-32 the measured 
permeability values (logPe), along with neutral speciation state at a physiologically 
relevant pH (vide supra, Figure 3.6), suggest that C1/C2, P1/P2, and PA1/PA2 could 
potentially permeate through the BBB and be available in the central nervous system 
(CNS+). Taken together, our structural alterations to DPP2 did not seem to change the 
structural properties necessary for BBB permeability. 
 
 
Figure 3.11. Cytotoxicity studies of C1/2, P1/2, and PA1/2 in human neuroblastoma SK-N-BE(2)-M17 
cells. Cells were treated with various concentrations of (a) C1/2 (2.550 M), (b) P1/2 (2.5200 M), and 
(c) PA1/PA2 (2.5200 M) for 24 h incubation. Cell viability was determined by the MTT assay. Values of 
cell viability (%) were calculated relative to that of cells incubated only with 1% v/v DMSO. Error bars 
represent the standard deviation from at least three independent experiments. 
 
3.3. Conclusion 
DPP2 derivatives, C1/C2, P1/P2, and PA1/PA2, were synthesized in order to 
improve reactivity of DPP2 toward A and metal–A species and lower its cytotoxicity, 
as well as to establish a structure-reactivity-cytotoxicity relationship. The ability of these 
structurally modified compounds to modulate in vitro metal-free and metal-induced A 
aggregation was significantly distinct. Particularly, C2, having a double bond between 
two structural moieties (2-pyridyl ketone and dimethylaniline) and a dimethylamino 
group, displayed noticeable reactivity with both metal-free and metal-treated A species. 
The difference in reactivity was associated with metal binding and A interaction 
properties of our compounds, which were confirmed by solution speciation and ITC 
studies. In addition, an increase in cell viability was indicated with C1/C2, P1/P2, and 
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PA1/PA2, relative to that with DPP2, possibly due to the alteration of the ,-ynone 
moiety. Taken together, through structural modifications of DPP2, we demonstrate a 
relationship between structures, reactivity with A and metal–A, and cytotoxicity.  
 
Table 3.2. Values (MW, clogP, HBA, HBD, PSA, logBB, and logPe) of C1/2, P1/2 and 
PA1/2. 
 
Calculationa C1/C2 P1/P2 PA1/PA2 DPP2c 
Lipinski’s rules  
& others 
MW 209/252 211/254 198/241 250 ≤ 450 
clogP 2.92/3.09 2.98/3.14 1.26/1.43 2.63 ≤ 5.0 
HBA 2/3 2/3 3/4 3 ≤ 10 
HBD 0/0 0/0 1/1 0 ≤ 5 
PSA 30.0/33.2 30.0/33.2 42.0/45.2 33.2 ≤ 90 Å2 
logBB 0.131/0.108 0.139/0.116 −0.300/−0.323 0.0390 
< −1.0 (poorly 
distributed in the 
brain) 
–logPe 
4.3 ± 0.1 
4.2 ± 0.1 
4.4 ± 0.1 
4.3 ± 0.1 
4.2 ± 0.1 
4.2 ± 0.1 
4.2 ± 0.1  
CNS+/− 
predictionb 
CNS+ 
CNS+ 
CNS+ 
CNS+ 
CNS+ 
CNS+ 
CNS+ 
−logPe < 5.4 (CNS+) 
−logPe > 5.7 (CNS–) 
      
a MW: Molecular weight; clogP: Calculated logarithm of the octanol-water partition coefficient; HBA: 
Hydrogen-bond acceptor atoms; HBD: Hydrogen-bond donor atoms; PSA: Polar surface area; logBB = 
−0.0148 × PSA  0.152 × clogP  0.130; −logPe values were determined using the Parallel Artificial 
Membrane Permeability Assay adapted for BBB (PAMPA-BBB). b Prediction of the ability of the 
compound to penetrate the central nervous system (CNS). Compounds categorized as CNS have the 
ability to permeate through the BBB and target the CNS. In the case of compounds assigned as CNS, 
they have poor permeability through the BBB and therefore, their bioavailability into the CNS is 
considered to be minimal. c The values for DPP2 have been previously reported.16 
 
The reactivity of our compounds with A and metal–A species, however, is 
shown to be limited in vitro;43 therefore, further structural optimization for interacting with 
metal ions and/or A species is desirable to accomplish their use in biological systems. 
Especially, the metal binding affinity of C, P, and PA could be improved through 
substitution of the carbonyl group in their backbones with a stronger metal binding 
group such as an amino or hydroxyl moiety, as well as variation of denticity. 
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3.4. Experimental section 
 
3.4.1. Materials and procedures 
All reagents were purchased from commercial suppliers and used as received 
unless otherwise stated. The compounds (C1/C2 and PA1/PA2) were synthesized 
following previously reported methods with modifications.23-26 A40 
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) was purchased from 
Anaspec (Fremont, CA). Optical spectra for metal binding and solution speciation 
studies were recorded on an Agilent 8453 UV-visible (UV-vis) spectrophotometer. 
Nuclear magnetic resonance (NMR) spectra for the characterization of small molecules 
and Zn2+ binding studies were acquired on a Varian 400 MHz NMR spectrometer. 
Isothermal calorimetric titrations of A40 with compounds were carried out with a 
MicroCal VP-ITC isothermal titration calorimeter (Northampton, MA). Transmission 
electron microscopy (TEM) images were recorded on a Philips CM-100 transmission 
electron microscope. A SpectraMax M5 microplate reader (Molecular Devices, 
Sunnyvale, CA) was used to measure the absorbance for MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) and Parallel Artificial Membrane Permeability 
Assay adapted for Blood-Brain Barrier (PAMPA-BBB) assays. 
 
3.4.2. Preparation of (E)-3-phenyl-1-(pyridin-2-yl)prop-2-en-1-one (C1) 
A flask was charged with a mixture of 2-acetylpyridine (300 mg, 2.5 mmol) and 
benzaldehyde (285 mg, 2.7 mmol) in H2O (15 mL). To the stirring mixture was added a 
10 % solution of NaOH (1.5 mL) dropwise. The mixture was stirred overnight at room 
temperature. The precipitates formed were filtered, washed with H2O (3 x 10 mL), and 
dried over anhydrous MgSO4. The product was concentrated in vacuo and purified by 
column chromatography (SiO2, 100% CH2Cl2) to afford a yellow solid (450 mg, 2.2 
mmol, 85%). 1H NMR (400 MHz, CDCl3)/ (ppm): 7.42 (3H, m), 7.49 (1H, m), 7.73 (2H, 
m), 7.88 (1 H, dt, J = 7.6 and 1.6), 7.95 (1H, d, J = 16.0 Hz), 8.20 (1H, d, J = 8.0 Hz), 
8.32 (1H, d, J = 16.0 Hz), 8.75 (1 H, m). 13C NMR (100 MHz, CDCl3)/(ppm): 189.4, 
154.1, 148.8, 144.8, 137.0, 135.1, 130.5, 128.8, 126.9, 122.9, 120.8. HRMS: Calcd for 
[MH]+, 210.0841; found for [MH]+, 210.0913.  
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3.4.3. Preparation of (E)-3-(4-(dimethylamino)phenyl)-1-(pyridin-2-yl)prop-2-en-1-
one (C2) 
A flask was charged with a mixture of 2-acetylpyridine (242 mg, 2.0 mmol) and 4-
dimethylaminobenzaldehyde (300 mg, 2.0 mmol) in EtOH (5 mL). To the stirring mixture 
was added a 20% solution of KOH (3 mL) dropwise. After stirring the mixture for 
overnight at room temperature, H2O (5 mL) was added to the flask before the red 
precipitates were filtered and washed with H2O (5 mL) and cold EtOH (5 mL). The 
product was concentrated in vacuo and purified by recrystallization from CH2Cl2 and 
hexanes to afford dark orange crystals (352 mg, 1.4 mmol, 70 %). 1H NMR (400 MHz, 
CDCl3)/ (ppm): 3.05 (6H, s), 6.07 (2H, J = 9.2 Hz), 7.46 (1H, m), 7.64 (2 H, J = 9.2 Hz), 
7.86 (1H, td, J = 7.6 and 2.0 Hz), 7.94 (1H, d, J = 16.0 Hz), 8.08 (1H, d, J = 16.0 Hz), 
8.19 (1 H, d, J = 8.0 Hz), 8.73 (1 H, m). 13C NMR (100 MHz, CDCl3)/(ppm): 189.2, 
155.0, 152.1, 148.7, 146.0, 136.9, 130.9, 126.4, 123.0, 122.8, 115.5, 111.7, 40.1. 
HRMS: Calcd for [MH]+, 253.1263; found for [MH]+, 253.1335. 
 
3.4.4. Preparation of 3-phenyl-1-(pyridin-2-yl)propan-1-one (P1) 
A flame dried flask was charged with (E)-3-phenyl-1-(pyridin-2-yl)prop-2-en-1-
one (300 mg, 0.71 mmol) and purged for 5 min prior to addition of dry CH3OH (9 mL). 
To the stirring solution was added 10 wt % Pd/C (30 mg, 10 mol%) and Ph2S (2.5 L, 
7.0 mol). The reaction was allowed to stir under H2 at room temperature for 24 h. The 
solution was then filtered through a 25 mm syringe filter, washed with CH3OH (3 x 10 
mL), and dried over anhydrous MgSO4. The product was concentrated in vacuo and 
purified by column chromatography (SiO2, 100% CH2Cl2) to afford an orange oil (108 
mg, 0.51 mmol, 72%). 1H NMR (400 MHz, CDCl3)/ (ppm): 3.07 (2H, t, J = 7.6 Hz), 3.57 
(2H, t, J = 7.6 Hz), 7.18 (1H, q), 7.25-7.26 (4H, br), 7.45-7.42 (1H, m), 7.81 (1H, td, J = 
9.2, 1.6 Hz), 8.02 (1H, dt, J = 8.0, 1.2 Hz), 8.64 (1H, d, J = 4.8 Hz). 13C NMR (100 MHz, 
CDCl3)/(ppm): 200.8, 153.4, 148.9, 141.7, 136.9, 128.4, 128.3, 127.1, 125.9, 121.5, 
39.2, 29.8. HRMS: Calcd for [MH]+, 212.1070; found for [MH]+, 212.1070. 
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3.4.5. Preparation of 3-(4-(dimethylamino)phenyl)-1-(pyridin-2-yl)propan-1-one 
(P2) 
A flame dried flask was charged with (E)-3-(4-(dimethylamino)phenyl)-1-(pyridin-
2-yl)prop-2-en-1-one (300 mg, 0.72 mmol) and purged for 5 min prior to addition of dry 
CH3OH (9 mL). To the stirring solution was added 10 wt % Pd/C (30 mg, 10 mol%) and 
Ph2S (2.5 L, 7.0 mol). The reaction was allowed to stir under H2 at room temperature 
for 24 h. The solution was then filtered through a 25 mm syringe filter, washed with 
CH3OH (3 x 10 mL), and dried over anhydrous MgSO4. The product was concentrated 
in vacuo and purified by column chromatography (SiO2, 1:1 ethyl acetate:hexanes) and 
washed several times with hexanes to afford the final product as a light green solid (93 
mg, 0.37 mmol, 51%). 1H NMR (400 MHz, CD2Cl2)/ (ppm): 2.89 (6H, s), 2.93 (2H, t, J = 
8.0 Hz), 3.48 (2H, t, J = 8.0 Hz), 6.67 (2H, d, J = 8.0 Hz), 7.11 (2H, d, J = 8.0 Hz), 7.47 
(1H, ddd, J = 12.0, 4.0, 1.0 Hz), 7.83 (1H, td, J = 7.6, 1.6 Hz), 7.99 (1H, dt, J = 7.6, 0.8 
Hz), 8.65 (1H, dd, J = 4.5, 1.2 Hz). 13C NMR (100 MHz, CD2Cl2)/ (ppm): 201.2, 153.5, 
149.2, 148.9, 136.8, 129.8, 128.9, 127.1, 121.5, 112.9, 40.7, 39.6, 28.9. HRMS: Calcd 
for [MH]+, 255.1492; found for [MH]+, 255.1496. 
 
3.4.6. Preparation of N-phenylpicolinamide (PA1) 
A dried flask was charged with picolinic acid (123 mg, 1.0 mmol) followed by 
addition of dry CH2Cl2 (10 mL). To the stirring mixture was added 
dicyclohexylcarbodiimide (DCC, 230 mg, 2.2 mmol), aniline (0.2 mL, 2.2 mmol) and 4-
dimethylaminopyridine (DMAP, 50 mg, 0.45 mmol). After the mixture was stirred 
overnight at room temperature, H2O (5 mL) was added to the flask before the white 
precipitates were filtered. The organic mixture was washed with H2O (3 x 10 mL) and 
dried over anhydrous MgSO4. The product was concentrated in vacuo and purified by 
column chromatography (SiO2, 6:1 CH2Cl2:ethyl acetate) to afford a white solid (147 mg, 
0.74 mmol, 74 %). 1H NMR (400 MHz, CDCl3)/ (ppm): 7.13 (1H, t, J = 7.4 Hz), 7.40 
(2H, dd, J = 7.8, 8.1 Hz), 7.46 (1H, m), 7.78 (2H, d, J = 7.8 Hz), 7.89 (2H, dt, J = 1.8, 7.8 
Hz), 8.29 (1H, d, J = 7.8 Hz), 8.60 (1H, d, J = 4.8 Hz). 13C NMR (100 MHz, 
CDCl3)/(ppm): 161.9, 149.8, 147.9, 137.7, 129.1, 126.4, 124.3, 122.4, 119.7. HRMS: 
Calcd for [MH]+, 199.0793; found for [MH]+, 199.0866. 
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3.4.7. Preparation of N-(4-(dimethylamino)phenyl)picolinamide (PA2) 
A dried flask was charged with picolinic acid (123 mg, 1.0 mmol) followed by 
addition of dry CH2Cl2 (10 mL). To the stirring mixture was added DCC (230 mg, 2.2 
mmol), N1,N1-dimethylbenzene-1,4-diamine (149 mg, 2.2 mmol), and DMAP (50 mg, 
0.45 mmol). After the mixture was stirred overnight at room temperature, H2O (5 mL) 
was added to the flask before the white precipitates were filtered. The organic mixture 
was washed with water (3 x 10 mL) and dried over anhydrous MgSO4. The product was 
concentrated in vacuo and purified by column chromatography (SiO2, 5:1 CH2Cl2:ethyl 
acetate) to afford a yellow solid (190 mg, 0.79 mmol, 79 %). 1H NMR (400 MHz, 
CDCl3)/ (ppm): 2.93 (6H, s), 6.75 (2H, d, J = 9.0 Hz), 7.43 (1H, m), 7.63 (2H, d, J = 9.0 
Hz), 7.86 (1H, dt, J =  1.7, 7.7 Hz), 8.27 (1H, d, J = 7.8 Hz), 8.58 (1H, d, J = 4.8 Hz), 
9.82 (1H, s). 13C NMR (100 MHz, DMSO)/(ppm): 162.0, 150.7, 148.7, 147.9, 138.5, 
128.5, 127.0, 122.5, 121.8, 112.9, 40.9. HRMS: Calcd for [MH]+, 242.1205; found for 
[MH]+, 242.1292. 
 
3.4.8. Amyloid- (A) peptide experiments 
A40 peptide was dissolved with ammonium hydroxide (NH4OH, 1% v/v, aq), 
aliquoted, lyophilized, and stored at −80 °C. A stock solution (ca. 200 M) was prepared 
by redissolving A with NH4OH (1% w/v, aq, 10 L) followed by dilution with ddH2O, as 
reported previously.13,16,27 Buffered solutions (20 M HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), pH 6.6 or 7.4, 150 M NaCl) were used for both 
inhibition and disaggregation studies (pH 6.6 for Cu2+ samples;34-36 pH 7.4 for metal-free 
and Zn2+ samples). For the inhibition experiment, A (25 M) was first treated with or 
without a metal chloride salt (CuCl2 or ZnCl2, 25 M) for 2 min followed by addition of 
C1/C2, P1/P2, or PA1/PA2 (50 M, 1% v/v final DMSO concentration). The resulting 
samples were incubated at 37 °C for 4, 8, or 24 h with constant agitation. For the 
disaggregation experiment, A in the absence or presence of a metal chloride salt 
(CuCl2 or ZnCl2) were initially incubated at 37 °C for 24 h with steady agitation. 
Compound was added afterwards followed by additional 4, 8, or 24 h incubation at 37 
°C with constant agitation. 
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3.4.9. Gel electrophoresis with Western blot 
The A peptide experiments described above were analyzed by gel 
electrophoresis followed by Western blotting using an anti-A antibody (6E10).13,16,27 
Each sample (10 L, [A] = 25 M) was separated using a 10-20% gradient Tris-tricine 
gel (Invitrogen, Grand Island, NY). The gel was transferred to a nitrocellulose 
membrane and blocked overnight with a bovine serum albumin solution (BSA, 3% w/v, 
Sigma, St. Louis, MO) in Tris-buffered saline (TBS, Fisher, Pittsburgh, PA) containing 
0.1% Tween-20 (Sigma; TBS-T). The membrane was treated with the A monoclonal 
antibody (6E10, Covance, Princeton, NJ; 1:2,000; BSA, 2% w/v, in TBS-T) for 4 h at 
room temperature and then probed with a horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (1:5,000; Cayman Chemical, Ann Arbor, MI) in 2% BSA in 
TBS-T solution for 1 h at room temperature. The protein bands were visualized using 
Thermo Scientific Supersignal West Pico Chemiluminescent Subtrate (Rockford, IL). 
 
3.4.10.  Transmission electron microscopy (TEM) 
Samples for TEM were prepared following a previously reported method.13,16,27 
Glow-discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, 
Hatfield, PA) were treated with samples from either inhibition or disaggregation 
experiments (5 L) for 2 min at room temperature. Excess sample was removed with 
filter paper and the grids were washed with ddH2O five times. Each grid was stained 
with uranyl acetate (1% w/v ddH2O, 5 L) for 1 min. Uranyl acetate was blotted off and 
grids were dried for 15 min at room temperature. Images of samples were taken by a 
Philips CM-100 transmission electron microscope (80 kV, 25,000x magnification). 
 
3.4.11.  Metal binding studies 
The interactions of C1/C2, P1/P2, and PA1/PA2 with Cu2+ and Zn2+ were 
investigated by UV-vis and 1H NMR spectroscopy, respectively, based on previously 
reported procedures.13,16,27 A solution of C1/C2 (20 M), P1/P2 (50 M), or PA1/PA2 
(50 M) in EtOH was treated with 1 to 5 equiv of CuCl2 with incubation of 2 min (for 
C1/2) or 10 min (for P1/P2 or PA1/PA2) at room temperature and was monitored by 
UV-vis. The interaction of C1/C2, P1/P2, or PA1/PA2 with ZnCl2 was observed by 1H 
 
74 
 
NMR spectroscopy upon addition of 1 to 3 equiv of ZnCl2 to a solution of C1 (2 mM), C2 
(4 mM), P1/P2 (4 mM), or PA1/PA2 (8 mM) in acetonitrile-d3 (CD3CN). In addition, 
metal selectivity of C1/C2, P1/P2, and PA1/PA2 was examined by measuring the 
optical changes upon addition of 1 equiv of CuCl2 to a solution of ligand ([C1/C2] = 20 
M or [P1/P2] = [PA1/PA2] = 50 M in EtOH) containing 1 or 25 equiv of another 
divalent metal chloride salt (MgCl2, CaCl2, MnCl2, FeCl2, CoCl2, NiCl2, or ZnCl2). The 
Fe2+ samples were prepared by purging the solutions with N2. Quantification of metal 
selectivity was calculated by comparing and normalizing the absorption values of 
metalligand complexes at 400 nm (for C1), 650 nm (for C2), 320 nm (for P1), 300 nm 
(for P2), 350 nm (for PA1), or 480 nm (for PA2) to the absorption at these wavelengths 
before and after the addition of CuCl2 (AM/ACu). 
 
3.4.12.  Solution speciation studies 
The pKa values for C1/C2, P1/P2, and PA1/PA2 were determined by UV-vis 
variable-pH titrations following previously reported methods.13,16 To obtain the pKa 
values, a solution (10 mM NaOH, pH 12, 100 mM NaCl) of C1/C2 (20 M), P1/P2 (50 
M), or PA1/PA2 (50 M) was titrated with small aliquots of HCl to obtain at least 30 
spectra in the range of pH 210 (for C1/C2 and P1/P2) or pH 112 (for PA1/PA2). In 
order to investigate the binding properties of ligands to Cu2+ at various pH values, a 
solution containing a compound ([C2] = 20 M, [P2] = 50 M, or [PA2] = 50 M) and 
CuCl2 in a ratio of 2:1 was incubated for 30 min, 2 h, and 30 min, respectively, and 
titrated with additions of HCl in a similar manner. At least 30 spectra were obtained over 
the range of pH 27 (for C2 and P2) or pH 17.5 (for PA2). The acidity (pKa) and 
stability (log) constants were calculated by using the HypSpec program (Protonic 
Software, UK).44 The speciation diagrams for C1/C2, P1/P2, PA1/PA2, Cu2+C2, 
Cu2+P2, and Cu2+PA2 complexes were modeled by the HySS2009 program (Protonic 
Software).45 
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3.4.13.  Isothermal titration calorimetry (ITC) 
Solutions of ligand (200 M) and A40 (20 M) in 20 μM HEPES buffer, pH 7.4, 
150 M NaCl (10% v/v DMSO) were prepared and degassed for 10 min prior to titration. 
The ligand solution (10 L per injection) was injected over 1 sec (25 times, with an 
interval of 200 sec between each injection) into a solution of A40 (1.4 mL) using a 
motor-driven 250 L syringe rotating at 310 rpm at 25 °C. As the control experiment, the 
ligand solution was injected into buffer solution without A to measure the heat of 
dilution. Heat values of binding were measured by subtracting the heat of dilution value 
from the experimental results. Titration data were analyzed by an evaluation software, 
MicroCal Origin, Version 7.0. The binding curves were fitted with one-site binding or 
sequential model affording the overall heat values of thermodynamic parameters.37 
 
3.4.14.  Docking studies 
Flexible ligand docking studies for C1/C2 against the A40 monomer from the 
previously determined aqueous solution NMR structure (PDB 2LFM)40 were conducted 
using AutoDock Vina.39 Ten conformations were selected from 20 conformations within 
the PDB file (1, 3, 5, 8, 10, 12, 13, 16, 17, and 20). The MMFF94 energy minimization in 
ChemBio3D Ultra 11.0 was used to optimize the ligand structures for docking studies. 
The structural files of C1/C2 and the peptide were generated by AutoDock Tools and 
imported into PyRx,46 which were used to run AutoDock Vina.39 The search space 
dimensions were set to contain the entire peptide. The exhaustiveness for the docking 
runs was set at 1024. Docked poses of the ligands with A were visualized using 
Pymol. 
 
3.4.15.  Cytotoxicity (MTT Assay) 
The human neuroblastoma SK-N-BE(2)-M17 cell line was purchased from the 
American Type Culture Collection (ATCC, Manassas, VA). The cell line was maintained 
in media containing 1:1 Minimum Essential Media (MEM, GIBCO, Grand Island, NY) 
and Ham’s F12K Kaighn’s Modification Media (F12K, GIBCO), 10% (v/v) fetal bovine 
serum (FBS, Sigma), 100 U/mL penicillin (GIBCO), and 100 mg/mL streptomycin 
(GIBCO). The cells were grown and maintained at 37 °C in a humidified atmosphere 
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with 5% CO2. M17 cells were seeded in a 96 well plate (15,000 cells in 100 L per well) 
according to previously reported methods.13,16,27 These cells were treated with various 
concentrations of C1/C2, P1/P2, or PA1/PA2 (2.550 M for C1/C2, 2.5200 M for 
P1/P2 and PA1/PA2, final 1% v/v DMSO). After 24 h incubation at 37 °C, 25 L MTT (5 
mg/mL in phosphate buffered saline (PBS), pH 7.4, GIBCO) was added to each well 
and the plates were incubated for 4 h at 37 °C. Formazan produced by the cells was 
dissolved in a solution containing N,N-dimethylformamide (DMF, 50% v/v aq, pH 4.5) 
and sodium dodecyl sulfate (SDS, 20% w/v) overnight at room temperature. The 
absorbance (A600) was subsequently measured on a microplate reader. 
 
3.4.16. Parallel Artificial Membrane Permeability Assay adapted for blood-brain 
barrier (PAMPA-BBB) 
PAMPA-BBB experiments of compounds were carried out using the PAMPA 
Explorer kit (Pion, Inc. Billerica, MA) with modification to previously reported 
protocols.16,30-32 Each stock solution was diluted with pH 7.4 Prisma HT buffer (Pion) to 
a final concentration of 25 M (1% v/v DMSO) and was added to the wells of the donor 
plate (200 L, number of replicates = 12). BBB-1 lipid formulation (5 L, Pion) was used 
to coat the polyvinylidene fluoride (PVDF, 0.45 M) filter membrane on the acceptor 
plate. The acceptor plate was placed on top of the donor plate forming a sandwich and 
brain sink buffer (BSB, 200 L, Pion) was added to each well of the acceptor plate. The 
sandwich was incubated for 4 h at ambient temperature without stirring. UV-vis spectra 
of the solutions in the reference, acceptor, and donor plates were measured on a 
microplate reader. The PAMPA Explorer software v. 3.5 (Pion) was used to calculate 
the value of −logPe for each compound. CNS+/− designations were assigned by 
comparison to compounds that were identified in previous reports.30-32 
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Chapter 4: Reactivity of a GdIIIDTPA-Curcumin Conjugate with Metal-Free and 
Associated Amyloid- Species 
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4.1. Introduction 
Alzheimer’s disease (AD) is the most common, incurable neurodegenerative 
disease that is currently projected to affect approximately 14 million Americans by the 
year 2050.1 Several pathological features, such as accumulation of amyloid- (A) 
peptide aggregates, metal ion dyshomeostasis, and oxidatie stress, have been 
observed and suggested to have potential link to AD onset and progression.2-8 An inter-
relationship between these factors have been indicated (e.g., upon binding to A, metal 
ions (i.e., Cu+/2+) have been shown to facilitate peptide aggregation, as well as generate 
reactive oxygen species (ROS) in vitro), which proposes the elusive, complex etiology 
of the disease.2,4,5,7,8  
In order to elucidate the interconnection between multiple pathological factors, 
small molecules, designs based on a rational structure-based approach where a metal 
binding site was incorporated into an A interacting framework, have been 
investigated.8-15 In addition, natural products, such as curcumin16-20 and ()-
epigallocatechin-3-gallate (EGCG; green tea extract),21-24 have been studied to possibly 
target and modulate metal-free and/or metal-associated A species, as well as reactive 
oxygen species (ROS). Senile plaques, composed of A peptide, have been used as 
disease diagnostic confirmation post mortem;2,4,5,25 making A plaques a viable 
detection marker for AD.26,27 Efforts have been put forth to develop magnetic resonance 
imaging (MRI) contrast agents to potentially overcome the limitations (e.g., limited 
resolution, bioavailability) of current A probes.28-32 In addition, A-targeting moieties 
(e.g., A peptides,33-36 antibodies37-41 and A-binding dye31) have been to appended to 
the framework of MRI contrast agents to gain A-targeting ability; however, their 
practical biological applications may be restricted due to possible blood-brain barrier 
(BBB) impermeability, amyloidogenic properties, and/or toxicity. 
A conjugate (Gd-cur) of GdIIIDTPA (DTPA = diethyleneaminepentaacetate), a 
clinically approved contrast agent, and curcumin (cur) was fashioned for as a potential 
MRI contrast agent specific for A plaques (Figure 4.1).42 Curcumin is a natural principal 
phenol in turmeric, a popular Indian spice in curry.43,44 Curcumin has been observed to 
inhibit the formation of A oligomers and fibrils,17,45 as well as aid in the reduction of 
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neuronal damage46 and oxidative stress,47-49 and amyloid accumulation17 in an AD 
transgenic mouse model. Additionally, curcumin has been used as a fluoresent dye for 
A plaque imaging.17,50,51 The conjugate, Gd-cur, was demonstrated as a potential 
multimodal contrasting agent to detect A plaques, applicable to MRI and fluorescence 
microscopy,42 which warrants further investigations of its reactivity toward metal-free 
and metal-associated A species. Herein, the influence of Gd-cur on metal-free and 
metal-induced A aggregation was studied in vitro, compared to individual structural 
components, [GdIIIDTPA (GdIIIDPTA), curcumin, (cur), and curcumin linker (cur-L)]. 
Our present results and observations indicate that Gd-cur could modulate Cu2+-induced 
A aggregation, showing greater reactivity toward A42 over A40. Moreover, the 
antioxidant activity of this series was assessed and Gd-cur was observed to have 
similar antioxidant capacity in comparison to Trolox, a vitamin E analogue. 
 
4.2. Results and discussion 
 
4.2.1. Rationale and characterization of Gd-cur 
 As mentioned above, the conjugate, Gd-cur, was designed based on a rational 
structure-based design, where a clinically approved MRI contrast agent (GdIIIDTPA) 
was linked to curcumin,42 a nontoxic natural product which has been shown to have 
anti-amyloidogenic activity.17,45 Although curcumin has many advantageous aspects, 
such as anti-inflammatory effects and mediation of neuropathogenic factors of AD (vide 
supra), the use of curcumin as a potential therapeutic has been severely hindered by its 
lack of solubility and stability in physiologically relevant conditions.52-54 Thus, Gd-cur 
was investigated to determine if its curcumin moiety would retain curcumin’s auspicious 
characteristics (i.e., nontoxicity, antioxidant activity, control of A aggregation), along 
with solubility improvements, after the conjugation to GdIIIDTPA. Curcumin’s insolubility 
in water has been previously reported.52-55 Linkage of the GdIIIDTPA to curcumin (Gd-
cur, Figure 4.1) vastly improved the solubility of curcumin (cur; Figure 4.1) in buffered 
solution. The stock solution (high mM concentration) of Gd-cur was made only using 20 
mM HEPES (4-(2-hydroxylethyl)-1-piperazineethane-sulfonic acid), pH 7.4, 150 mM 
NaCl).  
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Figure 4.1. Structures of curcumin derivatives. Top to bottom: Curcumin (cur) = (1E,4Z,6E)-5-hydroxy-
1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; curcumin-linker (cur-L) = tert-butyl(2-(2-(4-
((1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-3oxohepta-1,4,6-trien-1-yl)-2-methoxyphenoxy) 
acetoamido)ethyl)carbamate; GdIIIDTPA conjugated curcumin (Gd-cur) = GdIIIdiethylenetriaminepenta-
acetate-complexed-2-(4-((1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-3-oxohepta-1,4,6-trien-1-
yl)-2-methoxyphenoxy)-N-(2-(3-(p-tolyl)ethyl)acetamide. 
 
 The ability of cur, cur-L, and Gd-cur to bind Cu2+ and Zn2+ was investigated by 
UV-visible (UV-vis) spectroscopy (Figure 4.2). Changes in UV-vis spectra, such as new 
optical bands and/or change in absorbance intensity were observed upon CuCl2 or 
ZnCl2 treatment (1 to 2 equiv) with cur, cur-L, or Gd-cur in EtOH, indicating interaction 
between metal ions and these compounds. Optical shifts were detected from ca. 430 
and 455 nm (for cur), 427 nm and 450 nm (for cur-L), and 424 and 452 nm (for Gd-cur) 
(Figure 4.2a) after CuCl2 treatment. Upon introduction of ZnCl2, optical shifts were 
observed ca. 430 nm (for cur), 423 and 450 nm (for cur-L), and 424 and 459 nm (for 
Gd-cur) (Figure 4.2b). It should be noted that very minimal optical shift was observed 
for cur and cur-L upon the addition of ZnCl2. Overall, Cu2+ and Zn2+ binding cur, cur-L, 
and Gd-cur was confirmed by UV-vis. 
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Figure 4.2. Cu2+ and Zn2+ binding studies of cur, cur-L, and Gd-cur. UV-vis spectra of cur, cur-L, and 
Gd-cur with (a) CuCl2 (1-2 equiv) in EtOH or (b) ZnCl2 (1-2 equiv) in EtOH. Conditions: [cur, cur-L, or 
Gd-cur] = 10 M for Cu2+ binding studies; [cur or cur-L] = 20 M or [Gd-cur] = 10 M for Zn2+ binding 
studies; room temperature; incubation for 5 min. 
 
4.2.2. Influence of GdIIIDTPA, cur, cur-L, and Gd-cur on metal-free and metal-
triggered A aggregation in vitro 
The control of GdIIIDTPA, cur, cur-L, and Gd-cur upon in vitro metal-free and 
metal-induced A aggregation was investigated through two experiments: inhibition 
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(modulation of A aggregate formation) and disaggregation (transformation of 
preformed A aggregates) (Figures 4.3 and 4.4).10,11,15 The generated A species from 
both experiments were monitored via gel electrophoresis followed by Western blot with 
an anti-A antibody (6E10) for distribution of molecular weight (MW) and transmission 
electron microscopy (TEM) for identification of morphological changes.10,11,15  
As shown in Figure 4.3, the inhibition studies demonstrated different reactivity of 
GdIIIDTPA, cur, cur-L, and Gd-cur toward formation of metal-free and metal-induced 
A aggregates consisting of either A40 or A42. In the case of samples containing A40, 
reactivity was only observed with Cu2+ treatment, where slight reactivity was visualized 
with cur and cur-L and none with GdIIIDTPA (Figure 4.3a, left, lanes 2, 3, and 5). A40 
species with a wide distribution of MW was indicated with Gd-cur. TEM images of Cu2+-
treated A40 species incubates with cur, cur-L, or Gd-cur revealed smaller amorphous 
aggregates compared to untreated with compounds; while the resulting Cu2+-added 
A40 species from compound-free and GdIIIDTPA-incubated samples presented similar 
size and morphology to compound-free conditions (Figure 4.3b, left). 
Treatment of A42 with cur, cur-L, or Gd-cur showed distinct reactivity relative to 
A40 samples (Figure 4.3a, lanes 3, 4, and 5). In both metal-free and metal-associated 
A42 aggregation, various-sized A species were present with cur-L (lane 4). Moreover, 
samples consisting of A42, Cu2+, and cur, cur-L, or Gd-cur were visualized to have a 
different gel band pattern of varying MW (lanes 3, 4, and 5) in reference to compound-
free samples (lane 1). Similar to A40, the ability of GdIIIDTPA to control either metal-
free or metal-induced A aggregation was not demonstrated (lane 2).  
In addition, disaggregation studies indicated a similar pattern of reactivity for 
compounds with A40 samples (Figure 4.4). Minimal reactivity of GdIIIDTPA, cur, cur-L, 
or Gd-cur was visualized with metal-free and Zn2+-treated A species (Figure 4.4a, left, 
lanes 2, 3, 4, and 5), while a A40 aggregates with a wide distribution of MW was 
observed with cur, cur-L, or Gd-cur in the in presence of Cu2+ (lanes 3, 4, and 5). 
Morphological changes of Cu2+-treated A40 species upon compound incubation was 
distinguished by TEM. Unstructured A40 species were detected in the sample 
containing cur, cur-L, or Gd-cur (Figure 4.4b). In the case of metal-free A42, a slightly  
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Figure 4.3. In vitro inhibition experiments of GdIIIDTPA, cur, cur-L, and Gd-cur. (a) Visualization of 
various-sized A40 species (left) or A42 species (right) by gel electrophoresis with Western blot (anti-A 
antibody, 6E10). (c) TEM images of the 24 h incubated samples. Conditions: [A] = 25 M; [CuCl2 or 
ZnCl2] = 25 M; [compound] = 50 M; pH 6.6 (for Cu2+ samples) or 7.4 (for metal-free and Zn2+ samples); 
24 h incubation; 37 C; constant agitation. 
 
different smearing pattern was visualized for cur, cur-L, and Gd-cur (Figure 4.4a, right, 
lanes 3, 4, and 5) in comparison to that of compound-untreated A42 (lane 1). Cur and 
Gd-cur demonstrated distinct reactivity with ZnA42 (lanes 3 and 5). Interestingly, A42 
species having a wide range of MW was observed with cur-L with both metal-free and 
Zn2+-added samples (lane 4). As expected, the treatment of cur, cur-L, or Gd-cur with 
preformed Cu2+-induced A aggregates was shown to generate various-sized A42 
species (lanes 3, 4, and 5). Surprisingly, reactivity was observed with the addition of 
GdIIIDTPA in samples containing A42 and Cu2+ (lane 2).  
 
4.2.3. Antioxidant activity of cur, cur-L, and Gd-cur  
The ability of cur, cur-L, and Gd-cur to scavange free radicals was evaluated by 
the Trolox equivalent antioxidant capacity (TEAC) assay with cell lysates15 which 
measures the ability of the compounds to inhibit the oxidation of ABTS to ABTS cation 
radicals (ABTS•+; ABTS = 2,2‘-azino-bis(3-ethylbenzothiaxoline-6-sulfonic acid) in the  
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Figure 4.4. In vitro disaggregation experiments of GdIIIDTPA, cur, cur-L, and Gd-cur. (a) Visualization of 
various-sized A40 species (left) or A42 species (right) by gel electrophoresis with Western blot (anti-A 
antibody, 6E10). (c) TEM images of the 24 h incubated samples. Conditions: [A] = 25 M; [CuCl2 or 
ZnCl2] = 25 M; [compound] = 50 M; pH 6.6 (for Cu2+ samples) or 7.4 (for metal-free and Zn2+ samples); 
24 h incubation; 37 C; constant agitation. 
 
presence of metmyoglobin and H2O2. As shown in Figure 4.5, GdIIIDTPA and Gd-cur 
has similar antioxidant capacity as Trolox (vitamin E analogue) (1.2 ± 0.27 for 
GdIIIDTPA; 0.99 ± 0.12 for Gd-cur). The compounds cur and cur-L showed distinct 
differences in antioxidant activity in comparison to Trolox (TEAC value = 0.27 ± 0.15 
and 3.72 ± 1.69, respectively, Figure 4.5). Note that precipitation was observed with cur 
and cur-L in the cell lysate assay conditions (owing to their poor solubility in aqueous 
media). 
 
4.2.4. Cyotoxocity of GdIIIDTPA and Gd-cur in living cells 
The cytoxicity of GdIIIDTPA and Gd-cur, in the absence and presence of metal 
salt (CuCl2 or ZnCl2) were determined using an MTT assay8,11,14,15,21 (Figure 4.6). Due 
to the insolubility of cur and cur-L in aqueous environment, the cytotoxicity of the two 
compounds was not assessed at this time. Murine Neuro-2a (N2a) neuroblastoma cells 
were treated with various concentrations of compounds (2.525 M). No toxicity was  
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Figure 4.5. Antioxidant activity of GdIIIDTPA, cur, cur-L, and Gd-cur determined by the TEAC assay with 
cell lysates. TEAC values are relative to Trolox (vitamine E analogue; 6-hydroxy-2,5,7,8-
tetramethlchroman-2-carboxylic acid). * Indicates precipitation in cell lysate assay conditions. 
 
observed for both GdIIIDTPA and Gd-cur. (Figure 4.6a). Upon the addition of either 
CuCl2 or ZnCl2 (2.525 M) with compound (M2+: compound ratio = 1:1 or 1:2), 
GdIIIDPTA and Gd-cur showed relatively low cytotoxicity in the presence of either Cu2+ 
or Zn2+ (ca. 80% cell viability; Figure 4.6b). Overall, Gd-cur exhibited relatively high cell 
viability, indicating its potential use for biological application. 
 
  
Figure 4.6. Cytotoxicity of GdIIIDTPA, cur, cur-L, and Gd-cur in the absence and presence of CuCl2 or 
ZnCl2 (a) Treatment of N2a cells with various concentrations of compounds (2.525 M) for 24 h 
incubation. (b) Treatment of N2a cells with compound:M2+ ratio at 1:1 or 1:2. [M2+] and [compound] = 
2.550 M.  
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4.2.5. Blood-brain barrier permeability 
To assess the biological applicability of cur, cur-L, or Gd-cur, BBB permeability, 
initially predicted by Lipinski’s rules and logBB56-59 (Table 4.1), was verified by an in 
vitro Parallel Artificial Membrane Permeability Assay adapted for BBB (PAMPA-BBB), 
following a previously reported method.8,14,56,57,60 Based on the empirical classification of 
molecules known to be BBB-permeable (e.g., verapamil) 56,57,60 and the measured 
permeability values (logPe) indicate that cur, cur-L may potentially diffuse through the 
BBB, while Gd-cur may or may not passively permeate through the BBB. 
 
4.3. Conclusion 
A synthesized hybrid of GdIIIDTPA and curcumin (Gd-cur) was previously 
determined to be a viable contrast agent with the ability to target A fibrils.42 Therefore, 
the potential diagnostic tool was investigated to determine if Gd-cur could be used for 
therapeutic means. Gd-cur was examined to observe whether the curcumin moeity 
appended to the GdIIIDTPA still retained the advantageous aspects of curcumin, such 
as antioxidant activity and control A aggregation, after conjugation, as well as having 
the ability to target metal-free and metal-associated A species and modulate A 
aggregation. Gd-cur presented improved solubility aquous solution, while cur and cur-
L was shown to be relatively insoluble in aquous environments. Gd-cur was found to 
slightly modulate the assembly of Cu2+-associated A40 species, while in the case of 
A42, distinct reactivity was observed in the presence of Cu2+. Furthermore, Gd-cur was 
indicated to transform preformed Cu2+A40 aggregates, although, interestingly, 
reactivity was observed in both metal-free and metal-added conditions for A42 samples, 
suggesting that Gd-cur may be more preferential to A42 in comparison to A40. For 
biological ultilization, Gd-cur has similar antioxidant capability as Trolox and shows 
relatively no toxicity in living cells. It, however, may be limited to applications in the brain 
due to its BBB permeability property. Overall, the promising increase in solubility of Gd-
cur and its in vitro reactivity toward A and metalA species makes this conjugate 
worthy of further structural modifications for improvement of BBB permeability. Our 
studies, along with the previous report,42 have demonstrated the feasibility to potentially 
develop a thernostic agent (both diagnostic and therapeutic) in AD. 
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Table 4.1. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe) for cur, cur-L, or 
Gd-cur. 
 
Calculationa 
cur cur-L Gd-cur Lipinski’s rules and 
others 
MW 368 569 1161 500 
clogP          2.94          3.73            3.32 ≤ 5.0 
HBA    6   11     20 ≤ 10 
HBD    3     4       5 ≤ 5.0 
PSA     96.2 153   270 ≤ 90 
logBB 
0.838 1.56          3.36 < 1.0 (poor distribution 
in the brain) 
logPeb 4.7 ± 0.1 4.7 ± 0.1 5.7 ± 0.1  
CNS+/ predictionc CNS+ CNS+ CNS+/ –logPe < 5.4 (CNS+) 
    –logPe > 5.7 (CNS) 
     
a MW, molecular weight; clogP, calculated logarithm of the octonal-water partition coefficient; HBA, 
hydrogen-bond acceptor atoms; HBD, hydrogen-bond donor atoms; PSA, polar surface area; logBB = 
0.0148 x PSA + 0.152 x clogP + 0.130. b The values of –logPe were measured by the Parallel Artificial 
Membrane Permeability Assay adapted for blood-brain barrier (PAMPA-BBB). c CNS+/ prediction: 
prediction of compound to penetrate to the central nervous system (CNS). CNS: compounds have the 
ability to permeate through the BBB and be bioavailable in the CNS. CNS: poor permeability through the 
BBB and therefore, compound bioavailability into the CNS is considered to be minimal. 
 
4.4. Experimental section 
 
4.4.1. Materials and methods 
All reagents were purchased from commercial suppliers and used as received 
unless otherwise stated. The compound, gadolinium-conjugated 2-(4-((1E,4Z,6E)-5-
hydroxy-7-(4-hydroxy-3-methoxyphenyl)-3oxohepta-1,4,6-trien-1-yl)-2-methoxyphenoxy) 
-N-(2-(3-(p-tolyl)ethyl)acetamide (Gd-cur) was prepared following previously reported 
methods.35 A40 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) and 
A42 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were purchased 
from AnaSpec (Fremont, CA). Transmission electron microscopy (TEM) images were 
recorded with a Philips CM-100 transmission electron microscope (Microscopy and 
Image Analysis Laboratory, University of Michigan, Ann Arbor, MI). A SpectraMax M5 
microplate reader (Molecular Devices, Sunnyvale, CA) was employed for the 
measurement of absorbance for TEAC, MTT, and PAMPA-BBB assays. 
 
4.4.2. Metal binding studies 
The interactions of GdIIIDTPA, cur, cur-L, and Gd-cur with Cu2+ and Zn2+ were 
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investigated by UV-vis, based on previously reported procedures.11,15,21 A solution of 
cur (10 M for Cu2+ binding studies; 20 M for Zn2+ binding studies), cur-L (10 M for 
Cu2+ binding studies; 20 M for Zn2+ binding studies), or Gd-cur (10 M for either Cu2+ 
or Zn2+ binding studies) in EtOH was treated with 1 to 2 equiv of a metal chloride salt 
(CuCl2 or ZnCl2) with incubation of 5 min at room temperature. 
 
4.4.3. Amyloid- (A) peptide experiments 
A experiments were performed according to previously published 
procedures.10,11,15 A40 or A42 was dissolved in ammonium hydroxide (NH4OH, 1% v/v, 
aq), aliquoted, lyophilized overnight, and stored at −80 °C. A stock solution was 
prepared by dissolving A in 1% NH4OH and diluted with ddH2O. For the inhibition 
experiment, A (25 M) was treated with or without metal ions (CuCl2 or ZnCl2; 25 M) 
for 2 min, followed by addition of a compound (50 M; 1% v/v final DMSO 
concentration). The resulting samples were incubated for 24 h at 37 °C with constant 
agitation. For the disaggregation experiment, A (25 M) with and without metal ions 
(CuCl2 or ZnCl2, 25 µM) was first incubated for 24 h at 37 °C with constant agitation. 
Afterward, a compound (50 M, 1% v/v final DMSO concentration for cur and cur-L) 
was added and followed by an additional 24 h incubation at 37 °C with constant 
agitation. Both studies were performed using a buffered solution (20 M HEPES, pH 6.6 
(for CuCl2) or pH 7.4 (metal-free and ZnCl2), 150 M NaCl). 
 
4.4.4. Gel electrophoresis with Western blot 
The A peptide experiments described above were analyzed using gel 
electrophoresis followed by Western blotting with an anti-A antibody (6E10, Covance, 
Princeton, NJ).10,11,15 Each sample (10 µL) was separated using a 10–20% Tris-tricine 
gel (Invitrogen, Grand Island, NY). After the separation. the proteins were transferred 
onto a nitrocellulose membrane and blocked with bovine serum albumin (BSA, 3% w/v, 
Sigma-Aldrich) in Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) for 23 
h at ambient temperature. The membranes were incubated with an anti-A antibody 
(1:2000) in 2% BSA (w/v in TBS-T) for overnight at 4 C. After washing, membranes 
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were probed with the horseradish peroxidase-conjugated goat anti-mouse antibody 
(1:10,000) in 2% BSA for 1 h at ambient temperature. Thermo Scientific Supersignal 
West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) was used to 
visualize protein bands. 
 
4.4.5. Transmission electron microscopy (TEM) 
TEM samples were prepared following a previously reported method.10,11,15 Glow-
discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, 
PA) were treated with the samples (5 L) from either the inhibition or disaggregation 
experiment for 2 min at room temperature. Excess sample was removed with filter 
paper. The grids were washed 3 times with ddH2O, stained with uranyl acetate (1% w/v, 
ddH2O, 5 L) for 1 min, and dried for 15 min at room temperature. A Philips CM-100 
transmission electron microscope (80 kV, 25,000x magnification; Microscopy and Image 
Analysis Laboratory, University of Michigan, Ann Arbor, MI) was used for obtaining TEM 
images of the samples. 
 
4.4.6. Trolox Equivalent Antioxidant Capacity Assay with cell lysate 
The antioxidant activity of GdIIIDTPA, cur, cur-L, and Gd-cur was determined by 
the TEAC assay employing cell lysate following the protocol of the antioxidant assay kit 
purchased from Cayman Chemical Company (Ann Arbor, MI) with modifications. The 
N2a cells were used for this assay. This cell line purchased from ATCC was maintained 
in media containing 50% Dulbecco’s modified Eagle’s medium (DMEM) and 50% OPTI-
MEM (GIBCO), supplemented with 10% fetal bovine serum (FBS, Sigma), 1% Non-
essential Amino Acids (NEAA, GIBCO), 2 mM glutamine, 100 U/ml penicillin, and 100 
mg/ml streptomycin (GIBCO). The cells were grown and maintained at 37 °C in a 
humidified atmosphere with 5% CO2. For the antioxidant assay using cell lysates, cells 
were seeded in a 6 well plate and grown to approximately 80-90% confluence. Cell 
lysates were prepared following the previously reported method with modifications.61 
N2a cells were washed once with cold PBS (pH 7.4, GIBCO) and harvested by gently 
pipetting off adherent cells with cold PBS. The cell pellet was generated by 
centrifugation (2,000 x g for 10 min at 4 °C). This cell pellet was sonicated on ice (5 sec 
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pulses, 5 times with 20 sec intervals between each pulse) in 2 mL of cold Assay Buffer 
(5 mM potassium phosphate, pH 7.4, containing 0.9% NaCl and 0.1% glucose). The cell 
lysates were centrifuged at 5,000 x g for 10 min at 4 °C. The supernatant was removed 
and stored on ice until use. To standard and sample 96 wells, 10 L of the supernatant 
of cell lysates was delivered followed by addition of compound, metmyoglobin, ABTS, 
and H2O2 in order. After 5 min incubation at room temperature on a shaker, absorbance 
values at 750 nm were recorded. The final concentrations (0.045, 0.090, 0.135, 0.180, 
0.225, and 0.330 mM) of GdIIIDTPA, cur, cur-L, Gd-cur, and Trolox (Sigma-Aldrich; 
Trolox = 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; dissolved in DMSO) 
were used. The percent inhibition was calculated according to the measured 
absorbance (% Inhibition = (A0  A)/A0, where A0 is absorbance of the supernatant of 
cell lysates) and was plotted as a function of compound concentration. The TEAC value 
of ligands was calculated as a ratio of the slope of the standard curve of the compound 
to that of Trolox. The measurements were conducted in triplicate. 
 
4.4.7. Cell viability (MTT Assay) 
The N2a neuroblastoma cell line was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). The cell line was maintained in media containing 
50% DMEM and 50% OPTI-MEM (GIBCO), supplemented with 10% FBS (Sigma), 1% 
NEAA (GIBCO), 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin 
(GIBCO). The cells were grown and maintained at 37 °C in a humidified atmosphere 
with 5% CO2. Cell viability upon treatment of compounds was determined using the 
MTT assay. N2a cells were seeded in a 96 well plate (15,000 cells in 100 L per well). 
The cells were treated with various concentrations (2.525 M) with or without CuCl2 or 
ZnCl2 (2.550 M; either 1:1 or 1:2 compound:M2+ ratio), and incubated for 24 h. After 
incubation, 25 L MTT (5 mg/mL (Sigma) in phosphate buffered saline (PBS, pH 7.4, 
Gibco, Grand Island, NY, USA) was added to each well and the plate was incubated for 
4 h at 37 °C. Formazan produced by the cells was solubilized using an acidic solution of 
N,N-dimethylformamide (50%, v/v aq) and sodium dodecyl sulfate (SDS, 20%, w/v) 
overnight at room temperature in the dark. The absorbance was measured at 600 nm 
using a microplate reader. Cell viability was calculated relative to cells containing an 
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equivalent amount of HEPES.  
 
4.4.8. Parallel Artificial Membrane Permeability Assay adapted for blood-brain 
barrier (PAMPA-BBB) 
Previously reported protocols with modification using the PAMPA Explorer kit 
(Pion, Inc.) were applied to our PAMPA-BBB experiment.11,56,57,60 Each stock solution of 
the compounds was diluted to a final concentration of 10 M (1% v/v final DMSO 
concentration) with pH 7.4 Prisma HT buffer (Pion). The resulting solution (200 L) was 
added to each of the wells of the donor plate (number of replicates per sample = 12). 
The BBB-1 lipid (Pion formulation, 5 L) was used to coat the polyvinylidene fluoride 
(PDVF, 0.45 μM) filter membrane on the acceptor plate. The acceptor plate was placed 
on the top of the donor plate generating a “sandwich” and each well of the acceptor 
plate was filled with the brain sink buffer (200 L, Pion). The sandwich was incubated at 
rt for 4 h without stirring. A microplate reader was used to obtain the optical spectra 
(250-500 nm) of the solutions in the reference, acceptor, and donor plates. The –logPe 
for each compound was calculated using the PAMPA Explorer software c. 3.5 (Pion). 
CNS+/– assignment was determined in comparison to compounds identified 
previously.5656,57,60 Compounds categorized as CNS+ have the ability to permeate 
through the BBB and target the CNS. Compounds assigned as CNS– have poor 
permeability through the BBB and therefore, their bioavailability into the CNS is 
considered to be minimal. 
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Chapter 5: In Vitro Influence of Enediyne Derivatives on Metal-Free and Metal-
Induced Amyloid- Aggregation 
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5.1. Introduction 
Alzhiemer’s disease (AD) is a crippling and fatal neurodegenerative disease that 
is the sixth leading cause of death, making it the only cause within the top 10 in the US 
that has no preventative or therapeutic measures, or any means to impede the 
progression of the disease.1 AD is characterized by pathological features, including 
aggregation of misfolded proteins, (e.g., amyloid- (A)), miscompartmentalization and 
dyshomeostasis of metal ions, and environment of oxidative stress.2-8 A relationship 
between dysregulation of metal ions and A-related toxicity has been suggested. High 
concentrations of metals (i.e., Cu, Zn) have found in A plaques; these metals can 
interact with A species influencing aggregation and conformation of A peptides and/or 
formation of reactive oxygen species (ROS).2,6-9 The role of A as well as metal-bound 
A (metalA) in AD onset and progression still remains to be clearly elucidated. 
In order to understand the involvement of metalA in the AD etiology, chemical 
tools designed to specifically target metalA species and modulate their reactivity (i.e., 
A aggregation and ROS generation) is therefore necessary. Current studies have 
enlisted the use of a rational structure-based approach to develop bifunctional small 
molecules for such chemical tool development (in particular, incorporation approach: 
insertion of a metal chelating site into an A interacting framework, which can generate 
a single entity for metal chelation and A interaction (bifunctionality)).10-17 These 
molecules have demonstrated to the ability to control the interaction between metal ions 
and A, consequently altering its reactivity in vitro and/or in living cells. In addition to 
synthesized small molecules, natural products, including EGCG (green tea extract) 18-20 
and curcumin (spice in Indian curry),21-23 have been explored as well, as viable 
framework for the same purposes. 
 Naturally occurring enediynes (e.g., calicheamicin) have been extensively 
studied as a potential anti-cancer drugs.24-26 Upon activation (through normal biological 
redox events), these compounds have the ability to undergo Bergman cyclization which 
could perform a H-atom abstraction.27 Metal coordination to compounds has been 
shown to promote thermal Bergman cyclization, indicated in systems, including 
enediynes.28-32 Due to its biological relevancy and metal binding property, the enediyne 
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framework was investigated as a chemical tool for studying metalA related to AD. 
Herein, we report the reactivity of enediyne derivatives (PyED (uncyclized) and PyBD 
(cyclized)) toward metal-free and metal-induced A aggregation, employing both A40 
and A42, along with their metal binding properties (metal ions: Cu2+ and Zn2+). 
 
5.2. Results and discussion 
 
5.2.1. Rationale and characterization of PyED and PyBD investigated for 
modulating A aggregation in the absence and presence of metal ions 
PyED was selected as a potential chemical tool to be utilized for targeting and 
modulating metalA species, due to its proclivity to bind metal ions (i.e., Cu2+, Zn2+) 
and undergo a subsequent radical generation event leading to an H-atom abstraction 
under physiologically relevant conditions.27-32 In addition, the tetradentate ligand, PyED 
or PyBD, bears resemblance to previous bidentate and tetradentate compounds 
containing nitrogen and/or oxygen donor atoms that demonstrate the ability to control 
the formation of metal-triggered A aggregates as well as dissemble preformed metal-
treated A aggregates.10,11,13-17 For the purposes of an unreactive model for metal 
binding studies and differentiating compound activity due solely to metal chelation, as 
opposed to metal chelation and radical generation event, a fully cyclized structure 
(PyBD; Figure 5.1) with a binding site analogous to PyED was employed. Both PyED 
and PyBD were synthesized from previously reported procedures.33 
 
 
Figure 5.1. Structures of enediyne derivatives. PyED (1E,1'E)-N,N'-((Z)-octa-4-en-2,6-diyne-1,8-
diyl)bis(1-(pyridin-2-yl)methanimine) (left) and PyBD (1E,1'E)-N,N'-(1,2-phenylenebis(methylene))bis(1- 
(pyridine-2-yl)methanimine) (right). 
 
Variable-pH UV-visible (UV-vis) titrations were conducted to evaluate the ligand 
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species in solution, particularly at physiologically relevant pH (e.g., 7.4).10,12,15-17 
Speciation was determined using PyBD due the fact that PyED undergoes Bergman 
cyclization in the presence of metal ions (referred to as the reactivity of PyED in the all 
metal binding experiments; vide infra). Given the structural similarities between PyED 
and PyBD, PyBD should serve as a good model for both ligand systems. Titration 
results indicated a single acid ionization constant (pKa) for PyBD (pKa = 3.81(2)), 
suggesting that neutral and monoprotonated form may exist depending on pH. 
Furthermore, the generated solution speciation diagram depicted PyBD as expected to 
exist mainly in the neutral from at pH 7.4. (Figure 5.2). 
 
 
Figure 5.2. Solution speciation studies of PyBD. UV-vis variable-pH titration spectra (left) and solution 
speciation diagrams (right) of PyBD (pH 28) (FL = fraction of species at the given pH). Acidity constants 
(pKa) of PyBD is summarized in the table. Conditions: [PyBD] = 50 M; I = 0.10 M NaCl; room 
temperature. Charges are omitted for clarity. a The error in the last digit is shown in the parentheses. 
 
5.2.2. Metal binding properties of PyED and PyBD  
The divalent metal binding properties of PyED and PyBD were investigated by 
UV-vis. Addition of one equiv of ZnCl2 or CuCl2 to PyED or PyBD in EtOH, 
bathochromic shifts in all samples are observed for optical bands at 264 and 272 nm, 
respectively (Figure 5.3). The shifts observed in response to Cu2+ binding by PyED and 
PyBD are more noticeable than those seen upon Zn2+ binding. The optical changes 
shown in the spectra following metal addition indicated occurrence of metal binding by 
PyED and PyBD in the presence of either Zn2+ or Cu2+. 
The neutral form of PyBD is the major species in solution at experimental pH  
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Figure 5.3. Zn2+ and Cu2+ binding of PyED and PyBD, monitored by UV-vis. UV-vis spectra of (a) PyED 
and PyBD with ZnCl2 (1 equiv). (b) PyED and PyBD with CuCl2 (1 equiv) in EtOH. Conditions: [PyED or 
PyBD] = 100 M; room temperature; incubation for 10 min. 
 
(vide supra) and variable-pH UV-vis titrations10,12,15-17 were also conducted to elucidate 
complexation and binding properties of PyBD with Cu2+ in solution (Figure 5.4). Based 
the pKa value determined for PyBD above and these titration results, the stability 
constants (log) for the these complexes were determined to be 12.2(8) and 16.6(8) for 
CuL and Cu(LH), respectively. A solution speciation diagram was modeled using these 
stability constants, suggests complexation of PyBD with Cu2+ occurred in a ratio of 1:1 
metal to ligand, as well as neutral and protonated form of the Cu2+−PyBD complex may 
exist at different pH. The data implicates neutral Cu2+−PyBD form is the major species 
at pH 6.6 (Figure 5.4). The concentration of free Cu2+ in solution at pH 6.6 yielded a 
pCu value of 8.3(4) (pCu = −log[Cu2+]unbound). This value suggested an approximate 
dissociation constant (Kd) for Cu2+−PyBD to be ca. nanomolar range. When taken in 
consideration with the reported Kd values for Cu2+−A species (picomolar to nanomolar 
range),2,4,6-8,34 PyBD could interact with Cu2+ in Cu2+–A species. 
To assess the ability of PyED and PyBD to bind Cu2+ in a heterogeneous 
biological environment, metal selectivity studies were performed using PyBD as a 
model for both compounds due to the reactivity exhibited by PyED in the presence of  
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Figure 5.4. Solution speciation studies of the Cu2+PyBD complex. UV-vis variable-pH spectra (left) and 
solution speciation diagrams (right) of Cu2+PyBD (pH 38) (FCu = fraction of free Cu and CuL 
complexes at the given pH). Conditions: [Cu2+]/[PyBD] = 1:1, [PyBD] = 50 M; room temperature. 
Stability constant (log) of CuPyBD complexes are summarized in the table. Charges are omitted for 
clarity. a The error in the last digit is shown in the parentheses. 
 
metal ions. The selectivity of PyBD for Cu2+ compared to other biologically relevant 
metal ions (i.e., Ca2+, Co2+, Fe2+, Fe3+, Mg2+, Mn2+, Ni2+, and Zn2+) was investigated 
using UV-vis (Figure 5.5). Even in the presence of a large excess of a competing metal 
ion, PyBD displays relative moderate selectivity for Cu2+ over Ca2+, Co2+, Mg2+, Mn2+, 
Ni2+, and Zn2+. In the presence of Fe2+ and Fe3+ in solution, PyBD binding to these 
metal ions was also observed (Figure 5.5). This binding is likely due to the preferred 
octahedral binding geometry of the iron center and the structure of the binding moiety. 
Overall, these metal selectivity results demonstrate that the tetradentate pyridine-imine 
binding moiety of PyBD and PyED may be selective toward Cu2+ over other divalent 
metal ions found in biological environments, such as the brain. 
 
5.2.3. Effects of PyED and PyBD on metal-free and metal-induced A aggregation 
in vitro 
In order to assess the ability of PyED to modulate metal-induced A40 and A42 
aggregation pathways, in vitro disaggregation and inhibition experiments were 
conducted.10-17 For comparison to PyED’s reactivity, the influence of monofunctional 
PyBD on A aggregation was also examined. Disaggregation studies investigated the  
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Figure 5.5. Metal selectivity studies of PyBD (50 M) in HEPES buffer (20 mM, pH 7.35; NaCl 150 mM). 
Blue bars represent the addition of CuCl2 (9) to solutions containing the ligand and another divalent metal 
ion (black bars; 1, CaCl2; 2, CoCl2; 3, FeCl2; 4, FeCl3; 5, MgCl2; 6, MnCl2; 7, NiCl2; 8, ZnCl2) in a ratio of 
1:1 (a and b) and 25:1 (c and d) MCl2 or MCl3:CuCl2 followed by 30 min incubation at room temperature. 
Absorbance at 285 nm (a and b), 305 nm (b and d) were used for the calculation of AM/ACu. The observed 
higher absorbance after Cu2+ addition to solution containing ligand and another metal ion compared to 
that of the control (ligand and Cu2+ only) may be due to the absorbance from ligand binding to another 
metal ion at the wavelength selected for analysis. * Indicates precipitation in the solution or interference 
with unidentified species in spectra. 
 
ability of both PyED and PyBD to structurally alter preformed metal-free A and metal-
treated A aggregates (Figures 5.6 and 5.7), while inhibition experiments probed the 
compounds’ ability to control the formation of metal-free and metal-triggered A 
aggregates (Figures 5.8 and 5.9). The resultant A species were characterized using 
gel electrophoresis followed by Western blot with an anti-A antibody (6E10), and their 
morphologies were monitored by transmission electron microscopy (TEM).11-13,15-17  
In the disaggregation studies, PyED and PyBD presented different reactivity 
toward preformed metal-free and metal-associated A40 and A42 aggregates (Figures 
5.6 and 5.7). In the case of Zn2+ and Cu2+A40 samples treated with PyED, A 
species with an increasing range of molecular weight (MW) are observed at both 37 and 
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43 °C between 2 and 8 h, while a decrease in signal intensity occured between 8 and 
24 h for samples incubated at 37 °C (Fig. 5.6a, lanes 5 and 8). Interestingly, at 43 C, 
variable reactivity of PyED with preformed, Zn2+–treated A40 aggregates was detected. 
Addition of PyED to Zn2+–A40 presented an increasing distribution of MW throughout 
the time course (lane 5). In contrast, treatment of metal−A40 samples with PyBD led to 
the generation of lower MW species (MW ≤ 25 kDa) over the 24 h period (Fig. 5.6a, 
lanes 6 and 9). These data suggest that PyBD slightly affects the transformation of 
preformed metalA aggregates, indicating that the introduction of radical formation 
upon metal binding by PyED may be a key factor in the generation of metal-associated 
A species exhibiting a different array of MW. Furthermore, the reduction of gel band 
intensity in Cu2+A40 samples incubated with PyED for 24 h may imply the occurrence 
of further aggregation over time. No reactivity was observed for either PyED or PyBD in 
metal-free conditions, except for A40 samples incubated with PyED at 8 h at 43 C 
(Figure 5.6a, lanes 2, 3, and 8). The results suggest that PyED in the absence of metal 
ions may possibly go through radicalization with extended incubation and at higher 
temperature, generating A species with an array of MW. The disappearnace of the gel 
band at 24 h may suggest further aggregation occurred (lane 8). 
The trends in the gel analysis are consistent with TEM images of preformed 
metalA40 aggregates treated with PyED. At 37 °C, TEM images of metal−A40 show a 
mixture of fibrillar and amorphous structure types, while at 43 °C, amorphous 
Amorphologies are dominant. In comparison, parallel samples incubated with PyBD 
exhibit fibrillar structures similar to those under compound-free conditions at both 
temperatures (Figure 5.6b and c). Since PyED and PyBD show minimal change in the 
morphology of metal-free A40 aggregates relative to compound-untreated samples, this 
suggests that variations in the fibrillar morphology may be derived from compound’s 
functionality (i.e., chelation and chelation-induced radical formation) (Figure 5.6b and c). 
The ability of PyED and PyBD to transform preformed A42 aggregates was also 
examined (Figure 5.7). Relative to analogous A40 samples, a similar trend in both 
PyED and PyBD reactivity with A42 was confirmed by gel electrophoresis. A42 species 
with a wide distribution of MW are observed with PyED-treated metal-added A  
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Figure 5.6. Disaggregation experiment: disassembly of preformed, metal-free or metal-induced A40 
aggregates (scheme, top) by PyED and PyBD. (a) Analysis of the size distribution of the resulting A40 
species by gel electrophoresis with Western blot using an anti-A antibody (6E10) at either 37 or 43 C. 
(b) Visualization of the morphologies of the A40 species from samples that were incubated with PyED or 
PyBD for 24 h by TEM at 37 C. (c) Visualization of the morphologies of the A40 species from samples 
that were incubated with PyED or PyBD for 24 h by TEM at 43 C. Conditions: [A40] = 25 M; [CuCl2 or 
ZnCl2] = 25 M; [compound] = 50 M (compound = PyED or PyBD; pH 6.6 (for Cu2+ samples) or 7.4 (for 
metal-free and Zn2+ samples); various inhibition time; 37 or 43 C; constant agitation. 
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aggregates over the course of 24 h at both temperatures (Figure 5.7a, lanes 5 and 8), 
while low reactivity is visualized with metal−A42 aggregates incubated with PyBD 
(lanes 6 and 9). In the case of metal-free conditions, A42 species with slightly different 
array of MW are produced upon addition of PyED or PyBD (lanes 2 and 3) relative to 
compound-free samples (lane 1). In addition to these trends, the TEM images reveal 
that PyED treatment to metal−A42 samples induces changes in the morphology of 
preformed aggregates. Metal-treated A42 aggregates exposed to either PyED or PyBD 
show thinner fibrils of various lengths (37 and 43 C), as well as more amorphous 
species (37 C) than observed in compound-free samples (Figure 5.7b and c). As 
demonstrated for A40, no significantly distinct morphology changes are observed in the 
metal-free A42 aggregates treated with either compound when compared to the 
compound-untreated sample, indicating the potential importance of metal chelation in 
the disaggregation pathway. 
In conjunction with the disaggregation studies, the ability of PyED and PyBD to 
control A aggregation was also investigated (Figures 5.8 and 5.9). Upon incubation of 
Zn2+ and A40 with PyED, an increasing dispersion of various MW was visualized by gel 
analysis over prolonged incubation (Figure 5.8a, lane 5). In comparison, samples 
containing Cu2+, A40, and PyED generate different smearing patterns than those of 
Zn2+A40 samples (lanes 5 and 8). Similar to the disaggregation results, the gel band 
intensity of the Cu2+A40 samples also decreases between 8 and 24 h incubation time 
at both 37 and 43 °C. PyBD presented slight modulation of the metal-induced 
aggregation (lanes 6 and 9), while exposure of metal-free A40 to either PyED or PyBD 
results in little to no activity (lanes 2 and 3). Thus, similar to the disaggregation results, 
these data indicate that PyED demonstrates greater inhibition of metal-induced A 
aggregation compared to PyBD. Additionally, further progression of peptide aggregation 
may be occurring in Cu2+A40 samples treated with PyED for 24 h under hyperthermic 
conditions. These findings are supported by TEM images of A40 samples, incubated at 
43 °C, that reveal smaller, amorphous A species in the presence of divalent metal ions 
and PyED (Figure 5.8b and c). Importantly, morphological changes are not observed 
noticeably in the metal-free A samples exposed to either PyED or PyBD (Figure 5.8b  
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Figure 5.7. Disaggregation experiment: disassembly of preformed, metal-free or metal-induced A42 
aggregates by PyED and PyBD. (a) Analysis of the size distribution of the resulting A42 species by gel 
electrophoresis with Western blot using an anti-A antibody (6E10) at either 37 or 43 C. (b) Visualization 
of the morphologies of the A42 species from samples that were incubated with PyED or PyBD for 24 h by 
TEM at 37 C. (c) Visualization of the morphologies of the A42 species from samples that were incubated 
with PyED or PyBD for 24 h by TEM at 43 C. Conditions: [A42] = 25 M; [CuCl2 or ZnCl2] = 25 M; 
[compound] = 50 M (compound = PyED or PyBD; pH 6.6 (for Cu2+ samples) or 7.4 (for metal-free and 
Zn2+ samples); various inhibition time; 37 or 43 C; constant agitation. 
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and c).  
As expected, the trend in the inhibition of A42 aggregation upon addition of 
PyED or PyBD is comparable to that of A40 (Figure 5.9). Significant modification of the 
aggregation pathway is only visualized for metal-associated A species treated with 
PyED (Figure 5.9a, lanes 5 and 8). Additionally, TEM images that reveal thinner fibrils 
and/or amorphous aggregates are generated in PyED-treated metalA42 samples 
compared to compound-free conditions (Figure 5.9b and c). Taken together, the 
disaggregation and inhibition results demonstrate the enhanced ability of PyED (versus 
PyBD) to variably modulate metal-free and metal-induced A aggregation. 
 
5.2.4. Prediction of blood-brain barrier (BBB) permeability of PyED 
To evaluate the drug-likeness of PyED and its potential to penetrate the blood-
brain barrier (BBB), values for Lipinski’s rules and the logBB were calculated (Table 
5.1).35-38 PyED is indicated to have drug-like characteristic as well as BBB permeability 
based on the calculated values (Table 5.1). In order to confirm the predicted the ability 
of PyED penetrate the BBB, an in vitro PAMPA-BBB assay was performed following 
literature procedure.11,12,15-17,39 Using the empirical classification for BBB-permeable 
molecules, the measured permeability value, −logPe, for PyED (−logPe = 4.9  0.1) 
suggests that PyED is possibly penetrating the BBB. 
 
5.3. Conclusion 
An enediyne derivative, PyED, was investigated as a potential chemical tool that 
has the capability to target metalA species and alter metal-induced A aggregation in 
vitro. UV-vis titration studies of PyBD, instead of PyED due to the tendency of PyED to 
undergo Bergman cyclization in metal-added conditions, in the absence and presence 
of Cu2+ indicate that the enediyne derivative could interact with Cu2+ from Cu2+-bound 
A species. Through biochemical and TEM studies, PyED is demonstrated to be able to 
modulate both metal-triggered A40 and A42 aggregation. Additionally, PyED shows the 
potential to be BBB permeable, which suggests its futher biological applicability. Taken  
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Figure 5.8. Inhibition experiment: modulation of A40 aggregate formation in the absence and presence of 
metal ions (scheme, top) by PyED and PyBD. (a) Analysis of the size distribution of the resulting A40 
species by gel electrophoresis with Western blot using an anti-A antibody (6E10) at either 37 or 43 C. 
(b) Visualization of the morphologies of the A40 species from samples that were incubated with PyED or 
PyBD for 24 h by TEM at 37 C. (c) Visualization of the morphologies of the A40 species from samples 
that were incubated with PyED or PyBD for 24 h by TEM at 43 C. Conditions: [A40] = 25 M; [CuCl2 or 
ZnCl2] = 25 M; [compound] = 50 M (compound = PyED or PyBD; pH 6.6 (for Cu2+ samples) or 7.4 (for 
metal-free and Zn2+ samples); various inhibition time; 37 or 43 C; constant agitation. 
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Figure 5.9. Inhibition experiment: modulation of A42 aggregate formation in the absence and presence of 
metal ions (scheme, top) by PyED and PyBD. (a) Analysis of the size distribution of the resulting A42 
species by gel electrophoresis with Western blot using an anti-A antibody (6E10) at either 37 or 43 C. 
(b) Visualization of the morphologies of the A42 species from samples that were incubated with PyED or 
PyBD for 24 h by TEM at 37 C. (c) Visualization of the morphologies of the A42 species from samples 
that were incubated with PyED or PyBD for 24 h by TEM at 43 C. Conditions: [A42] = 25 M; [CuCl2 or 
ZnCl2] = 25 M; [compound] = 50 M (compound = PyED or PyBD; pH 6.6 (for Cu2+ samples) or 7.4 (for 
metal-free and Zn2+ samples); various inhibition time; 37 or 43 C; constant agitation. 
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Table 5.1. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe) of PyED. 
 
Calculationa PyED 
Lipinski’s rules & 
others 
MW 312 ≤ 450 
clogP         1.01 ≤ 5.0 
HBA            4 ≤ 10 
HBD            0 ≤ 5 
PSA      50.5 ≤ 90 
logBB          0.464 
< 1.0 (poorly 
distributed in the brain. 
logPeb 4.9 ± 0.01  
CNS +/ 
Predictionc 
CNS+ 
logPe < 5.4 (CNS+) 
           > 5.7 (CNS) 
   
a MW, molecular weight; clogP, calculated logarithm of the octonal-water partition coefficient; HBA, 
hydrogen-bond acceptor atoms; HBD, hydrogen-bond donor atoms; PSA, polar surface area; logBB = 
0.0148 x PSA + 0.152 x clogP + 0.130. b The values of –logPe were measured by the Parallel Artificial 
Membrane Permeability Assay adapted for BBB (PAMPA-BBB). c Compounds categorized as central 
nervous system, CNS+ have the ability to permeate through the BBB and target the CNS. In the case of 
compounds assigned as CNS they have poor permeability through the BBB and therefore, their 
bioavailability into the CNS is considered to be minimal. 
 
together, our studies present the framework of PyED could be utilized for developing 
novel chemical tools for investigating metalA species in vitro and further in vivo. This 
may warrant additional structural modifications (e.g., incorporating a dimethylamino 
moiety that has been suggested to be essential for A interaction)12,13,15,16,40 in order to 
improve properties for interactions and reactivity with A/metalA. 
 
5.4. Experimental section  
 
5.4.1. Materials and procedures 
All reagents were purchased from commercial suppliers and used as received 
unless otherwise stated. The ligands (Z)-N,N'-bis[1-pyridin-2-yl-meth-(E)-ylidene]oct-4-
ene-2,6-diyne-1,8-diamine (PyED) and pyridine-2-ylmethyl-(2-{[pyridine-2-ylmethylene)-
amino]-methyl}-benzyl)-amine (PyBD) were synthesized according to previously 
published procedure.33 A40 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG 
VV) and A42 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were 
purchased from AnaSpec (Fremont, CA). Absorbance measurements for the PAMPA-
BBB assay were recorded on a SpectraMax M5 microplate reader (Molecular Devices, 
Sunnydale, CA). Mass spectrometry for interaction studies was conducted on a Waters 
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Synapt G2/S mass spectrometer. TEM images were recorded on JEOL 1010 
transmission electron microscope (Electron Microscopy Center, Indiana University, 
Bloomington, IN) or a Philips CM-100 transmission electron microscope (Microscopy 
and Image Analysis Laboratory, University of Michigan, Ann Arbor, MI). Optical spectra 
were recorded on an Agilent 8453 UV-Vis spectrophotometer. 
 
5.4.2. Solution speciation determination for PyBD and the Cu2+PyBD complex 
UV-vis variable-pH titration was used to determine the pKa values for PyBD.12 A 
solution (100 mM NaCl, 10 mM NaOH, pH 12) of PyBD (50 M) was titrated with small 
aliquots of HCl and at least 30 spectra were recorded in the pH range of 2–9. 
Additionally, Cu2+ binding to ligand at various pH values was investigated. A solution 
(100 mM NaCl, 10 mM NaOH, pH 10) containing PyBD (50 M) and CuCl2 (50 M) was 
titrated with small aliquots of HCl and at least 30 spectra were recorded in the pH range 
of 3–8. The HypSpec program (Protonic Software, UK)41 was used to calculate the 
acidity and stability constants and the HySS2009 program (Protonoc Software)42 was 
used to model the speciation diagrams of ligand and its corresponding metal complex. 
 
5.4.3. Metal binding and selectivity studies 
The binding of PyED and PyBD with Cu2+ and Zn2+ was investigated by UV-vis.12 
A solution of ligand (20 M, 1% v/v DMSO) was treated with CuCl2 or ZnCl2 (1 equiv). 
Solutions were incubated at 4 C for 1 h and the optical spectrum of the resulting 
solution was recorded. 
The metal selectivity of PyBD was examined by measuring the optical changes 
upon addition of CuCl2 (1 equiv) to a solution of PyBD (50 M, 1% v/v DMSO) 
previously treated with another metal chloride salt (1 or 25 equiv; CaCl2, CoCl2, Fe Cl2, 
FeCl3, MgCl2, MnCl2, NiCl2, and ZnCl2). The Fe2+ and Fe3+ solutions were prepared 
anaerobically and spectra recorded under nitrogen. The quantification of metal 
selectivity was calculated by comparing and normalizing the absorption values for the 
metal–ligand complexes at 285 and 305 nm to the absorption at these wavelengths 
before and after Cu2+ addition. 
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5.4.4. A peptide experiments 
A experiments were performed according to previously published procedures 
with slight modifications.11,12,17 A40 or A42 was dissolved in ammonium hydroxide 
(NH4OH, 1% v/v, aq), aliquoted, lyophilized overnight, and stored at −80 °C. A stock 
solution was prepared by dissolving A in 1% NH4OH and diluted with ddH2O. For the 
disaggregation experiment, A (25 M) with and without metal ions (CuCl2 or ZnCl2, 25 
µM) was first incubated for 24 h at 37 or 43 °C with constant agitation. Afterward, a 
compound (50 M, 1% v/v final DMSO concentration) was added and followed by an 
additional 2, 8, or 24 h incubation at 37 or 43 °C with constant agitation. For the 
inhibition experiment, A (25 M) was treated with or without metal ions (CuCl2 or 
ZnCl2; 25 M) for 2 min, followed by addition of a compound (50 M; 1% v/v final DMSO 
concentration). The resulting samples were incubated for 2, 8, or 24 h at 37 or 43 °C 
with constant agitation. Both studies were performed using a buffered solution (20 M 
HEPES, pH 6.6 (for CuCl2) or pH 7.4 (metal-free and ZnCl2), 150 M NaCl). 
 
5.4.5. Gel electrophoresis 
The A peptide experiments described above were analyzed using gel 
electrophoresis followed by Western blotting with an anti-A antibody (6E10, Covance, 
Princeton, NJ).11,12,17 Each sample (10 µL) was separated using a 10–20% Tris-tricine 
gel (Invitrogen, Grand Island, NY). Following the separation, the proteins were 
transferred onto a nitrocellulose membrane and blocked with bovine serum albumin 
(BSA, 3% w/v, Sigma-Aldrich) in Tris-buffered saline (TBS) containing 0.1% Tween-20 
(TBS-T) for 12 h (A40) or 2–3 h (A42) at ambient temperature. The membranes were 
incubated with an anti-A antibody (1:2000) in 2% BSA (w/v in TBS-T) for 4 h at 
ambient temperature (A40) or overnight at 4 C (A42). After washing, membranes were 
probed with the horseradish peroxidase-conjugated goat anti-mouse antibody 
(1:10,000) in 2% BSA for 1 h at ambient temperature. Thermo Scientific Supersignal 
West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) was used to 
visualize protein bands. 
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5.4.6. Transmission electron microscopy (TEM) 
Samples for TEM were prepared following a previously reported method (A40 
samples; A42 samples).11,12,17 Glow discharge grids (Formar/Carbon 300 mesh; 
Electron Microscopy Sciences, Hatfield, PA) were treated with 24 h incubated samples 
from either disaggregation of inhibition experiments (5 L) for 5 min (A40 samples) or 2 
min (A42 samples) at room temperature and excess sample was removed with filter 
paper. (A40 samples): Each grid was incubated with uranyl acetate (2% w/v ddH2O, 5 
L, 5 min). Excess uranyl acetate was blotted and the grids were washed three time 
with ddH2O (5 L) and air-dried at room temperature. Images were acquired by a JEOL 
1010 transmission electron microscope (80 kV, 25,000x magnification). (A42 samples): 
Grids were washed with ddH2O three times. Each grid was stained with uranyl acetate 
(1% w/v ddH2O, 5 L). Excess uranyl acetate was blotted off and grids were air dried for 
15 min at room temperature. Images were acquired by a Philips CM-100 transmission 
electron microscope (80 kV, 25,000x magnification). 
 
5.4.8. Parallel Artificial Membrane Permeability Assay adapted for blood-brain 
barrier (PAMPA-BBB) 
PAMPA-BBB experiments were carried out using the PAMPA Explorer kit (Pion 
Inc., Billerica, MA) using previously reported protocols with modifications.12,17,35,36,39 
Each stock solution was diluted with Prisma HT buffer (pH 7.4, Pion) to a final 
concentration of 25 M (1% v/v final DMSO concentration). The resulting stock solution 
was added to wells of the donor plate (200 L, number of replicates = 12). The 
polyvinylidene fluoride (0.45 M) filter membrane on the acceptor plate was coated with 
the BBB-1 lipid formulation (5 L, Pion) and placed on top of the donor plate, forming a 
sandwich. Brain sink buffer (200 L, Pion) was added to each well of the acceptor plate. 
The sandwich was incubated at room temperature for 4 h without stirring. The UV-vis 
spectra of the solutions for reference, acceptor, and donor plates were measured using 
a microplate reader. The PAMPA Explorer software v.3.5 (Pion) was used to calculate 
the –logPe for each compound. Designation of CNS± was assigned by comparison to 
those that were identified in previous reports.35,36,39 
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Chapter 6:  A Novel Hybrid of 6-Chlorotacrine and Metal-Amyloid- Modulator 
for Inhibition of Acetylcholinesterase and Metal-Induced Amyloid- 
Aggregation 
 
 
 
 
 
 
 
The results presented in this chapter for 6-chlorotacrine derivatives were previously 
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Dr. Todd Eckroat for the analysis of AChE/BChE activity, docking studies, and synthesis 
of compounds, respectively. Michael Beck conducted Zn2+ binding studies. In the 
present work, I contributed to metal binding studies, the gel and TEM analyses of A 
aggreaton studies, and in vitro PAMPA assay. In addition to that, I was also involved in 
manuscript writing for metal binding, A aggregation studies, and blood-brain barrier 
(BBB) permeability sections.  
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6.1. Introduction 
Alzheimer’s disease (AD) is an age-related, neurodegenerative disorder 
estimated to affect over 5 million people in the United States alone.1 AD is progressive 
and ultimately fatal with symptoms ranging from cognitive dysfunction to psychiatric and 
behavioural disturbances. As the population ages, the prevalence of AD is expected to 
increase dramatically in the coming years and places an increasing burden on society. 
Many pathological hallmarks of the disease have been documented, yet the exact 
cause remains unknown. Current treatments for AD act mainly by inhibiting 
acetylcholinesterase (AChE). While these acetylcholinesterase inhibitors (AChEis) are 
moderately effective in treating cognitive symptoms, they are incapable of stopping or 
reversing disease progression.2 
Tacrine was the first AChEi approved by the FDA.3 Though its clinical use has 
been limited by hepatotoxicity,4 tacrine remains an important starting point in research 
towards developing new drugs for AD due to its straightforward synthesis and 
comparatively low cost.5,6 In fact, tacrine hybrids, bifunctional molecules where tacrine 
has been chemically linked to another molecule with beneficial anti-AD properties, have 
been well characterized in the literature. For example, tacrine-8-hydroxyquinoline 
hybrids, tacrine-ferulic acid hybrids, and tacrine-mefenamic acid hybrids have all shown 
promising results.7-11 The role of the linker in inhibitory activity of these hybrids towards 
AChE has also been investigated.12 
The presence and possible role of amyloid- (A) peptide aggregates in the 
brains of AD patients have been well documented.13-17 These aggregates provide an 
interesting pharmacological target in that drugs capable of disrupting already formed A 
aggregates or preventing A aggregation may be capable of halting or inverting the 
progression of AD.14,16 While AChE and butyrylcholinesterase (BChE) are important in 
AD because they control ACh levels, they also interact with A.18-20 Structurally, AChE 
consists of a catalytic active site (CAS) and a peripheral anionic site (PAS) connected 
by a 20-Å gorge.21-23 AChE is known to promote A aggregation through interaction at 
the PAS, and it is often found to be entangled in A plaques along with BChE.18,24 Thus, 
tacrine hybrids with the ability to simultaneously bind to the CAS and PAS by virtue of a 
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chemical linker spanning the active site gorge have the potential to disrupt A 
aggregation.25,26 
 
 
Figure 6.1. Structures of 6-chlorotacrine (1), 6-chlorotacrine linker (2), N1,N1-dimethyl-N4-(pyridin-2-
ylmethyl)benzene-1,4-diamine, metalA modulator (3), metalA modulator linker (4), and hybrid of 6-
chlorotacrine-metalA modulator (5). 
 
Metal ions such as Cu2+ and Zn2+ are known to interact with A peptides and 
promote their aggregation, which has been suggested to be involved in neurotoxicity.27-
33 Given this fact, small molecules for modulation of metalA interaction and reactivity 
have been developed. For example, N1,N1-dimethyl-N4-(pyridin-2-ylmethyl)benzene-1,4-
diamine (3) (Figure 6.1) has shown the ability to chelate Cu2+ and Zn2+ and interact with 
A, effectively regulating metal-induced A aggregation and neurotoxicity in vitro and in 
human neuroblastoma cells.34 We reasoned that chemically linking an AChEi with the 
metalA modulator 3 would create a hybrid molecule (5; Figure 6.1) potentially capable 
of multifunctionality (inhibition of AChE at the CAS, prevention of AChEA interaction 
by blocking the PAS, as well as alteration of the interaction between metal ions and A 
with subsequent moderation of the reactivity of metal-associated A species). Herein, 
we describe the design, synthesis, and initial biochemical evaluation of such a hybrid (5; 
Figure 6.1). 
 
6.2. Results and discussion 
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6.2.1. Hybrid design and synthesis 
Hybrid 5 (Figure 6.1) was designed to contain an AChEi moiety (blue), a linker 
region (black), and a metalA modulating moiety (orange). 6-Chlorotacrine (1), which 
was chosen as the AChEi moiety, has shown potent inhibition of AChE5 and has been 
incorporated into other AChE-directed hybrid molecules with favourable results.9 For 
comparison in biochemical studies, compound 1 was prepared by heating 2-amino-4-
chlorobenzonitrile and cyclohexanone in the presence of anhydrous ZnCl2 (Scheme 
6.1a), as previously reported.5,6 A decamethylene linker region was chosen due to its 
appropriate length to span the gorge of AChE and produce a compound capable of 
simultaneously interacting with the CAS and PAS.9 This linker moiety was attached to 6- 
chlorotacrine to give analogue 2 as previously reported.9 Compound 3 was chosen as 
 
Scheme 6.1. Synthesis of (a) compound 1, (b) compound 4 and 6, and (c) compounds 
5 and 7-9 
 
 
(a) 
(b) 
(c) 
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the metalA modulating moiety because of its ability to chelate metal ions (i.e., Cu2+ 
and Zn2+) as well as effectively interact with A and was prepared as established in 
previous procedures.34 For comparison in biochemical studies, metalA modulator 
linker 4 was prepared from 6-bromo-2-pyridinecarboxaldehyde via reductive amination 
with N,N-dimethyl-p-phenylenediamine followed by subsequent nucleophilic 
displacement of the bromo substituent by 1,10-diaminodecane (Scheme 6.1b). Hybrid 5 
was prepared using a copper-catalyzed Ullmann-type reaction between 2 and the cyclic 
ethylene acetal-protected form of 6-bromo-2-pyridine carboxaldehyde. Subsequent 
deprotection and reductive amination with N,N-dimethyl-p-phenylenediamine gave the 
desired target hybrid 5 in 8% overall yield (Scheme 6.1c). 
 
6.2.2. AChE inhibition 
The AChE inhibitory properties of compounds 1-5 were assessed against AChE 
from Electrophorus electricus (EeAChE) using the well established Ellman method35 to 
determine IC50 (Table 6.1). We previously tested tacrine with AChE (Table 6.1).9 
However, since 6-chlorotacrine (1) is 25-fold more potent than tacrine itself, herein, we 
used it as the standard against which we compare all compounds. 6-Chlorotacrine (1) 
presented potent inhibition of AChE with an IC50 = 2.41 ± 0.48 nM, which is in good 
agreement with the literature value.36 The IC50 of compound 2 has recently been 
reported,12 and it also exhibited potent AChE inhibition. MetalA modulator 3 showed 
very poor inhibition (IC50 > 200 M), which was expected given that it was not originally 
designed to interact with AChE. Introduction of the 1,10-diaminodecane moiety to 3, 
however, provides a remarkable increase (> 200-fold) in potency (IC50 = 757 ± 279 nM 
for 4). Hybrid 5 was observed to have an IC50 = 2.37 ± 0.29 nM, identical to that of 1. 
Many tacrine hybrids reported in the literature showed an increase in potency compared 
to their parent compound. While this is not the case for 5 because the parent 6-
chlorotacrine (1) is already highly potent, this compound is still of interest given its 
potential for metal chelation and A interaction. In addition, the IC50 value of 5 is within 
the range reported for structurally similar metal/A-targeted tacrine hybrids in the 
literature.37-40  
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The AChE inhibitory properties of compounds 1-5 were also assessed using a 
method described by Muraoka and Miura41 to determine IC50 in the presence of reactive 
oxygen species (ROS IC50, Table 6.1). Inflammation and oxidative stress from ROS are 
thought to play a role in AD, and tacrine-mefenamic acid hybrids have shown an 
increase in potency towards AChE in the presence of ROS, which may be beneficial for 
anti-AD compounds.9 As such, we aimed to establish if the compounds of interest in this 
study displayed similar results. Unfortunately, only metalA modulator 3 showed a 
significant increase in potency in the presence of ROS. Although, even with this 
increase, 3 remains a relatively poor inhibitor. In the case of 4 and hybrid 5, there was 
actually a reduction in potency. Compounds 1 and 2 indicated virtually no change 
between IC50 and ROS IC50. To investigate the effect on enzyme inhibition of covalent 
linkage between the AChEi, linker, and metalA modulating moieties of hybrid 5, we 
examined combinations of molecules (2 + 3, 1 + 4 in 1:1 equimolar mixtures) in each of 
our inhibition assays (Table 6.1). Results indicate that covalent linkage is not essential 
for hybrid 5 in terms of IC50 as the values for 5, 2 + 3, and 1 + 4 were nearly identical. 
Similar results have been observed for tacrine-mefenamic acid hybrids.9,12 Interestingly, 
in terms of ROS IC50, covalent linkage may actually be detrimental for hybrid 5 as it was 
outperformed by both mixtures in this assay. However, the covalent linkage may still be 
beneficial to simultaneously deliver all components of the hybrid to the same location in 
the brain. 
 
6.2.3. BChE inhibition 
BChE is also commonly associated with characteristic A plaques. Thus, 
inhibition of BChE from equine serum (esBChE) by compounds 1-5 was also tested. 
With an IC50 = 2.41 ± 0.52 nM against BChE, 6-chlorotactine (1) showed inhibitory effect 
identical to that of AChE (2.41 ± 0.48 nM). Compounds 2 and 4 were found to be less 
active towards BChE than AChE with IC50 values of 13.6 ± 3.0 nM (13-fold diminution) 
and >200 M, respectively. Meanwhile, as similarly observed with AChE, compound 3 
exhibited no inhibitory activity with BChE and hybrid 5 demonstrated similar inhibition 
towards BChE (IC50 = 2.01 ± 0.12 nM) and AChE (IC50 = 2.37 ± 0.29 nM). 
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Table 6.1. Inhibition of EeAChE and esBChE activity by compounds 1-5 and effect of 
M2+ and A on IC50 of hybrid 5 under various conditions.  
              EeAChE            esBChE 
Compound IC50 (nM) ROS IC50 (nM) IC50 (nM) ROS IC50 (nM) 
Tacrinea 52.4 ± 7.3 183 ± 21 NDe ND 
1 2.41 ± 0.48 1.86 ± 0.37 2.41 ± 0.52 188 ± 43 
  2b 0.932 ± 0.220 2.18 ± 0.27 13.6 ± 3.0 2.18 ± 0.27 
3  1858 ± 235   
4 757 ± 279 1906 ± 490  0.162 ± 0.049 
5 2.37 ± 0.29 96.5 ± 24.3 2.01 ± 0.12 1.51 ± 0.18 
2 + 3c 0.544 ± 0.123 1.13 ± 0.33 0.034 ± 0.007 0.012 ± 0.003 
1 + 4c 1.61 ± 0.19 1.93 ± 0.24 2.85 ± 0.71 0.604 ± 0.223 
 Effect of M2+ on IC50 of hybrid 5 
                         EeAChE esBChE 
Conditionsd CuCl2 ZnCl2 CuCl2 ZnCl2 
A 75.4 ± 12.4 2.46 ± 0.55 1.78 ± 0.22 0.713 ± 0.065 
B 144 ± 11 2.08 ± 0.37 8.14 ± 1.00 1.28 ± 0.08 
c 4.14 ± 0.43 6.99 ± 2.26 6.09 ± 0.54 2.76 ± 0.22 
                              Effect of A on IC50 of hybrid 5 
 EeAChE  esBChE  
D 14.4 ± 5.2  0.554 ± 0.138  
E 2003 ± 647  1.02 ± 0.21  
f 7.26 ± 2.40  3.70 ± 0.48  
                              Effect of M2+ and A on IC50 of hybrid 5 
                         EeAChE esBChE 
 CuCl2 ZnCl2 CuCl2 ZnCl2 
G 82.8 ± 8.3 8.80 ± 0.84 4.52 ± 1.54 2.38 ± 0.49 
H 8.87 ± 1.22 9.42 ± 1.49 23.0 ± 3.2 4.70 ± 0.94 
I 182 ± 66 111 ± 30 65.4 ± 6.7 41.5 ± 8.4 
     
a Values from ref.9 b Values from ref.12 c Tested as 1:1 equimolar mixture. d Conditions: (a) Dilute 
compound 5, add AChE or BChE, wait 10 min, add M2+, wait 10 min, and initiate reaction. (b) Dilute 
compound 5, add M2+, wait 10 min, add AChE or BChE, wait 10 min, and initiate reaction. (c) Dilute 
compound 5, add mixture of AChE or BChE and M2+, wait 10 min, and initiate reaction. (d) Dilute 
compound 5, add AChE or BChE, wait 10 min, add A, wait 10 min, and initiate reaction. (e) Dilute 
compound 5, add A, wait 10 min, add AChE or BChE, wait 10 min, and initiate reaction. (f) Dilute 
compound 5, add mixture of AChE or BChE and A, wait 10 min, and initiate reaction. (g) Dilute 
compound 5, add AChE or BChE, wait 10 min, add A treated with M2+ for 2 min, wait 10 min, and initiate 
reaction. (h) Dilute compound 5, add A treated with M2+ for 2 min, wait 10 min, add AChE or BChE, wait 
10 min, and initiate reaction. (i) Dilute compound 5, add mixture of AChE or BChE, A, and M2+, wait 10 
min, and initiate reaction.e ND = not determined. 
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As with AChE, the inhibitory effect of compounds 1-5 on BChE was also 
examined under a ROS environment. With the exception of compounds 1 and 4, the 
introduction of ROS seemed to have little effect on the inhibition of BChE. Compound 1 
showed ca.75-fold reduction in activity while compound 4 displayed vastly improved 
inhibitory properties (IC50 = 0.162 ± 0.049 nM) suggesting that in the absence of the 
tacrine moiety, the oxidized form of compound 4 may block enzymatic turnover of BChE 
at an increased efficiency compared to other compounds. As with AChE, the covalent 
bond linkage requirement for inhibitory activity was investigated. While an equimolar 
combination of compounds 1 and 4 showed no improvement in inhibitory activity for 
BChE, an equimolar mixture of compounds 2 and 3 presented a 59-fold increase in 
activity over hybrid 5. In the presence of ROS, equimolar mixtures of compounds 1 and 
4 as well as 2 and 3 yield values 2.5-fold and 125-fold better, respectively, than those 
observed for the covalently linked hybrid 5. Although the covalent link seems to have an 
adverse effect upon the inhibitory activity of BChE, it still may be purposeful in 
transporting both components to the same site. It is important to note that the current 
linker used has been optimized for AChE not BChE. 
 
6.2.4. Effect of metals and A on AChE inhibition 
As previously mentioned, AChE is often found to be entangled in A plaques, 
and aggregation of A is promoted through binding at the PAS of AChE.18,24 
Additionally, metal ions, such as Cu2+ and Zn2+, have been observed to interact with 
Aand promote peptide aggregation.27-31 Composed of tacrine and a metalA 
modulating moiety, the hybrid 5 was envisioned to interact with AChE, A, and 
Cu2+/Zn2+ simultaneously within the complex environment of an AD-affected brain. 
However, interaction with A and Cu2+/Zn2+ could potentially be detrimental to the ability 
of 5 to function as an AChEi. The ability of hybrid 5 to inhibit AChE in the presence of 
M2+ (Cu2+ or Zn2+) and A was examined (Table 6.1). It is important to note that 
although other tacrine-derived hybrids have been shown to successfully co-inhibit 
cholinesterases and A aggregation,37-40 to our knowledge, the effects of metals and A 
on cholinesterases inhibition have not been studied for these compounds. Various 
conditions (a-i, Table 6.1) were tested as it was anticipated that the order of interaction 
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with AChE, A, and M2+ could affect the IC50 of 5. For example, 5 could potentially 
interact with AChE before being exposed to M2+ (condition a), with M2+ before being 
exposed to AChE (condition b), or with AChE and M2+ simultaneously (condition c). 
Similarly, 5 could interact with AChE before being exposed to A (condition d), with A 
before being exposed to AChE (condition e), or with AChE and A simultaneously 
(condition f). Finally, 5 could interact with AChE before being exposed to A treated with 
M2+ (condition g), with A treated with M2+ before being exposed to AChE (condition h), 
or with AChE, A, and M2+ simultaneously (condition i). 
In general, hybrid 5 retained good inhibition of AChE in the presence of M2+ and 
A. With only one exception, 5 showed an IC50 < 200 nM under all conditions tested. 
The lone exception (condition e, Table 6.1) occurred when 5 was exposed to A for 10 
min before introduction of AChE. Under these conditions, 5 indicated a nearly 850-fold 
reduction in potency (IC50 = 2003 ± 647 nM), which was not unexpected given that 
interaction of 5 with A could likely lead to a complex that simply cannot fit into the 
AChE binding site as before. Only slight increases in IC50 were seen in the presence of 
A in other cases (conditions d,f). 
Hybrid 5 showed moderate reduction in potency in the presence of Cu2+ in two 
cases (conditions a,b, Table 6.1) but virtually no change under condition c. Similar to 
the case seen with A, the largest reduction in potency was seen when 5 was exposed 
to Cu2+ for 10 min before introduction of AChE (condition b). However, in contrast to the 
case seen with A, the reduction was only around 60-fold (IC50 = 144 ± 11 nM). 
Interestingly, 5 presented essentially no change in IC50 in the presence of Zn2+ under 
the conditions tested (conditions a, b, c, Table 6.1). 
Hybrid 5 exhibited varying IC50 values in the presence of M2+ and A 
simultaneously (conditions g, h, i, Table 6.1). A moderate reduction in potency was 
indicated when 5 interacted with AChE before being exposed to Cu2+-treated A (IC50 = 
82.8 ± 8.3 nM), but this effect is not seen with Zn2+-added A samples (condition g). 
Only slight increases in IC50 were visible when 5 interacted with Cu2+/Zn2+-treated A 
before being exposed to AChE (condition h). These results are interesting given the 
observation for condition e (described above) and may indicate that compound 5 
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interacts differently with A and M2+-treated A. Moderate reductions in potency were 
observed when 5 interacted with AChE, A, and M2+ simultaneously (condition i). In the 
presence of AChE/A/Cu2+, hybrid 5 showed a nearly 80-fold reduction (IC50 = 182 ± 66 
nM). In the presence of AChE/A/Zn2+, the reduction was nearly 50-fold (IC50 = 111 ± 30 
nM). The case of AChE/A/Zn2+ should be noted in that, of all the conditions tested with 
Zn2+ present, it was the only one that showed a significant change in IC50. 
 The fact that 5 maintains much of its inhibition potential when exposed to M2+-
treated A prior to AChE but not when exposed to A prior to AChE may have 
implications for future in vivo studies. However, it is difficult to predict the order of 
interaction between these components in complex living systems. Regardless, the 
results described above indicate that hybrid 5 remains a relatively potent AChEi when 
interacting with M2+ and A. 
 
6.2.5 Effect of metals and A on BChE inhibition 
The effect of Cu2+, Zn2+, A, and M2+-treated A on BChE inhibition was also 
tested. In general, hybrid 5 maintained good inhibition of BChE, never losing more than 
32-fold activity compared to compound alone. Interestingly, with BChE, Cu2+ never 
changed the IC50 value by more than 4-fold (BChE added to the Cu2+-inhibitor complex), 
while with AChE, the presence of Cu2+ increased the IC50 value by up to 72-fold. On the 
other hand, Zn2+ actually improved the inhibitory activity by ca. 3-fold when added to the 
inhibitor-BChE complex. 
Similarly to the addition of Zn2+, the addition of A to the inhibitor-BChE complex 
resulted a 4-fold increase in inhibitory activity (0.554 ± 0.138 nM) when compared to 
hybrid 5. The IC50 value was decreased by a factor of 2 when BChE was added to the 
A-inhibitor complex (1.02 ± 0.21 nM) and no relative change was observed when the 
A and BChE were added simultaneously (3.70 ± 0.48 nM). 
When A was initially treated with M2+, a larger shift occurred than with A or 
metal alone. The effect on inhibition was minimal when metal-treated A was added to 
the inhibitor-BChE complex. The inhibitory activity of hybrid 5 was decreased 11-fold 
(23.0 ± 3.2 nM) when A was treated with Cu2+ and added to hybrid 5 followed by 
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addition of BChE. The worst perturbation of activity arose when the metal-treated A 
and BChE were simultaneously added to hybrid 5. The inhibitory activity was reduced 
32-fold and 21-fold by Cu2+- and Zn2+-treated A, respectively. While the inhibition of 
BChE is disturbed in the presence of A and metal species, the resulting change is less 
severe than that observed with AChE. 
 
6.2.6. Metal binding  
The ability of compounds 1, 2, 4, and 5 to bind Cu2+ and Zn2+ was studied by UV-
visible (UV-vis) and nuclear magnetic resonance (NMR) spectroscopy (Figure 6.2a-d). 
The Cu2+ and Zn2+ binding properties of compound 3 were previously reported.34,42 In 
addition to 3, new optical bands were observed in the UV-vis spectra of compounds 1 
and 2 upon the addition of CuCl2 or ZnCl2, suggesting that these compounds were able 
to interact with Cu2+/Zn2+ (Figure 6.2a, b). More importantly, compound 4 and hybrid 5, 
which were designed as metal chelators, showed promising metal binding properties. 
Upon incubation of CuCl2 with ligand (4 or 5) in EtOH, new optical bands (ca. 450 nm 
and 440 nm for 4 and 5, respectively) were indicated, implicating complex formation via 
metal chelation (Figure 6.2c, d). Moreover, 4 or 5 treated with ZnCl2 displayed a new 
optical band at ca. 440 nm suggesting Zn2+ binding (Figure 6.2c, d). In addition, 1H NMR 
investigation was used to examine possible interaction between compound 4 or 5 and 
Zn2+. Distinguishable downfield chemical shifts of the pyridyl, methylene, and aromatic 
protons were seen in the resulting spectrum of 4 or 5 when incubated with Zn2+ (Figure 
6.2c, d, right panel). This suggests that both compounds are able to bind Zn2+ through 
the N-donor atoms on the pyridine ring and amino group. 
Furthermore, the interaction of hybrid 5 with Cu2+/Zn2+ was examined by UV-vis 
in the presence of A with or without AChE (Figure 6.3a, b). For solutions containing A 
and Cu2+ or Zn2+ with or without AChE, optical changes upon addition of 5 were similar 
to those observed from the samples containing 5 incubated with Cu2+ or Zn2+ alone, 
which suggests that 5 has the ability to interact with Cu2+ or Zn2+ in the presence of A 
and AChE. While other metal/A-targeted tacrine hybrids have shown the ability to bind 
biometals,8,37 this is the first instance where a tacrine-metal chelator hybrid has been 
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shown to bind Cu2+ or Zn2+ in the presence of A and AChE. Overall, the UV-vis and 
NMR results demonstrate Cu2+ and Zn2+ interaction of compounds 1, 2, 4, and 5, as well  
 
 
Figure 6.2. Metal binding studies of (a) cpd 1, (b) cpd 2, (c) cpd 4, and (d) cpd 5 with CuCl2 (left) or ZnCl2 
(middle) by UV-vis. Conditions: [compound] = 40 M; [CuCl2 or ZnCl2] = 20800 M; 30 min incubation (4 
h for Zn2+ binding for cpd 4); room temperature. (c) and (d) right panel = Zn2+ binding of 4 or 5 by 1H 
NMR. NMR spectra of 4 or 5 (black, 2.0 mM) with ZnCl2 (red, 3.2 mM) in CD3OD at room temperature. 
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as the potential interaction of 5 with Cu2+ and Zn2+ surrounded by A and AChE. These 
results may correlate to the reactivity of the compounds towards metalA species in 
vitro (vide infra). 
 
 
Figure 6.3. Metal binding studies of 5 with (a) CuCl2 or (b) ZnCl2 in the absence and presence of A 
and/or AChE at pH 6.6 (Cu2+) and 7.4 (Zn2+), monitored by UV-vis. Spectra of A, 5, [A + 5], [A + MCl2], 
[MCl2 + 5], and [A + MCl2 + 5 ± AChE] are depicted in black, light blue, yellow, red, green, and blue, 
respectively. Conditions: [A] = 10 M; [CuCl2 or ZnCl2] = 10 M; [AChE] = 10 M; [5] = 10 M (5% v/v 
DMSO); 20 mM HEPES, pH 6.6 (Cu2+) and 7.4 (Zn2+), 150 mM NaCl; room temperature. 
 
6.2.7 A aggregation inhibition 
In addition to examining the AChE inhibitory activity and metal binding properties 
of hybrid 5, its influence, compared to compounds 1-4, on metal-free and metal-induced 
A40 aggregation in the absence and presence of AChE was studied in vitro. Two 
different A aggregation studies were carried out: inhibition (Figure 6.4) and 
disaggregation (Figure 6.5). The distribution of various-sized A species in both 
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experiments was analyzed by gel electrophoresis followed by Western blot with an anti-
A antibody (6E10), and morphologies of the resulting A species were identified by 
transmission electron microscopy (TEM). 
 The inhibition experiment was conducted to determine whether compounds 1-5 
were able to control the formation of metal-free and metal-associated A aggregates in 
the absence and presence of AChE (Figure 6.4a-c). A species having a dispersion of  
 
 
Figure 6.4. In vitro studies of the influence of 1, 2, 3, 4, and 5 on metal-free and metal-associated A40 
aggregation with and without AChE. (a) Scheme of the inhibition experiment. (b) Visualization of various-
sized A species in the absence (left) and presence (right) of AChE by gel electrophoresis with Western 
blot (anti-A antibody, 6E10). (c) TEM images of the 24 h incubated samples. Conditions: [A] = 25 M; 
[CuCl2 or ZnCl2] = 25 M; [AChE] = 25 M; [compound] = 50 M; pH 6.6 (for Cu2+ samples) or 7.4 (for 
metal-free and Zn2+ samples); 24 h incubation; 37 C; constant agitation. 
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molecular weight (MW) were observed with both metal-free and metal-treated 
conditions with and without AChE upon treatment with hybrid 5 (Figure 6.4b, lanes 6). 
Noticeable differences in the MW distribution of the generated A species were 
indicated between Cu2+-treated and Zn2+-treated samples with and without AChE upon 
incubation with 5 (Figure 6.4b, lanes 6). In addition, TEM analysis of metal-free and 
metal-induced A species with and without AChE upon treatment with hybrid 5 
displayed a mixture of amorphous and structured peptide species distinct from those of 
untreated samples (Figure 6.4c). Metal/A-targeted tacrine hybrids have been shown to 
inhibit self-induced and AChE-induced A aggregation in previous studies.37-39,43,44 
However, there exists little precedent for demonstrating modulation of metal-
associated A species among these hybrids making the results seen with 5 unique. The 
reactivity of metalA modulator linker 4, which has the same metal chelation moiety 
and linker region as 5 minus the AChEi moiety, towards both metal-free and metal-
triggered A aggregation with and without AChE was similar to that of 5 (Figure 6.4b, 
lanes 5 and 6). However, metalA modulator 3, which lacks the linker region and 
AChEi moiety, showed distinguishable reactivity with metal-treated samples with and 
without AChE compared to metal-free samples resulting in A species that have MW ≤ 
32 kDa (Figure 6.4b, lanes 4).34 Comparing the results across all compounds of interest, 
the presence of the linker region in compounds 2, 4, and 5 gave greater reactivity 
towards metal-free and metal-associated A species with and without AChE (Figure 
6.4b, 2/5 versus 1 and 4/5 versus 3). These results suggest the importance of the linker 
region, possibly by virtue of the increased hydrophobicity that it lends, for A reactivity. 
Overall, hybrid 5 displayed the desired multifunctionality by presenting varying degrees 
of regulatory activity towards metal-free and metal-mediated A aggregation with and 
without AChE in vitro. This activity may be resulted from combined properties of metal 
chelation, A interaction, and hydrophobicity. 
 
6.2.8. Disaggregation of A aggregates 
Disaggregation of preformed A aggregates by other tacrine-derived hybrids has, 
to our knowledge, not been reported. Here, the disaggregation experiment was 
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performed to assess the ability of compounds 1-5 to disassemble preformed metal-free 
and metal-associated A40 aggregates in the absence and presence of AChE (Figure 
6.5a, b). Similar to the results from the inhibition experiment, a wide array of both metal-
free and metal-induced A species in the absence of AChE were observed upon 
treatment with hybrid 5 (Figure 6.5b, lanes 6). However, in the presence of AChE, 
diverse-sized A species generated by incubation with 5 were only visualized under 
metal-involved conditions. Also, as before, A species having variable MW were 
detected between Cu2+- and Zn2+-treated samples with and without AChE upon 
treatment with 5 (Figure 6.5b, lanes 6). The overall reactivity of 4 towards preformed 
metal-free and metal-mediated A aggregates with and without AChE was similar to 
that of 5 (Figure 6.5b, lanes 5). Relative to 5, samples containing A and 3 presented a 
smaller range of MW in both metal-free and metal-treated cases with and without AChE. 
(Figure 6.5b, lanes 4). Analogous to the inhibition results, compounds containing the 
linker region were shown to have the greater reactivity towards metal-free and metal-
associated A aggregates in the absence and presence of AChE (Figure 6.5b, in  
 
 
Figure 6.5. Disaggregation studies using 1, 2, 3, 4, and 5 with and without AChE. (a) Scheme of the 
disaggregation experiment. (b) Visualization of various-sized A40 species in the absence (left) and 
presence (right) of AChE by gel electrophoresis with Western blot (anti-A antibody, 6E10). Conditions: 
[A] = 25 M; [CuCl2 or ZnCl2] = 25 M; [AChE] = 25 M [compound] = 50 M; pH 6.6 (for Cu2+ samples) 
or 7.4 (for metal-free and Zn2+ samples); 24 h incubation; 37 C; constant agitation. 
 
particular, 3 versus 4). Taken together, these results suggest that hybrid 5, in addition to 
(b) 
(a) 
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being able to modulate the formation of metal-free and metal-induced A aggregates 
with and without AChE, has the ability to impact preformed metal-free and metal-
triggered A aggregates with and without AChE to different extents. 
 
6.2.9 Molecular modelling 
Molecular modelling was performed in an effort to visualize the interactions of 
hybrid 5 with AChE and A. Modelling was performed with GOLD45 using AChE from 
Torpedo californica (TcAChE) and A40 (PDB codes: 1ACJ46 and 2LFM,47 respectively). 
Hybrid 5 was docked into the tacrine-binding site of an energy optimized A40-TcAChE  
 
 
Figure 6.6. Hybrid 5 docked with A40-TcAChE complex. (a) Interaction of 5 withTcAChE (grey) and A40 
(yellow/orange). (b) Close-up of important interactions between 5 and W84, H440, and F330 (grey) from 
TcAChE and H6, H13, and H14 (yellow) form A40. Carbon and nitrogen atoms of 5 are shown in green 
and blue, respectively. 
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complex, and the first-ranked conformation is shown (Figure 6.6a, b). The energy 
optimized A40-TcAChE complex showed a close association between the two 
components (Figure 6.6a). As expected, the 6-chlorotacrine moiety of 5 was positioned 
in the CAS of the enzyme with the quinoline ring system stacked between W84 and 
F330 and the nitrogen of the quinoline ring in close proximity to H440 (Figure 6.6b). The 
linker region of 5 was positioned such that it extended from the CAS to the PAS of the 
enzyme by spanning the gorge region. These modelling results are consistent with 
previous docking studies on tacrine-based linkers and hybrids with TcAChE.9,12,48,49 Of 
more interest is the predicted binding of the metal chelation moiety of 5 and its potential 
interactions with A. This moiety was predicted to bind near the PAS of AChE and in 
close proximity to H6, H13, and H14 of A40 (Figure 6.6b). These residues are known to 
be important for interaction of M2+ with A.27-31,50 In addition, N-donor atoms from the 
pyridine ring and amino group of the metal chelation moiety of 5 were predicted to be in 
the correct geometry to coordinate M2+. 
 
6.2.10.  Blood-brain barrier permeability 
An essential characteristic for any anti-AD compound is the ability to cross the 
blood-brain barrier (BBB) and gain access to the central nervous system (CNS). BBB 
permeability for compounds 1-5 was first predicted based on the calculated values of 
Lipinski’s rules and logBB (Table 2), which suggested that they might be able to cross 
the BBB.30,51,52 Along with this theoretical prediction, the potential BBB penetration of 1-
5 was verified by an in vitro Parallel Artificial Membrane Permeability-BBB (PAMPA-
BBB) Assay (Table 2).34,53 Permeability values (logPe) of 1-5 were measured to be 5.1 
± 0.1 (for 1, 2, and 4), 4.0 ± 0.1 (for 3),34 and 4.8 ± 0.1 (for 5). Based on empirical 
classification of known BBB permeable molecules (e.g., verapamil), our chemical 
scaffolds (in particular, hybrid 5) could potentially be BBB permeable. Similar results 
have been seen in this type of assay with tacrine-8-hydroxyquinoline hybrids and 
pyrano[3,2-c]quinoline-6-chlorotacrine hybrids.8,38 However, the PAMPA-BBB prediction 
only takes into account passive diffusion across the BBB. Permeability is likely more 
complex given the enzymes and efflux transporters (e.g., P-glycoprotein) that are known 
to prevent xenobiotic entry into the CNS, and future studies will aim to elucidate how 
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hybrid 5 interacts with these biochemical barriers. 
 
Table 6.2. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe) for 1-5. 
 
Calculationa 1 2 3b 4 5 
Lipinski’s rules 
and others 
MW 233 388 227 398 613 500 
clogP 4.08 7.76 1.76 5.10 10.7 ≤ 5.0 
HBA 2 3 3 5 6 ≤ 10 
HBD 2 3 1 4 3 ≤ 5.0 
PSA 38.9 50.9 28.2 66.2 65.1 ≤ 90 
logBB 0.174 0.555 –0.0197 –0.0744 0.785 
< 1.0 (poor distribution 
in the brain) 
logPec 5.1 ± 0.1 5.1 ± 0.1 4.0 ± 0.1 5.1 ± 0.1 4.8 ± 0.1  
CNS+/ 
predictiond 
CNS+ CNS+ CNS+ CNS+ CNS+ logPe < 5.4 (CNS+) 
      logPe > 5.7 (CNS–) 
       
a MW, molecular weight; clogP, calculated logarithm of the octonal-water partition coefficient; HBA, 
hydrogen-bond acceptor atoms; HBD, hydrogen-bond donor atoms; PSA, polar surface area; logBB = 
0.0148 x PSA + 0.152 x clogP + 0.130. b The values for cpd 3 were previously reported.34 c The values 
of –logPe were measured by the Parallel Artificial Membrane Permeability Assay adapted for BBB 
(PAMPA-BBB). d CNS+/ prediction: prediction of compound penetration to the central nervous system 
(CNS). Compounds categorized as CNS could permeate through the BBB and target the CNS. In the 
case of compounds assigned as CNS, they have poor permeability through the BBB and therefore, their 
bioavailability into the CNS is considered to be minimal. 
 
6.3. Conclusion 
In conclusion, a novel hybrid 5 of 6-chlorotacrine and metalA modulator has 
been synthesized and evaluated in vitro. This compound show potent inhibition of both 
AChE and BChE, and this potent inhibition was largely retained in the presence of ROS, 
M2+, and A. Additionally, 5 showed the ability to bind Cu2+ and Zn2+, and it was able to 
effectively modulate the assembly of metal-free and metal-induced A aggregates in the 
absence and presence of AChE. Furthermore, this compound presented the ability to 
transform preformed metal-free and metal-associated A aggregates with and without 
AChE. Molecular modelling predicted that 5 was able to simultaneously interact with the 
CAS and PAS of AChE and with histidine residues known to be involved in M2+ binding 
in the A peptide. A PAMPA-BBB assay predicted the BBB penetrability of 5. Together, 
these results make hybrid 5 a worthy candidate for additional studies. As both a tacrine-
8-hydroxyquinoline hybrid and a tacrine-melatonin hybrid have shown the ability to 
decrease A deposits using an in vivo mouse model,11,54 similar results would be 
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anticipated for hybrid 5. However, due to the hepatotoxicity associated with tacrine, the 
next generation of hybrids capable of disaggregating metal-free and metal-triggered 
preformed A aggregates as well as inhibiting cholinesterases and A aggregation for in 
vivo studies will be composed of other currently used AD treatments, such as donepezil 
and galantamine. The synthesis and in vitro studies of such hybrids are currently 
underway in our laboratories. 
 
6.4. Experimental section  
 
6.4.1. Materials and instrumentation 
Compounds 29 and 334 were prepared as previously reported. A40 
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) was purchased from 
Anaspec (Fremont, CA). All reagents for chemical synthesis were purchased from 
Sigma-Aldrich (St. Louis, MO) and used without further purification. Reactions were 
monitored by TLC (Merck, Silica gel 60 F254). Visualization was achieved using the 
following methods: UV absorption by fluorescence quenching or a ninhydrin stain 
(ninhydrin (1.5 g, n-butanol (100 mL), AcOH (3 mL)). Compounds were purified by SiO2 
flash chromatography (Dynamic Adsorbents Inc., Flash Silica Gel 32-63u). 1H and 13C 
NMR spectra were recorded on a Bruker AvanceTM DPX 500 or Varian 400 MHz 
spectrometer. Liquid chromatography mass spectrometry (LCMS) was performed on a 
Shimadzu LCMS-2019EV equipped with a SPD-20AV UV-vis detector and a LC-20AD 
liquid chromatograph. HRMS was performed on a Micromass AutoSpec Ultima 
Magnetic sector mass spectrometer. Optical spectra for metal binding studies were 
obtained by using an Agilent 8453 UV-visible (UV-vis) spectrophotometer. Analyses by 
UV-vis assays (determination of IC50 values and Parallel Artificial Membrane 
Permeability blood-brain barrier penetration (PAMPA-BBB) Assay) were carried out on 
a multimode SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA) using 
96-well plates (Fisher Scientific). Transmission electron microscopy (TEM) images were 
recorded on a Philips CM-100 transmission electron microscope (Microscopy and 
Image Analysis Laboratory, University of Michigan, Ann Arbor, MI). Molecular modeling 
was performed using Sybyl-X and GOLD.45 
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6.4.2. Preparation of 6-chlorotacrine (1) 
The known compound 1 was prepared in a manner similar to those previously 
established in the literature.5,6 Briefly, 2-amino-4-chlorobenzonitrile (382 mg, 2.5 mmol, 
1 equiv), cyclohexanone (1.26 mL, 12.2 mmol, 4.86 equiv), and anhydrous ZnCl2 (750 
mg, 5.5 mmol, 2.2 equiv) were combined and heated at 125 °C for 3 h. The reaction 
mixture was cooled to room temperature and treated with H2O (50 mL). The remaining 
solid was collected by vacuum filtration, treated with 1 M aq. NaOH (50 mL), and heated 
to reflux for 16 h. The reaction mixture was then cooled to room temperature and 
extracted with CHCl3 (3 x 50 mL). The combined organic layers were washed with brine 
(50 mL), dried (MgSO4), filtered, and concentrated under reduced pressure to afford a 
crude yellow solid, which was purified by flash column chromatography (SiO2, 
9:1/EtOAc:MeOH, Rf 0.15) to yield 1 (135 mg, 23%) as an off-white solid: 1H NMR 
((CD3)2SO, 400 MHz)  8.18 (d, 1H, J = 9.0 Hz), 7.62 (d, 1H, J = 2.0 Hz), 7.28 (dd, 1H, 
J1 = 9.0 Hz, J2 = 2.0 Hz,), 6.48 (s, 2H), 2.81 (t, 2H, J = 5.4 Hz), 2.53 (t, 2H, J = 5.5 Hz), 
1.81 (m, 4H); 13C NMR ((CD3)2SO, 100 MHz)  158.8, 148.3, 147.0, 132.4, 126.4, 
124.2, 122.7, 115.6, 109.4, 33.5, 23.6, 22.5, 22.4; LRMS m/z calcd for C13H13ClN2: 
232.08; found 233.00 [M+H]+. 
 
6.4.3. Preparation of N1-[(6-bromopyridin-2-yl)methyl]-N4,N4-dimethylbenzene-1,4-
diamine (6) 
6-Bromo-2-pyridinecarboxaldehyde (1 g, 5.38 mmol, 1 equiv), N,N-dimethyl-p-
phenylenediamine (733 mg, 5.38 mmol, 1 equiv), and EtOH (40 mL) were combined 
and heated to reflux for 1 h. The reaction was cooled to room temperature, and NaBH4 
(1.1 g, 28.8 mmol, 5.4 equiv) was added. The reaction was again heated to reflux for 1 
h before being cooled to room temperature, quenched with H2O (100 mL), and 
extracted with Et2O (3 x 50 mL). The combined organic layers were washed with brine 
(100 mL), dried (MgSO4), filtered, and concentrated under reduced pressure to afford a 
crude brown oil, which was purified by flash column chromatography (SiO2, 
1:1/hexanes:EtOAc, Rf 0.43) to yield 6 (1.5 g, 91%) as a brown solid: 1H NMR (CDCl3, 
400 MHz)  7.48 (t, 1H, J = 7.7 Hz), 7.35 (d, 1H, J = 7.8 Hz), 7.32 (d, 1H, J = 7.6 Hz), 
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6.76-6.58 (m, 4H), 4.41 (br s, 2H), 2.83 (br s, 6H); 13C NMR (CDCl3, 100 MHz)  161.5, 
144.3, 141.6, 139.9, 139.1, 126.3, 120.3, 115.8, 114.5, 50.1, 42.2; LRMS m/z calcd for 
C14H16BrN3: 305.05; found 305.75 [M+H]+. 
 
6.4.4. Preparation of N1-{[6-((10-aminodecyl)amino)pyridin-2-yl]methyl}-N4,N4-
dimethylbenzene-1,4-diamine (4) 
Compound 6 (136 mg, 0.443 mmol, 1 equiv), 1,10-diaminodecane (305 mg, 1.77 
mmol, 4 equiv), and 1-pentanol (2 mL) were combined and heated to reflux for 14 h. 
The reaction was cooled to room temperature, diluted with CH2Cl2 (50 mL), and washed 
with 10% aq. KOH (2 x 50 mL), H2O (2 x 50 mL), and brine (50 mL). The organic layer 
was dried (MgSO4), filtered, and concentrated under reduced pressure to afford a crude 
yellow oil, which was purified by flash column chromatography (SiO2, 7:3/CH2Cl2:MeOH 
with NH4OH (7 mL/L of solvent), Rf 0.76). Further purification by flash column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.23) 
removed remaining impurities and gave 4 (47 mg, 27%) as a dark yellow solid: 1H NMR 
(CDCl3, 400 MHz)  7.36 (t, 1H, J = 7.9 Hz), 6.73 (d, 2H, J = 8.8 Hz), 6.65 (d, 2H, J = 
8.8 Hz), 6.58 (d, 1H, J = 7.3 Hz), 6.23 (d, 1H, J = 8.2 Hz), 4.56 (br t, 1H, J = 5.1 Hz), 
4.19 (s, 2H), 3.22 (q, 2H, J = 6.6 Hz), 2.80 (s, 6H), 2.68 (t, 2H, J = 7.0 Hz), 1.61 (p, 2H, 
J = 7.2 Hz), 1.46-1.36 (m, 4H), 1.29 (s, 10H); 13C NMR (CDCl3, 100 MHz)  158.8, 
157.4, 144.2, 141.0, 138.1, 116.0, 114.6, 110.4, 104.1, 50.4, 42.5, 42.4, 42.2, 33.5, 
29.7, 29.63, 29.62, 29.53, 29.49, 27.2, 27.0; HRMS m/z calcd for C24H39N5: 397.3205; 
found 398.3260 [M+H]+ 
 
6.4.5. Preparation of 2-bromo-6-(1,3-dioxolan-2-yl)pyridine (7) 
The known compound 7 was prepared by following a modified protocol of 
previously reported procedures.55,56 A solution of 6-bromo-2-pyridinecarboxaldehyde 
(2.0 g, 10.8 mmol, 1 equiv), ethylene glycol (1.2 mL, 21.5 mmol, 2 equiv), and 
methanesulfonic acid (230 L, 3.55 mmol, 0.33 equiv) in toluene (65 mL) was heated to 
reflux in a Dean-Stark apparatus for 24 h prior to being cooled to room temperature and 
neutralized with saturated aq. NaHCO3. The organic layer was separated and the 
aqueous phase was extracted with Et2O (3 x 50 mL). The combined organic layers were 
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washed with H2O (3 x 50 mL) and brine (50 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure to afford a crude yellow oil, which was purified by 
flash column chromatography (SiO2, 1:1/hexanes:EtOAc, Rf 0.66) to yield 7 (1.81 g, 
73%) as a pale yellow oil: 1H NMR (CDCl3, 500 MHz)  7.49 (t, 1H. J = 7.7 Hz), 7.38 (d, 
1H, J = 7.3 Hz), 7.35 (d, 1H, J = 7.9 Hz), 5.68 (s, 1H), 4.06-3.99 (m, 2H), 3.97-3.90 (m, 
2H); 13C NMR (CDCl3, 125 MHz)  158.3, 141.3, 139.0, 128.2, 119.3, 102.5, 65.4. 
 
6.4.6. Preparation of N1-[6-(1,3-dioxolan-2-yl)pyridin-2-yl]-N10-(6-chloro-tacrine) 
decane-1,10-diamine (8) 
Compound 7 (500 mg, 2.17 mmol, 1 equiv), compound 2 (1.25 g, 3.23 mmol, 1.5 
equiv), CuI (21 mg, 0.109 mmol, 0.05 equiv), L-proline (25 mg, 0.217 mmol, 0.10 equiv), 
K2CO3 (45 mg, 0.326 mmol, 0.15 equiv), DMSO (8 mL), and H2O (800 L) were 
combined and stirred at 90 °C for 47 h. The reaction was cooled to room temperature, 
diluted with H2O (150 mL), and extracted with CH2Cl2 (3 x 50 mL). The combined 
organic layers were washed with H2O (3 x 50 mL) and brine (50 mL), dried (MgSO4), 
filtered, and concentrated under reduced pressure to afford a crude brown oil, which 
was purified by flash column chromatography (SiO2, 49:1/CH2Cl2:MeOH with NH4OH (7 
mL/L of solvent) to 19:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.41 
(9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent))) to yield 8 (249 mg, 21%) as a 
yellow oil: 1H NMR (CDCl3, 400 MHz)  7.84 (d, 1H, J = 9.0 Hz), 7.83 (s, 1H), 7.39 (t, 
1H, J = 7.8 Hz), 7.20 (dd, 1H, J1 = 9.0 Hz, J2 = 1.4 Hz), 6.73 (d, 1H, J = 7.3 Hz), 6.29 (d, 
1H, J = 8.4 Hz), 5.63 (s, 1H), 4.65 (br t, 1H, J = 5.0 Hz), 4.13-4.05 (m, 2H), 4.02-3.96 
(m, 2H), 3.94 (br s, 1H), 3.42 (br t, 2H), 3.15 (q, 2H, J = 6.6 Hz), 2.97 (br t, 2H), 2.60 (br 
t, 2H), 1.85 (br p, 4H), 1.59 (p, 2H, J = 7.0 Hz), 1.54 (p, 2H, J = 7.3 Hz), 1.32-1.29 (m, 
4H), 1.23 (br s, 8H); 13C NMR (CDCl3, 100 MHz)  159.4, 158.8, 155.4, 150.8, 148.1, 
138.0, 133.8, 127.5, 124.6, 124.0, 118.4, 115.6, 108.9, 106.0, 103.6, 65.3, 49.6, 42.3, 
34.0, 31.7, 29.42, 29.38, 29.27, 29.26, 27.0, 26.8, 24.5, 22.9, 22.6; LRMS m/z calcd for 
C31H41ClN4O2: 536.29; found 537.35 [M+H]+ 
  
6.4.7. Preparation of 6-{[10-((6-chloro-1,2,3,4-tacrine) amino)decyl]amino}picolin 
aldehyde (9)  
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A solution of compound 8 (91 mg, 0.170 mmol) in MeCN (2.2 mL) and 2 M aq. 
HCl (1.1 mL) was stirred at 60 °C for 23 h. The reaction was cooled to room 
temperature, slowly quenched with saturated aq. NaHCO3, and extracted with CH2Cl2 (3 
x 25 mL). The combined organic layers were washed with brine (50 mL), dried (MgSO4), 
filtered, and concentrated under reduced pressure to yield 9 (81 mg, 96%) as a yellow 
oil, which was used without any further purification: 1H NMR (CDCl3, 400 MHz)  9.82 
(s, 1H), 7.85 (d, 1H, J = 9.1 Hz), 7.84 (s, 1H), 7.48 (t, 1H, J = 7.8 Hz), 7.20 (dd, 1H, J1 = 
9.1 Hz, J2 = 1.9 Hz), 7.15 (d, 1H, J = 7.2 Hz), 6.53 (d, 1H, J = 8.4 Hz), 4.86 (br t, 1H), 
4.03-3.97 (m, 1H), 3.43 (t, 2H, J = 7.2 Hz), 3.27 (q, 2H, J = 6.7 Hz), 2.98 (br t, 2H), 2.61 
(br t, 2H), 1.85 (br p, 4H), 1.62 (p, 2H, J = 7.2 Hz), 1.57 (p, 2H, J = 7.4 Hz), 1.34-1.30 
(m, 4H), 1.24 (br s, 8H); 13C NMR (CDCl3, 100 MHz)  193.8, 159.4, 159.1, 151.3, 
150.9, 148.0, 137.8, 133.9, 127.4, 124.7, 124.1, 118.3, 115.6, 112.0, 111.5, 49.6, 42.1, 
34.0, 31.8, 29.5, 29.4, 29.31, 29.28, 27.0, 26.9, 24.6, 22.9, 22.6; m/z calcd for 
C29H37ClN4O: 492.27; found 493.20 [M+H]+. 
 
6.4.8. Preparation of N1-{[6-((10-((6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino) 
decyl)amino)pyridin-2-yl]methyl}-N4,N4-dimethylbenzene-1,4-diamine (5) 
To a solution of compound 9 (64 mg, 0.129 mmol, 1 equiv) in EtOH (2.5 mL) was 
added N,N-dimethyl-p-phenylenediamine (18 mg, 0.129 mmol, 1 equiv). The reaction 
mixture was heated to reflux for 1 h and cooled to 0 °C prior to addition of NaBH4 (33 
mg, 0.864 mmol, 6.7 equiv). The reaction mixture was stirred at 0 °C for 5 min, warmed 
to room temperature, and stirred for an additional 30 min before quenching with H2O (10 
mL) and extracting with Et2O (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated under reduced pressure to afford a crude yellow oil, 
which was purified by flash column chromatography (SiO2, 19:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.20) to yield 5 (41 mg, 52%) as a yellow oil: 1H NMR 
(CDCl3, 400 MHz)  7.888 (d, 1H, J = 1.5 Hz), 7.886 (d, 1H, J = 8.8 Hz), 7.35 (t, 1H, J = 
7.7 Hz), 7.25 (dd, 1H, J1 = 8.8 Hz, J2 = 1.5 Hz), 6.73 (d, 2H, J = 8.6 Hz), 6.64 (d, 2H, J = 
8.6 Hz), 6.58 (d, 1H, J = 7.3 Hz), 6.22 (d, 1H, J = 8.3 Hz), 4.56 (br t, 1H, J = 4.9 Hz), 
4.19 (s, 2H), 3.97 (br s, 1H), 3.47 (t, 2H, J = 7.0 Hz), 3.22 (q, 2H, J = 6.6 Hz), 3.02 (br t, 
2H), 2.80 (s, 6H), 2.65 (br t, 2H), 1.90 (br p, 4H), 1.64 (p, 2H, J = 7.1 Hz), 1.61 (p, 2H, J 
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= 7.4 Hz), 1.39-1.35 (m, 4H), 1.29 (s, 9H); 13C NMR (CDCl3, 100 MHz)  159.5, 158.7, 
157.4, 150.9, 148.2, 144.1, 141.0, 138.1, 134.0, 127.6, 124.7, 124.2, 118.5, 115.9, 
115.7, 114.6, 110.4, 104.1, 50.3, 49.7, 42.44, 42.36, 34.1, 31.9, 29.7, 29.5, 29.44, 
29.39, 27.2, 27.0, 24.6, 23.0, 22.7; HRMS m/z calcd for C37H49ClN6: 612.3707; found 
613.3600 [M+H]+. 
 
6.4.9. In vitro acetyl- and butyrylcholinesterase (AChE and BChE) assay 
Compounds of interest were dissolved in sodium phosphate (dibasic) buffer ((100 
L), 0.1 M, pH 8.0 adjusted at room temperature). AChE was added to the solution of 
inhibitors (50 L, containing 0.08 U/mL (ca. 0.29 nM) AChE (final concentration) 
(Sigma-Aldrich cat #C2888 from eel) in sodium phosphate (dibasic) buffer (100 mM, pH 
8.0 adjusted at room temperature)). The mixture of inhibitor and enzyme was incubated 
for 10 min before initiation with a DTNB:acetylthiocholine (ATC) (0.25 mM:0.5 mM final 
concentration, respectively) mixture (50 L) in phosphate buffer (100 mM, pH 8.0 
adjusted at room temperature). The reaction was monitored at 412 nm taking 
measurements every 30 sec for 20 min on a SpectraMax M5 plate reader. Data was 
corrected with the negative control (no ATC) and normalized to the positive control (no 
inhibitor) using the initial rates (first 25 min). All assays were performed in triplicate. 
The data was fitted to a Hill-plot and IC50 values calculated using KaleidaGraph 4.1.1. 
All IC50 values are reported in Table 6.1. All butyrylcholinesterase (BChE) experiments 
were performed using identical conditions substituting butyrylthiocholine (BTC) for ATC. 
 
6.4.10.  In vitro AChE and BChE inactivation assay in a ROS environment 
In the wells of a 96-well plate, horseradish peroxidase (0.25 M), H2O2 (100 M), 
AChE (0.08 U/mL, ca. 0.29 nM), inhibitors (25 M to 13 pM), and DETAPAC (100 M) 
were dissolved in sodium acetate buffer (50 mM, pH 6.0 adjusted at room temperature) 
and incubated at 37 °C for 30 min. Note: all concentrations are reported as final 
concentrations. A DTNB:acetylthiocholine (ATC) (0.25 mM:0.5 mM final concentration, 
respectively) mixture in sodium phosphate (dibasic) buffer (50 mM, pH 7.4 adjusted at 
room temperature) was added to the AChE/inhibitor solution to initiate the reactions. 
The crude data was processed to obtain IC50 values as described in section 6.4.9. All 
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IC50 values are reported in Table 6.1. BChE experiments were done in an identical 
manner substituting BTC for ATC. 
 
6.4.11.  Metal binding studies by UV-vis and NMR spectroscopy 
The interaction of compounds 1-5 with 0.5-2 equiv of Cu2+ or Zn2+ in EtOH was 
monitored by UV-vis ([compound] = 40 M (1% v/v final DMSO concentration; 
incubation for 30 min (4 h for Zn2+ binding for cpd 4); room temperature). Metal binding 
properties of compound 5 in the presence of A and/or AChE were also studied by UV-
vis. A (10 M) was treated for 2 min with CuCl2 or ZnCl2 (10 M) in HEPES (20 mM, 
pH 6.6 (for Cu2+) or pH 7.4 (for Zn2+) and NaCl (150 mM). AChE (10 M) was added to 
the solution containing A and Cu2+ or Zn2+. The resulting sample was incubated for 5 
min at room temperature and treated with compound 5 (10 M, 5% v/v final DMSO 
concentration) followed by 5 min incubation. For comparison, optical spectra of the 
samples generated from incubation of compound 5 (10 M) with CuCl2 or ZnCl2 (10 M) 
for 5 min were measured. The interaction of compounds 4 and 5 with ZnCl2 was 
observed by 1H NMR. Compound 4 or 5 (2 mM) was dissolved in CD3OD and treated 
with 1 equiv of ZnCl2. The resulting solution was incubated for 30 min prior to NMR 
measurement. Sequentially, 0.2 equiv of ZnCl2 was added to this solution until no 
further change in the NMR spectrum or precipitation was observed. 
 
6.4.12.  Amyloid- (A) peptide experiments 
To aliquot the A40 (1 mg), it was completely dissolved with the NH4OH provided 
by the supplier, split into 5 aliquots, lyophilized, and stored at 80 °C. For assays, A40 
solutions were prepared by addition of NH4OH (10 L, 1% v/v, aq) to the above aliquots 
and diluted with ddH2O to obtain ca. 200 M as determined by UV-vis (280 nm, room 
temperature). For both inhibition and disaggregation experiments, the buffer solution (20 
M HEPES, pH 6.6 (for Cu2+) or pH 7.4 (for metal-free and Zn2+), 150 M NaCl) was 
used. For the inhibition experiment, A (25 M) was first treated with either CuCl2 or 
ZnCl2 (25 M) for 2 min at room temperature followed by addition and incubation of 
AChE (25 M) for 5 min (only for AChE-indicated samples). The resulting samples were 
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then incubated with compounds 1-5 (50 M, 1% v/v final DMSO concentration) at 37 °C 
for 24 h with constant agitation. For the disaggregation experiment, A (25 M) was first 
incubated with CuCl2 or ZnCl2 (25 M) at 37 °C for 24 h with continuous agitation. The 
samples were then treated sequentially with AChE (25 M, only for AChE-indicated 
samples) for 5 min followed by addition of compounds 1-5 (50 M; 1% v/v final DMSO 
concentration). These resulting solutions were incubated for an additional 24 h at 37 °C 
with constant agitation. 
 
6.4.13.  Gel electrophoresis with Western blot 
The A peptide experiments (described in section 6.5.12) were analyzed by gel 
electrophoresis with Western blot using anti-A antibody (6E10).34,57 Various Aspecies 
generated by both inhibition and disaggregation experiments were separated by a 10-
20% Tris-tricine gel (Invitrogen). The gel was transferred to a nitrocellulose membrane 
and blocked for 2 h with BSA (Sigma, 3% w/v) dissolved in Tris-buffered saline (TBS, 
Fisher) containing 0.1% Tween-20 (TBS-T, Sigma). The membrane was treated with 
6E10 (1:2,000; 2% BSA in TBS-T, Covance, Princeton, NJ) overnight at 4 °C with gentle 
agitation and probed with a horseradish peroxidase-conjugated goat anti-mouse 
secondary antibody (1:5,000; Cayman Chemical, Ann Arbor, MI) in 2% BSA in TBS-T 
solution for 1 h at room temperature. The protein bands were visualized by using the 
ThermoScientific Supersignal West Pico Chemiluminescent Substrate (Fisher). 
 
6.4.14.  Transmission electron microscopy (TEM) 
TEM samples were prepared following a previously reported method.34,57 Glow-
discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, 
PA) were treated with the samples (5 L) from either the inhibition or disaggregation 
experiment for 2 min at room temperature. Excess sample was removed with filter 
paper. The grids were washed 5 times with ddH2O, stained with uranyl acetate (1% w/v, 
ddH2O, 5 L) for 1 min, and dried for 15 min at room temperature. A Philips CM-100 
transmission electron microscope (80 kV, 25,000x magnification) was used for obtaining 
TEM images of the samples. 
 
 
144 
 
6.4.15. Effect of metals and A peptide on AChE and BChE inhibition by 
compound 5 
The AChE inhibitor 5 (10 M to 5 pM) was dissolved in phosphate buffer (100 L, 
100 mM final concentration, pH 8.0 adjusted at room temperature room temperature) 
and one of three conditions was followed. Conditions (a), (d), and (g): AChE (25 L, 
0.08 U/mL final concentration) was added to the inhibitor solutions (100 L) and 
incubated for 10 min prior to addition of CuCl2 or ZnCl2 or A peptide (25 L, 10 M final 
concentration). After 10 min, the reactions were initialized with a DTNB:ATC (0.25 
mM:0.5 mM final concentration, respectively) mixture (50 L) in phosphate buffer (100 
mM final concentration, pH 8.0 adjusted at room temperature). Conditions (b), (e), and 
(h): CuCl2 or ZnCl2 or A peptide (25 L, 10 M final concentration) were added to the 
inhibitor solutions (100 L) and incubated for 10 min prior to addition AChE (0.08 U/mL 
final concentration). After 10 min, the reactions were initialized with a DTNB:ATC (0.25 
mM:0.5 mM final concentration, respectively) mixture (50 L) in phosphate buffer (100 
mM final concentration, pH 8.0 adjusted at room temperature). Conditions (c), (f), and 
(i): A mixture (50 L) of AChE (0.08 U/mL final concentration) and CuCl2 or ZnCl2 or A 
peptide (10 M final concentration) (50 L total) was added to the inhibitor solutions 
(100 L). After 10 min, the reactions were initialized with a DTNB:ATC (0.25 mM:0.5 
mM final concentration, respectively) mixture (50 L) in phosphate buffer (100 mM final 
concentration, pH 8.0 adjusted at room temperature). IC50 values were determined as 
described in section 3.1 and are reported in Table 1. Outside of using BTC in lieu of 
ATC, all BChE experiments were performed as AChE experiments. 
 
6.4.16.  Molecular modeling 
Compound 5 was built using the Sybyl-X software and minimized to 0.01 
kcal/mol by the Powell method, using Gasteiger-Hückel charges and the Tripos force 
fields. The coordinates of acetylcholinesterase (TcAChE) and amyloid-beta (A40) were 
downloaded from the Protein Data Bank website (PDB codes: 1ACJ and 2LFM, 
respectively). The H2O molecules and all other ligands were removed from the two 
proteins. Hydrogen atoms were added and the energy of both proteins was minimized 
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separately using the Amber force fields with Amber charges. Then, the energy-
optimized ligand (compound 5) was docked into the tacrine-binding site in the energy 
minimized tacrine-free TcAChE using GOLD.45 The parameters were set as the default 
values for GOLD. The maximum distance between hydrogen bond donors and 
acceptors for hydrogen bonding was set to 3.5 Å. After docking, the first-ranked 
conformation of compound 5 was merged into the corresponding tacrine-free TcAChE 
(to determine the proper binding area for A40 binding). 
The energy-optimized A was then docked close to the surface of TcAChE using 
GOLD. A distance constraint was applied between the H6 residue of A40 and the Gln74 
of TcAChE (that was chosen due its vicinity to the metal-chelator portion of compound 5 
in the compound 5TcAChE complex). Here again, the parameters were set as the 
default values for GOLD. The maximum distance between hydrogen bond donors and 
acceptors for hydrogen bonding was set to 3.5 Å. After docking, the first-ranked 
conformation of A40 was merged into the corresponding tacrine-free TcAChE. The new 
A40TcAChE complex was subsequently subjected to energy minimization using the 
Amber force fields with Amber charges. During the energy minimization, the structure of 
A40 and residues within a 7-Å radius were allowed to move. The remaining residues 
were kept frozen in order to save calculation time. The energy minimization was 
performed using the Powell method with a 0.05 kcal/mol energy gradient convergence 
criterion and a distance dependent dielectric function. Compound 5 was then docked 
into the tacrine-binding site in the obtained energy optimized A40TcAChE complex as 
described above. The first-ranked conformation of compound 5 was merged into the 
tacrine-free A40TcAChE complex. 
 
6.4.17. Parallel Artificial Membrane Permeability Assay adapted for blood-brain 
barrier (PAMPA-BBB) 
Previously reported protocols with modification using the PAMPA Explorer kit 
(Pion, Inc.) were applied to our PAMPA-BBB experiment.34,53,58,59 Each stock solution of 
the compounds was diluted to a final concentration of 10 M (1% v/v final DMSO 
concentration) with pH 7.4 Prisma HT buffer (Pion). The resulting solution (200 L) was 
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added to each of the wells of the donor plate (number of replicates per sample = 12). 
The BBB-1 lipid (Pion formulation, 5 L) was used to coat the polyvinylidene fluoride 
(PDVF, 0.45 μM) filter membrane on the acceptor plate. The acceptor plate was placed 
on the top of the donor plate generating a “sandwich” and each well of the acceptor 
plate was filled with the brain sink buffer (200 L, Pion). The sandwich was incubated at 
room temperature for 4 h without stirring. A microplate reader was used to obtain the 
optical spectra (250500 nm) of the solutions in the reference, acceptor, and donor 
plates. The –logPe for each compound was calculated using the PAMPA Explorer 
software c. 3.5 (Pion). CNS+/– assignment was determined in comparison to 
compounds identified previously.53,58,59 Compounds categorized as CNS+ have the 
ability to permeate through the BBB and target the CNS. Compounds assigned as 
CNS– have poor permeability through the BBB and therefore, their bioavailability into 
the CNS is considered to be minimal. 
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Chapter 7: Concluding Remarks and Perspectives 
 
To understand the highly complex nature of the neuropathogenesis of 
Alzheimer’s disease (AD), the fundamental understanding of how multiple factors (i.e., 
A, metal ions, proteins) intertwine together that lead to the onset and progression of 
the disease is critical. For this purpose, recent efforts have been made for the 
development of small molecules as chemical tools that have the potential to target these 
factors and modulate their reactivity. In literature, a wide range of libraries of small 
molecules with various molecular scaffolds has been utilized to illustrate some inkling of 
metal-peptide-protein interactons and their effects upon neurotoxicity leading to AD. 
Advancements in this particular area will be essential as AD etiology becomes slowly 
elucidated. 
The studies presented in Chapters 2-6 of this dissertation demonstrate the 
feasibility of developing small molecules as chemical tools to understand the role of 
multiple factors play in AD neuropathogenesis. The small molecules investigated in this 
thesis were developed using a rational structure-based approach where critical moieties 
(i.e., A interaction, metal chelation, inhibition of protein activity) were designed into a 
single molecule. As shown in Chapters 2 and 3, DPP derivatives reveal a structure-
reactivity-cytotoxicity relationship that explains the compounds’ reactivity toward metal-
associated A (metalA) species. Tuning of reactivity (in particular, A aggregation) 
via structural modifications allows us to understand that the balance of compounds’ 
properties (i.e., A interaction and metal chelation) is necessary for achieving noticeable 
their reactivity with the target, metalA. Chapters 4 and 5 (Gd-cur and PyED, 
respectively) present alternative aspects of the framework, where small molecules could 
be used as a thernostic agent (Gd-cur) or a potential tool that could be used for A 
clearance through radical formation (PyED). From these studies, both scaffolds show 
the ability to target metalA species and control A aggregation as well, and we now 
can discern some nuances of how molecular structure could be designed to incorporate 
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other potential uses to study AD etiology. Hybrid 5, presented in Chapter 6, displays 
interactions toward multiple facets (A, metal ions, and acetylcholinesterase (AChE)) as 
well as abilities to modulate metal-induced A aggregation with and without AChE, and 
to inhibit the activity of AChE, capable of breaking down the neurotransmitter 
acetylcholine (ACh), in the absence and presence of A and/or metal ions under both 
normal and oxidative stress conditions. For hybrid 5, the modulating framework, L2-b, 
for bifunctionality (A interaction and metal chelation) was conjugated with tacrine 
moiety for AChE inhibition in order to target and regulate metal ions, A/metal–A, and 
AChE. All compounds (Chapters 2-6) are shown to modulate metal-induced A 
aggregation to different extents in comparison to metal-free A aggregation. Overall 
these studies provide us insight into the development of potential viable chemical tools 
to elucidate the multifaceted cause of AD. 
 The reactivity of presently investigated compounds with A and metalA, 
however, has been observed to be limited in vitro, and therefore subsequent structural 
optimization for interacting with metal ions and A species is necessary for their 
potential biological applicability. DPP derivatives show varying degrees of ability to 
control metal-induced A aggregation; DPP2 and C2 (exhibiting cytotoxicity at low M 
concentrations) exhibit the greatest reactivity toward A/metal–A, while PA2 (relatively 
nontoxic up to high M concentrations) demonstrates slight reactivity toward metal-
triggered A aggregation. The different metal binding affinities of these derivatives are 
suggested to have an impact in controlling the formation of A aggregates. Therefore, 
the metal binding affinity of DPP series could be improved ( 10-6 M) upon substitution 
with stronger donor atoms for metal binding as well as altering dencitiy, which could 
allow DPP derivatives to be applied for biological systems. Limitation of Gd-cur for its 
uses for brain applications comes from its BBB permeability properties. Scaffold 
modifications, such as lowering the MW or HBA of the compound by employing an 
alternate MRI agent (GdIIIDTPA contains 10 HBA with MW = 546) or changing the 
curcumin with the linker (contains 10 HBA; MW = 617), could provide a viable 
theranostic candidate for biological applications. PyED, though having metal chelating 
abilities, do not have an A interaction moiety within the framework. Incorporation of a 
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dimethylamino moiety, which has been suggested to be essential for A interaction,1-3 
may improve properties for interactions and reactivity toward A/metalA direct its 
utilitzation in biological settings. Due to it solubility and hepatoxicity associated with the 
tacrine moiety, the next generation of hybrid 5 would be composed of a more 
hydrophilic linker (to improve compound solubility) for conjugation of a metalA 
modulating moiety and an AChE inhibiting moiety, as well as employing other current 
therapeutics employed for AD treatments (AChE inhibition). In addition, L2-b (metalA 
modulating moiety incorporated in hybrid 5) has recently presented promising in vivo 
data toward A species and its derivatives are being developed and investigated for 
greater bioavailability (e.g., higher amount of neutral species at physiologically relevant 
pH (i.e., 7.4), mitigation of compound’s cytotoxicity in the presence of metal ions). Over 
the course of time, research in the AD field will highly benefit from the continuing 
development of small molecules as chemical reagents to aid in illustrating the complex, 
multifaceted cause of AD neuropathology, which may lead to discovery of diagnotics 
and therapeutics for AD. To contribute to this aspect, further tuning of chemical 
properties of present molecules and other lead compounds for optimization of biological 
applications (e.g., solubility, BBB permeability, cytotoxicity) via structural refinement is 
essential. 
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Appendix A: Reactivity of Triazole-Pyridine Derivatives Toward Metal-
Associated A Species 
 
The work presented herein was conducted in collaboration with Dr. Matteo Tegoni at 
University of Parma, Italy. In this present work, I have contributed to studies of metal 
binding, docking, A aggregation (gel/TEM), antioxidant activity, cytotoxicity, and in vitro 
blood-brain barrier (BBB) permeability. 
 
A.1. Introduction 
Alzheimer’s disease is the most common form of dementia that is currently 
afflicting the aging population; cases of AD diagnosis has steadily risen, making it the 
sixth leading cause of death in the United States.1 One of the hallmarks of AD is the 
accumulation of amyloid-beta (A) peptide aggregates; through an amyloidogenic 
aggregation pathway, starts with the generation of monomers, which have the 
propensity to self-aggregate into higher MW A species, such as oligomers, protofibrils 
and fibrils that ultimately form the senile plaques that are seen in AD brain.2-8 Other 
multiple factors (i.e., metal ion dyshomeostasis, oxidative stress) have been correlated 
to A itself, where increased levels of metal ions (i.e., Cu, Zn, and Fe) have been found 
within the senile plaques 2,4,6-8 and metal ions, upon binding to A, facilitate peptide 
aggregation as well as enhance reactive oxygen species formation.2,6-9  
To further illustrate the potential correlation between metal-associated 
(metalA) species in the onset and progression of the disease, efforts have been 
made in the development of chemical tools which have been designed to target 
metalA species, regulate the interaction between metal ions and A, and modulate 
their reactivity.6,7,9,10 Our laboratory has made strides in developing small molecules 
fashioned using a rational structure-based incorporation approach where a metal 
chelation site is integrated onto an A interacting moiety.11-18 Among them, reactivity of 
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triazole-pyridine derivatives toward metalA species were investigated and shown to 
have a modulating affect upon metal-induced A aggregation.15 In addition, triazoles 
have be incorporated into a wide variety of therapeutic drug frameworks due to 
observed its biological relevant properties, such as anti-inflammatory, anti-depressant, 
anticancer, and analgesic activities.19-23 In particular, metal binding (specifically with 
copper through nitrogen/nitrogen or nitrogen/sulfur donor atoms) and antipoliferative 
activity of small molecules with 1,2,4-triazole-pyridine core framework have been 
studied.21,24-27 Herein, we report the characterization of 1,2,4-triazole-pyridine 
derivatives (PR1, PR2, PR3, and PR4) toward A, metal ions, metalA and reactivity 
toward metal-free and metal-induced A aggregation (Figure A.1). Overall, the results 
indicate that the 1,2,4-triazole-pyridine scaffold may be a possible framework for 
chemical reagent development to study metal-associated A species. 
 
 
Figure A.1. Chemical structures of PR1 (4-amino-5-ethyl-2,4-dihydro-3H-1,2,4-triazole-3-thione), PR2 (3-
(methylthio)-5-pyridin-2-yl)-4H-1,2,4-triazol-4-amine), PR3 (4-methyl-5-(pyridin-2-yl)-2,4-dihydro-3H-1,2,4-
triazole-3-thione, and PR4 (4-ethyl-5-(quinolin-2-yl)-2-4-dihydro-3H-1,2,4-triazole-3-thione. 
 
A.2. Results and discussion 
 
A.2.1. Metal binding properties of PR1, PR2, PR3, and PR4 
Cu2+ and Zn2+ binding was first examined by UV-vis and 1H NMR spectroscopy, 
respectively (Figure A.2). Spectral changes, such as an appearance of a new optical 
band and/or variation in absorbance intensity, were observed upon the addition of CuCl2 
(1-5 equiv) to a ligand solution in EtOH, indicating Cu2+ interaction. Due to the minute 
optical shift displayed with Zn2+ treatment, Zn2+ binding of PR1, PR2, PR3, or PR4 was 
investigated by 1H NMR. Upon the addition of 2 equiv of ZnCl2 to a solution of PR1, 
PR2, PR3, or PR4 (in CD3CN for PR1, PR3, or PR4; in CD2OH for PR2), a slight 
 
155 
 
downfield shift of the pyridine protons (PR2, PR3, or PR4) or triazole proton (PR1, PR3, 
or PR4) was recorded, suggesting that the N donor atom from the pyridine ring (PR2, 
PR3, or PR4) or triazole ring (PR1, PR3, or PR4) may be involved in metal chelation 
(Figure A.2). Overall, the UV-vis and NMR studies implied that PR1, PR2, PR3, and 
PR4 are capable of binding with Cu2+ and Zn2+. 
 
 
Figure A.2. Cu2+ or Zn2+ binding of PR1, PR2, PR3, and PR4. (a) UV-vis spectra of PR1-4 with CuCl2 
(120 equiv) in EtOH at room temperature. (b) 1H NMR spectra of PR1-4 (black) with ZnCl2 (red) in 
CD3CN at room temperature ([compound] = 4 mM; [ZnCl2] = 4 mM). 
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A.2.2. Influence of PR1, PR2, PR3, and PR4 on metal-free and metal-induced A 
aggregation 
The ability of PR1, PR2, PR3, and PR4 to modulate A aggregate formation 
(inhibition) and transform preformed A aggregates (disaggregation) (Figure A.3) was 
investigated by gel electrophoresis followed by Western blot using an anti-A antibody 
(6E10).12,18,28  
As shown in Figure A.3a, for inhibition studies with A40, reactivity was not 
indicated for PR1, PR2, PR3, and PR4 in metal-free and Zn2+-treated conditions. A40 
species (MW ≤ 20 kDa) was visualized upon the treatment with PR1, PR3, and PR4 to 
Cu2+A40 species (Figure A.3a, lanes 2, 4 and 5). In the case of sample containing 
A42, similar to results observed (in metal-free conditions) in comparison to that of A40, 
where no reactivity was exhibited upon compound addition (Figure A.3a). Very slight 
reactivity was shown from the samples containing A42, Zn2+, and PR2 (lane 3). Minimal 
reactivity was indicated with PR1/2-treated Cu2+A species (lanes 2 and 3).  
Disaggregation experiments were also conducted to verify the ability of PR1, 
PR2, PR3, and PR4 to disassemble preformed Aaggregates (Figure A.3b). Similar to 
the inhibition experiment, no noticeable reactivity was observed for compounds in 
metal-free and Zn2+-induced A aggregation for A40. When PR1 and PR3 were 
incubated with Cu2+-treated A aggregates, A40 species having MW ≤ 20 kDa were 
detected (Figure A.3b, lanes 2 and 4). In the case of A42, no reactivity was indicated 
metal-free conditions, while nominal reactivity was shown for PR1/3-added metal-
associated A42 species. Taken together, the inhibition and disaggregation results 
suggest that PR1, PR2, PR3, and PR4 have the ability to slightly modulate A 
aggregation to varying degrees. 
 
A.2.3. Docking studies of PR1, PR2, PR3, and PR4 
To visualize the possible interaction between A40 and PR1, PR2, PR3, or PR4, 
docking studies were performed using AutoDock Vina,29 employing monomeric A40 
NMR structure (PDB 2LFM)30 (Figure A.4). The compounds and A were predicted to 
interact through non-specific interactions, with most conformations exhibiting 
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Figure A.3. Inhibition and disaggregation experiments (for A40 or A42). Analysis of various-sized A 
species by gel electrophoresis with Western blot using an anti-A antibody (6E10) for (a) inhibition 
experiment and (b) disaggregation experiment. Conditions: [A] = 25 M; [CuCl2 or ZnCl2] = 25 M; 
[compound] = 50 M; pH 6.6 (for Cu2+ samples) or 7.4 (for metal-free and Zn2+ samples); 24 h incubation; 
37 °C; constant agitation. 
 
compounds being docked between the -helix and N-terminal random coil. These 
interactions had calculated to have binding energies ranging from 3.5 to 4.0, 4.5 to 
5.1, 4.2 to 5.2, and 5.1 to 6.1 for PR1, PR2, PR3, and PR4, respectively. The 
ligands were shown to either be docked at different sites or be offset from each other 
when docked at similar sites on the peptide. Observations from the preliminary docking 
studies suggest that PR1, PR2, PR3, and PR4 could interact with A differently, which 
may result in the varying reactivity displayed toward A aggregation in vitro (vide supra). 
 
A.2.3. Isothermal titration calorimetry studies of PR3 
Possible interactions of PR3 with A40 was investigated by isothermal titration 
calorimetry (ITC) experiments.31 The heat changes measured during the titration 
suggested possible interaction of PR3 with A40. The titration data was fitted using a 
sequential binding model, where the best fit was achieved with N = 3; the 
thermodynamic values (binding constants (KA), enthalpy changes (ΔH), entropy  
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Figure A.4. Docking studies of PR1-4. Cartoon (left) and surface (right) versions of possible 
conformations of PR1 (red), PR2 (turquoise), PR3 (yellow), and PR4 (pink) docked with A40 (PDB 2LFM) 
by AutoDock Vina. The helical region of A (H13-D23) in the surface representation is highlighted in color 
(light grey). 
 
changes (TΔS), and Gibbs free energy (ΔG) were then determined, based on the 
binding model (Table A2.1). The first and third binding are entropically favorable, 
however enthapically unfavorable (Table A2.1), indicating that the binding may be 
driven by hydrophobic interactions. The second binding is enthalpically favored and 
entropically unfavored (Table A2.1), suggesting interaction may be occuring via 
hydrogen bonding. Overall, the ITC data demonstrate possible A40 interaction, which 
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may correspond to the reactivity observed with A aggregation (vide supra; Figure A.3). 
 
Table A2.1. Thermodynamic parameters for the interaction of PR3 with A40 determined 
by isothermal titration calorimetry (ITC).  
 
Binding site 1 Binding site 2 Binding site 3 
KA (M-1) 1.5 x 104 ± 9.7 x 103 1.0 x 105 ± 7.3 x 104 2.6 x 105 ± 1.8 x 104 
G (kJ/mol) −23.8 ± 1.6 −28.6 ± 1.7 −30.9 ± 1.7 
H (kJ/mol) 9.89  ± 3.3 −3.70 ± 1.6 2.51  ± 1.2 
−TS (kJ/mol) −33.7 ± 3.7 8.41 ± 15.9 −56.1 ± 12.4 
 
A.2.5. Antioxidant capacity, cell toxicity, and BBB permeability of PR1, PR2, PR3, 
and PR4 
To determine whether PR1, PR2, PR3, and PR4 has biological applications, the 
antioxidant capacity of compounds were determined using a Trolox equivalent 
antioxidant capacity (TEAC) assay,32,33 which measures the ability of compound to 
quench the generated ABTS cation radicals (ABTS•+; ABTS = 2,2’-azino-bis(3-
ethylbenzothiazoline-6-sufonic acid)) in solution (Figure A.5). The compounds were less 
effective in scavenging free radicals in comparison to that of Trolox (a vitamin E 
analogue), but differences between the compounds were observed. PR3 had the 
greatest activity followed by PR1 < PR4 < PR2 (PR2; minimal if not any antioxidant 
capacity).  
Cytotoxicity of PR1, PR2, PR3, and PR4 was determined employing human 
neuroblastoma SK-N-BE(2)-M17 cells and assessed by the MTT assay.11,12,18,28 The 
compounds themselves did not exhibit any cell toxicity (up to 100 M; Figure A.6a). In 
the presence of Zn2+, toxicity was not observed up to 50 M. Upon addition of 
compound to Cu2+-treated M17 cells,  80% cell viability was shown with PR1 and PR2 
at 50 M CuCl2; however, PR3 and PR4 indicated ca. 60% or lower cell viability at 50 
M CuCl2 (Figure A.6b).  
The BBB permeability of PR1, PR2, PR3, and PR4 was identified initially based 
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Figure A.5. Antioxidant activity of PR1, PR2, PR3, and PR4 measured by the TEAC assay. The TEAC 
values are relative to Trolox, a vitamin E analogue (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic 
acid). 
 
on the values of the Lipinski’s rules and logBB.34-37 The calculated values suggest that 
PR1, PR2, PR3, and PR4 have drug-like characteristics and may be BBB permeable. 
An in vitro PAMPA-BBB assay was performed to verify the theoretical prediction for 
BBB permeability of our compounds. The permeability value (logPe) of PR1, PR2, 
PR3, and PR4 (logPe = 6.1 ± 0.1, 5.8 ± 0.1, 5.7 ± 0.1, and 4.9 ± 0.1, respectively; 
Table A2.2), along with the empirical classification of known molecules to permeate 
through the BBB (e.g., verapamil),34,35,38 indicated that PR4 could potentially passively 
diffuse across the BBB membrane. Overall, our results to determine potential biological 
applicability suggest that PR4 may be a possible candidate that is BBB permeable and 
not cytotoxic at lower copper concentration (i.e., 5 M) 
 
A.3. Conclusion and future directions 
Reactivity of triazole-pyridine derivatives was investigated toward A, metal ions, 
and metal-associated A species as a potential chemical reagent framework that could 
target and alter the interaction between the two factors (A and metal ions) to alter their 
reactivity. Based on the data presented herein, PR1, PR3, and PR4 show slight ability 
to modulate in vitro Cu2+-induced A aggregation, specifically A40 aggregation. As for  
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Table A2.2. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe) of PR1-4.  
Calculationa PR1 PR3 PR4 PR5 
Lipinski’s rules  
& others 
MW 144 207 192 256 ≤ 450 
clogP          0.225            0.693 0.926            0.987 ≤ 5.0 
HBA    4     5    4    4 ≤ 10 
HBD    3     2    1    1 ≤ 5 
PSA     59.6      69.6     46.5      46.5 ≤ 90 
logBB 0.786 0.795 0.699 0.408 
< 1.0 (poorly distributed 
in the brain. 
logPeb 6.1 ± 0.1 5.8 ± 0.1 5.7 ± 0.1 4.9 ± 0.1  
CNS +/ 
Predictionc CNS - CNS - CNS - CNS + 
logPe < 5.4 (CNS+) 
           > 5.7 (CNS) 
      
aMW, molecular weight; clogP, calculated logarithm of the octonal-water partition coefficient; HBA, 
hydrogen-bond acceptor atoms; HBD, hydrogen-bond donor atoms; PSA, polar surface area; logBB = 
0.0148 x PSA + 0.152 x clogP + 0.130. b The values of –logPe were measured by the parallel artificial 
membrane permeability assay (PAMPA). c Compounds categorized as CNS+ have the ability to permeate 
through the BBB and target the CNS. In the case of compounds assigned as CNS they have poor 
permeability through the BBB and therefore, their bioavailability into the CNS is considered to be minimal. 
 
biological applicability, PR1, PR3, and PR4 were observed to have modest antioxidant 
ability, relatively non-toxic in the absence of metal ions (CuCl2 or ZnCl2) and presence 
of ZnCl2. Varying cell viability was observed in the presence of CuCl2, with PR1 and 
PR2 being the least cytotoxic, and PR4 predicted to be BBB permeable. Overall, our 
studies present a viable framework that could be used to develop chemical reagents to 
studying the correlation between A and metal ions in AD. Furthermore modifications, 
such as the incorporation of a dimethylamino moiety, which has been suggested to be 
important for A interaction,12,16,39 could lead to better reactivity toward metal-free and 
metal-associated A species.  
 
A.4. Experimental section 
 
A.4.1. Materials and procedures 
All reagents were purchased from commercial suppliers and used as received 
unless otherwise stated. The compounds PR1 (4-amino-5-ethyl-2,4-dihydro-3H-1,2,4-
triazole-3-thione),40 PR2 (3-(methylthio)-5-pyridin-2-yl)-4H-1,2,4-triazol-4-amine),24 PR3 
(4-methyl-5-(pyridin-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione,41 and PR4 (4-ethyl-5-
(quinolin-2-yl)-2-4-dihydro-3H-1,2,4-triazole-3-thione)42 were synthesized according to  
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Figure A.6. Cytotoxicity of PR1, PR2, PR3, and PR4 in SK-N-BE(2)-M17 neuroblastoma cells. (a) Cells 
were treated with various concentrations of compounds (2.550 M) and (b) various concentrations of 
compound and metal chloride salts. ([cpd]:[M2+] = 1:1 and 1:2 ratio; M2+ = CuCl2 or ZnCl2), incubated for 
24 h. The cell viability was assessed by a MTT Assay. The values of cell viability (%) were calculated to 
cells treated with 1% v/v DMSO. 
 
previous literature. A40 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) 
and A42 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) was 
purchased from AnaSpec (Fremont, CA). An Agilent 8453 UV-Visible (UV-Vis) 
spectrophotometer was used to measure the optical spectra. Nuclear magnetic 
resonance (NMR) spectra of small molecules and for Zn2+ binding studies were 
obtained by a Varian 400 MHz NMR spectrometer. Isothermal calorimetric titrations of 
A40 with compounds were carried out with a MicroCal VP-ITC isothermal titration 
calorimeter (Northhampton, MA). A SpectraMax M5 microplate reader (Molecular 
Devices, Sunnyvale, CA) was employed for the measurement of absorbance for 3-(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and PAMPA-BBB assays.  
 
A.4.2. Metal binding studies 
The interaction of PR1, PR2, PR3, and PR4 with Cu2+ and Zn2+ was determined 
by UV-vis and 1H NMR spectroscopy, respectively, based on previously reported 
procedures.11,12,18 A solution of ligand (25 M in EtOH) was prepared, treated with 1 to 5 
equiv of CuCl2, and incubated at room temperature for 5 min. The optical spectra of the 
resulting solutions were measured by UV-vis. The interaction of PR1, PR2, PR3, or PR4 
with ZnCl2 was observed by 1H NMR. ZnCl2 (1 equiv) was added to a solution of PR1/3 
(8 mM) or PR4 (4 mM) in CD3CN. Zinc binding (1 equiv) was performed for PR2 (8 mM) 
in CD3OH. 
 
A.4.3. Isothermal calorimetry studies 
Solutions of ligand (200 M) and A40 (20 M) HEPES buffer (20 M, pH 7.4; 
NaCl 150 M; 10% v/v DMSO) were prepared and degassed for 10 min prior to titration. 
The ligand solution (10 L/injection) was injected over 1 s (25 times, with 200 sec 
interval between each injection) into a solution of A40 using a motor-driven 250 L 
syringe (rotating speed of 310 rpm) at 25 C. The heat of dilution was calculated by 
titrating ligand solution into buffer solution without the presence of A40. Heat values of 
binding were measured by subtracting the heat of dilution values from the experimental 
results. Titration data were analyzed by using MicroCal Origin, version 7.0 software. 
The binding curves were fitted with a one-site binding or sequential model, affording the 
overall heat values of thermodynamic parameters.31 
 
A.4.4. Docking studies 
Flexible ligand docking studies using AutoDock Vina29 for PR1, PR2, PR3, and 
PR4 were conducted against the A40 monomer from the previously determined 
aqueous solution NMR structure (PDB 2LFM).30 Ten conformations were selected from 
20 conformations within the PDB file (1, 3, 5, 8, 10, 12, 13, 16, 17, and 20). The 
MMFF94 energy minimization in ChemBio3D Ultra 11.0 was used to optimize the 
structures of the ligands for the docking studies. The structural files of PR1, PR2, PR3, 
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PR4, and the peptide were generated by AutoDock Tools and imported into PyRx,43 
which was used to run AutoDock Vina. The search space dimensions were set to 
contain the entire peptide. The exhaustiveness for the docking runs was set at 1024. 
Docked poses of the ligands were visualized with A using Pymol. 
 
A.4.5 Amyloid- (A) peptide 
A40 was used in all A experiments. A40 peptide (1 mg) was dissolved with 
ammonium hydroxide (NH4OH, 1% v/v, aq), aliquoted, lyophilized, and stored at 80 C. 
A stock solution (ca. 200 M) was prepared by redissolving A with NH4OH (1% v/v, aq, 
10 L) followed by dilution with ddH2O. All A solutions were prepared following 
previously reported procedures.11,12,18,28 The buffered solutions (20 M HEPES, pH 6.6 
(for Cu2+ samples) or pH 7.4 (for metal-free and Zn2+ samples), 150 M NaCl) were 
used for both inhibition and disaggregation studies. For the inhibition experiment, A (25 
M) was first treated with a metal chloride salt (CuCl2 or ZnCl2, 25 M) for 2 min 
followed by addition of a compound (PR1, PR2, PR3, or PR4, 50 M in DMSO, 1% v/v 
final DMSO concentration). The resulting samples were incubated at 37 C for 24 h with 
constant agitation. For the disaggregation experiment, A and a metal chloride salt 
(CuCl2 or ZnCl2) were initially incubated at 37 C for 24 h with steady agitation. The 
compound was added afterwards followed by additional 24 h incubation at 37 C with 
constant agitation. 
 
A.4.6. Gel electrophoresis with Western blot 
The A peptide experiments (as described above) were analyzed by gel 
electrophoresis with Western blot using an anti-A antibody (6E10).11,12,18,28,44 Each 
sample containing 25 M A (10 L) was separated using either a 1020% gradient 
Tris-tricine gel (Invitrogen, Grand Island, NY). The gel was transferred to a nitrocellulose 
membrane and blocked overnight with bovine serum albumin (BSA, 3% w/v, Sigma, St. 
Louis, MO) dissolved in Tris-buffered saline (TBS, Fisher, Pittsburg, PA) containing 
0.1% Tween-20 (TBS-T, Sigma). The membrane was treated with 6E10 (1:2,000; 2% 
BSA in TBS-T, Covance, Princeton, NJ) for 4 h at room temperature. The membrane 
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was probed with a horseradish peroxidase-conjugated goat anti-mouse secondary 
antibody (1:5,000; Cayman Chemical, Ann Arbor, MI) in 2% BSA in TBS-T solution for 1 
h at room temperature. The protein bands were visualized using the Thermo Scientific 
Supersignal West Pico Chemiluminescent Subtrate (Rockford, IL). 
 
A.4.7. Trolox Equivalence Antioxidant Capacity assay (TEAC) 
The TEAC assay was used to determine the antioxidant ability based on the 
extent of decolorization of ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
diammonium salt) cation radical relative to that of the vitamin E analogue, Trolox.32 The 
assay was performed according to the previously reported method with slight 
modifications.18,32,33,45 First, blue ABTS+• cation radicals were generated by dissolving 
ABTS (19 mg, 7.0 mM) with potassium persulfate (3.3 mg, 2.5 mM) in 5 mL water and 
incubating for 16 h in the dark at room temperature. The resulting ABTS+• solution was 
diluted with EtOH to an absorbance of ca. 0.7 at 734 nm. The assay was conducted in a 
clear 96 well plate to which 200 L diluted ABTS+• solution was added and incubated at 
30 C for 5 min in the plate reader. Each ligand was added from a stock solution 
prepared in DMSO (1% v/v) or in EtOH (for Trolox) and was incubated with the ABTS+• 
solution at 30 C for different time periods (2 min intervals up to 20 min). The percent 
inhibition was calculated according to the measured absorbance at 734 nm (% Inhibition 
= 100  (A − A0)/A0) and was plotted as a function of ligand concentration. The TEAC 
value of compounds for each time point was calculated as a ratio of the slope of the 
standard curve of the compound to that of Trolox. The measurements were carried out 
in triplicate.  
 
A.4.8. Cytotoxicity (MTT Assay) 
The human neuroblastoma SK-N-BE(2)-M17 (M17) cell line was purchased from 
the American Type Cell Collection (ATCC, Manassas, VA, USA). M17 cells were 
maintained in media containing [1:1 Minimum Essential Media (MEM, Invitrogen)/Ham’s 
F12 Nutrient Mixture (Invitrogen)], respectively, supplemented with 10% FBS (Atlanta 
Biologicals, Atlanta, GA, USA) and 100 U/mL penicillin and 100 mg/mL streptomycin 
(Invitrogen). The cells were grown in a humidified atmosphere with 5% CO2 at 37 °C. 
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For the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide), M17 cells were seeded in a 96 well plate (15,000 cells/100 L). The M17 cells 
were treated in parallel with only metal salts (CuCl2 or ZnCl2), PR1, PR2, PR3, and 
PR4, or metal/PR1, PR2, PR3, and PR4 (1:2 metal/compound ratio). After incubation, 
25 L MTT (5 mg/mL in phosphate buffered saline (PBS, pH 7.4, Gibco, Grand Island, 
NY, USA) was added to each well and the plate was incubated for 4 h at 37 °C. 
Formazan produced by the cells was solubilized using an acidic solution of N,N-
dimethylformamide (50%, v/v aq) and sodium dodecyl sulfate (SDS, 20%, w/v) 
overnight at room temperature in the dark. The absorbance was measured at 600 nm 
using a microplate reader. Cell viability was calculated relative to cells containing an 
equivalent amount of DMSO. 
 
A.4.9. Parallel Artificial Membrane Permeability Assay adapted for blood-brain 
barrier (PAMPA-BBB) 
PAMPA-BBB experiments were carried out using the PAMPA Explorer kit (Pion 
Inc. Billerica, MA) with modification to previously reported protocols.12,34,35,38 Each stock 
solution was diluted with pH 7.4 Prisma HT buffer (Pion) to a final concentration of 25 
M (1% v/v final DMSO concentration) and 200 L were added to the wells of the donor 
plate (number of replicates = 12). BBB-1 lipid formulation (5 L, Pion) was used to coat 
the polyvinylidene fluoride (PVDF, 0.45 M) filter membrane on the acceptor plate. The 
acceptor plate was placed on top of the donor plate forming a sandwich and the brain 
sink buffer (BSB, 200 L, Pion) was added to each well of the acceptor plate. The 
sandwich was incubated for 4 h at ambient temperature without stirring. UV-vis spectra 
of the solutions in the reference, acceptor, and donor plates were measured using a 
microplate reader. The PAMPA Explorer software v. 3.5 (Pion) was used to calculate 
the −logPe for each compound. CNS± designations were assigned by comparison to 
compounds that were identified in previous reports.12,34,35,38 
 
A.5. References 
(1) Thies, W.; Bleiler, L. Alzheimers Dement. 2013, 9, 208. 
(2) Kepp, K. P. Chem. Rev. 2012, 112, 5193. 
 
167 
 
(3) Hardy, J. A.; Higgins, G. A. Science 1992, 256, 184. 
(4) Jakob-Roetne, R.; Jacobsen, H. Angew. Chem., Int. Ed. 2009, 48, 3030. 
(5) Rauk, A. Chem. Soc. Rev. 2009, 38, 2698. 
(6) Scott, L. E.; Orvig, C. Chem. Rev. 2009, 109, 4885. 
(7) DeToma, A. S.; Salamekh, S.; Ramamoorthy, A.; Lim, M. H. Chem. Soc. Rev. 
2012, 41, 608. 
(8) Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. ACS Chem. Biol. 2013, 8, 856. 
(9) Pithadia, A. S.; Lim, M. H. Curr. Opin. Chem. Biol. 2012, 16, 67. 
(10) Rodríguez-Rodríguez, C.; Telpoukhovskaia, M.; Orvig, C. Coord. Chem. Rev. 
2012, 256, 2308. 
(11) Hindo, S. S.; Mancino, A. M.; Braymer, J. J.; Liu, Y.; Vivekanandan, S.; 
Ramamoorthy, A.; Lim, M. H. J. Am. Chem. Soc. 2009, 131, 16663. 
(12) Choi, J. S.; Braymer, J. J.; Nanga, R. P.; Ramamoorthy, A.; Lim, M. H. Proc. 
Natl. Acad. Sci. U. S. A. 2010, 107, 21990. 
(13) Braymer, J. J.; Choi, J.-S.; DeToma, A. S.; Wang, C.; Nam, K.; Kampf, J. W.; 
Ramamoorthy, A.; Lim, M. H. Inorg. Chem. 2011, 50, 10724. 
(14) Choi, J.-S.; Braymer, J. J.; Park, S. K.; Mustafa, S.; Chae, J.; Lim, M. H. 
Metallomics 2011, 3, 284. 
(15) Jones, M. R.; Service, E. L.; Thompson, J. R.; Wang, M. C.; Kimsey, I. J.; 
DeToma, A. S.; Ramamoorthy, A.; Lim, M. H.; Storr, T. Metallomics 2012, 4, 910. 
(16) Pithadia, A. S.; Kochi, A.; Soper, M. T.; Beck, M. W.; Liu, Y.; Lee, S.; DeToma, A. 
S.; Ruotolo, B. T.; Lim, M. H. Inorg. Chem. 2012, 51, 12959. 
(17) Liu, Y.; Kochi, A.; Pithadia, A. S.; Lee, S.; Nam, Y.; Beck, M. W.; He, X.; Lee, D.; 
Lim, M. H. Inorg. Chem. 2013, 52, 8121. 
(18) Lee, S.; Zheng, X.; Krishnamoorthy, J.; Savelieff, M. G.; Park, H. M.; Brender, J. 
R.; Kim, J. H.; Derrick, J. S.; Kochi, A.; Lee, H. J.; Kim, C.; Ramamoorthy, A.; 
Bowers, M. T.; Lim, M. H. J. Am. Chem. Soc. 2014, 136, 299. 
(19) Ashour, H. M.; Shaaban, O. G.; Rizk, O. H.; El-Ashmawy, I. M. Eur. J. Med. 
Chem. 2013, 62, 341. 
(20) Varvaresou, A.; Siatra-Papastaikoudi, T.; Dalla Tsotinis, A.; Tsantili-Kakoulidou, 
A.; Vamvakides, A. Farmaco 1998, 53, 320. 
(21) Tardito, S.; Bassanetti, I.; Bignardi, C.; Elviri, L.; Tegoni, M.; Mucchino, C.; 
Bussolati, O.; Franchi-Gazzola, R.; Marchio, L. J. Am. Chem. Soc. 2011, 133, 
6235. 
(22) Khan, I.; Ibrar, A.; Abbas, N. Eur. J. Med. Chem. 2013, 63, 854. 
(23) Ferreira, V. F.; da Rocha, D. R.; da Silva, F. C.; Ferreira, P. G.; Boechat, N. A.; 
Magalhaes, J. L. Expert Opin. Ther. Pat. 2013, 23, 319. 
(24) Dallavalle, F.; Gaccioli, F.; Franchi-Gazzola, R.; Lanfranchi, M.; Marchio, L.; 
Pellinghelli, M. A.; Tegoni, M. J. Inorg. Biochem. 2002, 92, 95. 
(25) Ferloni, E.; Lanfranchi, M.; Marchio, L.; Metta, G.; Pellinghelli, M. A.; Tegoni, M. 
Inorg. Chim. Acta 2005, 358, 147. 
(26) Gaccioli, F.; Franchi-Gazzola, R.; Lanfranchi, M.; Marchio, L.; Metta, G.; 
Pellinghelli, M. A.; Tardito, S.; Tegoni, M. J. Inorg. Biochem. 2005, 99, 1573. 
(27) Tardito, S.; Bussolati, O.; Maffini, M.; Tegoni, M.; Giannetto, M.; Dall'asta, V.; 
Franchi-Gazzola, R.; Lanfranchi, M.; Pellinghelli, M. A.; Mucchino, C.; Mori, G.; 
Marchio, L. J. Med. Chem. 2007, 50, 1916. 
 
168 
 
(28) Hyung, S. J.; DeToma, A. S.; Brender, J. R.; Lee, S.; Vivekanandan, S.; Kochi, 
A.; Choi, J. S.; Ramamoorthy, A.; Ruotolo, B. T.; Lim, M. H. Proc. Natl. Acad. Sci. 
U. S. A. 2013, 110, 3743. 
(29) Trott, O.; Olson, A. J. J. Comput. Chem. 2010, 31, 455. 
(30) Vivekanandan, S.; Brender, J. R.; Lee, S. Y.; Ramamoorthy, A. Biochem. 
Biophys. Res. Commun. 2011, 411, 312. 
(31) Wang, S. H.; Liu, F. F.; Dong, X. Y.; Sun, Y. J. Phys. Chem. B 2010, 114, 11576. 
(32) Re, R.; Pellegrini, N.; Proteggente, A.; Pannala, A.; Yang, M.; Rice-Evans, C. 
Free Radic. Biol. Med. 1999, 26, 1231. 
(33) Schugar, H.; Green, D. E.; Bowen, M. L.; Scott, L. E.; Storr, T.; Bohmerle, K.; 
Thomas, F.; Allen, D. D.; Lockman, P. R.; Merkel, M.; Thompson, K. H.; Orvig, C. 
Angew. Chem., Int. Ed. 2007, 46, 1716. 
(34) Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. Eur. J. Med. Chem. 
2003, 38, 223. 
(35) Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. J. 
Pharm. Sci. 2007, 96, 2893. 
(36) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Delivery 
Rev. 2001, 46, 3. 
(37) Clark, D. E.; Pickett, S. D. Drug Discovery Today 2000, 5, 49. 
(38) BBB Protocol and Test Compounds; Pion Inc.; Wolburn, MA, 2009. 
(39) Leuma Yona, R.; Mazeres, S.; Faller, P.; Gras, E. ChemMedChem 2008, 3, 63. 
(40) Cingi, M. B.; Lanfranchi, M.; Pellinghelli, M. A.; Tegoni, M. Eur. J. Inorg. Chem 
2000, 703. 
(41) Gennari, M.; Giannetto, M.; Lanfranchi, M.; Marchio, L.; Pellinghelli, M. A.; 
Tegoni, M. Polyhedron 2004, 23, 1829. 
(42) Keshk, E. M.; El-Desoky, S. I.; Hammouda, M. A. A.; Abdel-Rahman, A. H.; 
Hegazi, A. G. Phosphorus, Sulfur, and Silicon 2008, 183, 1323. 
(43) Wolf, L. K. Chem. Eng. News 2009, 87, 31. 
(44) Reinke, A. A.; Seh, H. Y.; Gestwicki, J. E. Bioorg. Med. Chem. Lett. 2009, 19, 
4952. 
(45) He, X.; Park, H. M.; Hyung, S. J.; DeToma, A. S.; Kim, C.; Ruotolo, B. T.; Lim, M. 
H. Dalton Trans. 2012, 41, 6558. 
 
 
